Maximising the Value of HTA RDS Conference Centre, Dublin, Ireland 6–9th June 2010

Conference Programme

www.htai2010.org Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

TABLE OF CONTENTS

1. Welcome Messages ...... 3

2. Organisation ...... 6

3. General Information ...... 7

4. Social Activities ...... 10

5. Tourist Information ...... 11

6. Information for Presenters ...... 12

7. Scientifi c Programme at a Glance ...... 13

8. Venue Map ...... 14

9. Satellite Symposia ...... 15

10. Special Sessions ...... 20

11. Conference Schedules ...... 23

12. Posters ...... 83

13. Acknowledgements ...... 124

14. Exhibition Maps and Exhibitor Information ...... 125

15. HTAi Policy Forum Members ...... 132

16. HTAi 2009-2010 Membership Directory ...... 133 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA 11 WELCOME MESSAGES

A message from the HTAi President

On behalf of our Board of Directors, I warmly welcome you to HTAi’s 7th annual conference, “Maximising the Value of HTA.” WELCOME MESSAGES WELCOME MESSAGES This year’s conference theme is a timely one. Interest in HTA is increasing around the world, as health systems grapple with economic challenges and demands for better performance. As global economies recover, we can expect that health systems will continue to face pressure to deliver better outcomes and value for money, and that HTA will play an increasingly central role.

The conference plenary sessions will take a focused look at maximising the value in meeting the needs of decision-makers, conducting HTAs, and working for international collaboration. These sessions will address some of the most powerful questions facing HTA users and producers in 2010, and should stimulate discussions into the future.

For the fi rst time, the conference will also include a panel session led by the HTAi Policy Forum. Since 2005, the Policy Forum has been a meeting place for senior leaders from agencies, industry, and governments to hold strategic discussions about key global issues in health policy. The Policy Forum’s members are committed to advancing discussion for the HTA community as a whole, and this session is an important step forward.

One of the main objectives of HTAi’s Strategic Plan is to hold conferences “that address the interests and needs of members from all disciplines and backgrounds with an interest in HTA and healthcare technology.” This means that our conferences should not only refl ect the latest work in HTA around the world, but should also help to build international networks and support collaboration.

This year’s excellent programme shows that we are meeting this goal, thanks to the energy and commitment of HTAi’s members. I would like to extend a personal thanks to all members who have submitted abstracts, and contributed ideas for panels, plenary sessions and workshops. I continue to be inspired by the diversity of members’ contributions and expertise. Please complete the conference evaluation form so that we can continue to improve!

I am also grateful to the International Scientifi c Programme Committee (ISPC). The committee is comprised of leaders in HTA from a variety of professional and geographic backgrounds, and has worked hard to ensure that the global diversity of health system contexts is represented in Dublin.

Finally, I want to congratulate the Local Organising Committee for its work in coordinating this event. The Health Information and Quality Authority (HIQA) has invested three years in bidding for and planning HTAi 2010, and I would like to thank HIQA for its outstanding contribution to the HTA community. With such an excellent programme and setting, I have no doubt that this will be HTAi’s most successful meeting yet!

Dr Laura Sampietro-Colom HTAi President

3 HTAi 7th ANNUAL MEETING DUBLIN 2010 1 Maximising the Value of HTA

A MESSAGE FROM THE HEALTH INFORMATION AND QUALITY AUTHORITY AND THE LOCAL ORGANISING COMMITTEE WELCOME MESSAGES Dear colleagues and friends,

On behalf of the host organisation, the Health Information and Quality Authority (HIQA), we would like to extend a “Céad Míle Fáilte - a hundred thousand welcomes” to the 7th Annual Meeting of HTAi to be held in Dublin, June 6th to 9th 2010.

The selection of Dublin, Ireland as the venue for this prestigious conference in 2010 affords delegates from all over the world a unique opportunity to come together in this cosmopolitan city for what promises to be an inspiring event.

As we meet old friends and make new ones, it is important to take time to enjoy the social programme and the city’s many attractions, not least the friendly atmosphere and the best of Irish culture and tradition. Why not take a few extra days to enjoy the Irish countryside and for those of you of Irish descent, avail of an ideal opportunity to trace your roots?

More importantly however, we want you to focus on our conference proceedings, and we hope that we have selected a theme that resonates with our delegates. In increasingly challenging economic conditions, budgets for HTA may be subject to scrutiny or restrictions, while the role of HTA in optimising the use of healthcare resources to maximise patient outcomes is more important than ever. We have worked hard with the International Scientifi c Committee to provide a high quality scientifi c meeting to allow healthcare practitioners, researchers, policy makers, administrators, industry representatives, consumer organisations, consultancies and other stakeholders gain knowledge, share ideas and explore how best to maximise the value of HTA.

This meeting would not have been possible without the support of our many sponsors and the large number of individuals who have worked tirelessly for this meeting – we have no doubt that their contributions will make it an outstanding occasion.

Finally, we are proud to be hosting this conference on behalf of HTAi. We look forward to meeting you in Dublin.

Dr Máirín Ryan Professor Mark Sculpher Dr Lesley Tilson

Co-Chairs, Local Organising Committee

4 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA 1

WELCOME FROM THE SCIENTIFIC PROGRAMME CHAIRS

Dear colleague, WELCOME MESSAGES

On behalf of the International Scientifi c Programme Committee (ISPC) we would like to welcome you to Dublin’s fair city. We had a phenomenal response to the call for abstracts this year and the result is an exciting programme for HTAi 2010. In addition to the three plenary sessions, we have 24 panel sessions, 136 oral presentations and 447 poster presentations. In addition there are 4 special sessions, 7 sponsored sessions and 12 workshops. New features this year include 2 interactive sessions on HTA Policy and Practice and some special activities for students.

If you are not totally exhausted by the conference programme, we hope that you will join us at the Welcome Reception in the RDS and the Conference Dinner at the iconic Guinness Storehouse. Take time to visit the Guinness museum before joining us for dinner with fi ne wine and, of course, a glass or two of the ‘black stuff’.

We also hope that you will have time to discover the city itself, with its historic pubs, fi ne restaurants, music and colourful street life. Please ask at the Registration Desk if you have any queries about social activities.

We are grateful to the International Scientifi c Programme Committee (ISPC), the Local Organising Committee, 87 abstract reviewers and staff of the Health Information and Quality Authority for all their hard work in making this a successful meeting. Please see the following pages and the Abstract Book for recognition of everyone’s efforts.

We sincerely hope that your visit to Dublin will be a rewarding one. Remember, you are here for the ‘craic’!

Yours sincerely,

Michael Drummond, Michael Barry

Co-Chairs, International Scientifi c Programme Committee

5 HTAi 7th ANNUAL MEETING DUBLIN 2010 2 Maximising the Value of HTA ORGANISATION

LOCAL ORGANISING Jens Grueger, Pfi zer, UK Laszlo Gulacsi, Corvinus University, Budapest, Hungary COMMITTEE Brendon Kearney, S.A. Pathology, Australia Carole Longson, National Institute for Clinical CHAIRS Excellence, UK Andres Pichon-Riviere, Institute for Clinical ORGANISATION Máirín Ryan Effectiveness and Health Policy (IECS), Argentina Director of Health Technology Assessment Karen Rascati, University of Texas at Austin, USA Health Information and Quality Authority Máirín Ryan, Health Information and Quality Authority, Ireland Mark Sculpher Laura Sampietro-Colom, Hospital Clinic, Barcelona, Professor of Health Economics Spain University of York Nelson Sewankambo, University of Makerere, Kampala, Uganda Lesley Tilson Uwe Siebert, University of Health Sciences, Medical Chief I Pharmacist Informatics and Technology, Austria National Centre for Pharmacoeconomics

MEMBERS OF THE COMMITTEE CONFERENCE ADVISORY GROUP Michael Barry, National Centre for Pharmacoeconomics Mike Drummond, University of York CHAIRS Jean Evans, MCI Dublin, Event Management Martin Flattery, Health Information and Quality Máirín Ryan Authority Director of Health Technology Assessment Patricia Harrington, Health Information and Quality Health Information and Quality Authority Authority Rachel O’Hare, MCI Dublin, Event Management Lesley Tilson Sinead Whooley, Health Information and Quality Chief I Pharmacist Authority National Centre for Pharmacoeconomics

INTERNATIONAL SCIENTIFIC MEMBERS OF THE COMMITTEE PROGRAMME COMMITTEE Elaine Breslin, Irish Medicines Board Justin Carty, The Irish Medical & Surgical Trade CHAIRS Association Eibhlin Connolly, Department of Health and Children Mike Drummond Martin Donnelly, Department of Health, Social Services Professor of Health Economics & Public Safety, Northern Ireland University of York Martin Flattery, Health Information and Quality Authority Michael Barry Paula Guerin, Abbott Laboratories Medical Director Jenny Hughes, GlaxoSmithKline National Centre for Pharmacoeconomics, Mary Morrissey, Health Service Executive Ciaran O’Neill, Department of Economics, University MEMBERS OF THE COMMITTEE College Galway Mary Vasseghi, WHO, Patients for Patient Safety Alvaro Atallah, Brazilian Cochrane Centre, Brazil Valerie Walshe, Health Service Executive Kathy Cargill, Medtronic International, Switzerland Sinead Whooley, Health Information and Quality Susan Cleary, University of Cape Town, South Africa Authority Tammy Clifford, Canadian Agency for Drugs and Technologies in Health (CADTH) Hans Peter Dauben,The German Institute for Medical Documentation and Information (DIMDI) Laurent Degos, Haute Autorite Sante (HAS), France Karen Facey, HTAi Policy Forum Past Chair, UK

6 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA 3 GENERAL INFORMATION

CONFERENCE VENUE BALLSBRIDGE INN 3* Royal Dublin Society (RDS) 4 Pembroke Rd Anglesea Road Ballsbridge, Dublin 4 Ballsbridge Phone: + 353 1 668 4468 Dublin 4 Fax: +353 1 667 4381 Tel: +353 (0)1 668 0866 Fax: +353 (0)1 660 4014 BEWLEYS HOTEL BALLSBRIDGE 3*

Email: [email protected] INFORMATION GENERAL Merrion Road Ballsbridge, Dublin 4 CONFERENCE SECRETARIAT Phone: +353 1 668 1111 HTAi 2010 Conference Secretariat Fax: +353 1 668 1999 MCI Dublin Offi ce 1 Clarinda Park North TRINITY CAPITAL HOTEL 3* Dun Laoghaire Pearse Street Co Dublin Ireland Dublin 2 Tel: +353 (0)1 280 2641 Phone: +353 1 648 1000/ +353 1 6481221 Fax: +353 (0)1 280 5405 Fax: +353 1 648 1010 Email: [email protected] AIRPORT ACCOMMODATION Dublin Airport is located approx. 45 minutes from the The following are HTAi 2010’s offi cial hotels: city centre and is among the 10 busiest airports in Europe in terms of international fl ights: 98 airlines serving 170 FOUR SEASONS HOTEL 5* destinations. Simmonscourt Road Ballsbridge, Dublin 4 BUSES Phone +353 (1) 665 4000 Dublin Bus operates the city’s bus routes running Fax +353 (1) 665 4099 from 06.00-23.30. Buses 4, 4a, 7 and 45 stop outside

the RDS, the conference venue. All Dublin Bus services SHELBOURNE HOTEL 5* operate on an exact fare only policy and the driver 27 St Stephen’s Green cannot accept Euro notes or give change. A bus ticket Dublin, 2 Ireland from Dublin City Centre to the RDS conference venue is Phone: +353 1 6634500 €1.60. Prepaid journey cards can be bought Fax: + 353 1 6616006 in shops, displaying the Dublin Bus logo. For more information, log onto: www.dublinbus.ie. HERBERT PARK HOTEL 4* CAR RENTAL 158 Shelbourne Rd Ballsbridge, Dublin 4 Hertz, Budget, Avis, Sixt and Europcar are rental Phone: +353 1 667 2200 companies based in Dublin airport. The daily opening Fax: +353 1 667 2595 hours for all car rental companies in the airport are 06.00hrs - 23.00 hrs. BALLSBRIDGE TOWERS 4* CATERING Pembroke Road, Ballsbridge, Dublin 4 Catering stations are available in both the Industries and Phone: + 353 1 668 4468 Sepentine Halls at the RDS. Vouchers will be included Fax: +353 1 667 4381 in your registration pack. A lunch bag is available for collection from the catering stations for those who wish BALLSBRIDGE COURT 4* to attend the lunchtime sessions. Lansdowne Road, CLOAKROOM Ballsbridge, Dublin 4 Phone: + 353 1 668 4468 A cloakroom will be available in the Industries Hall, Fax: +353 1 667 4381 opening one hour before sessions start and closing 30 minutes after the last session ends.

7 HTAi 7th ANNUAL MEETING DUBLIN 2010 3 Maximising the Value of HTA

CURRENCY EXCHANGE INTERNET/WiFi The Euro is the only currency recognised as legal tender Free WiFi and a public internet corner are available to in the Republic of Ireland. In general, banks open all attendees and exhibitors. Access codes are available Monday to Friday, 10.00 to 16.00, with late opening from the Registration Desk. on Thursdays until 17.00. Foreign exchange facilities are widely available. All major credit cards are widely LANGUAGE accepted. English is the spoken language throughout Ireland and GENERAL INFORMATION GENERAL the offi cial language of the conference. Irish (or Gaelic) ELECTRICITY is the original native language of Ireland and while it The standard domestic supply voltage in the Republic is mandatory to learn Irish in schools in Ireland, it is of Ireland is 230 VAC at 50Hz. Plugs are 3 pin 1363 rarely spoken in everyday conversation. Place names and type. Most shaving sockets also support 110 VAC with signage are usually in both languages. the 2 pin international shaving plug. Many hotel rooms provide hair dryers. LIABILITY & INSURANCE Neither the organisers nor the Conference Secretariat EMERGENCY SERVICES will assume any responsibility whatsoever for damage Police – Ambulance – Fire Brigade: Dial 999 or or injury to persons or property during the Conference. 112. Telephone numbers for doctors, dentists Participants are recommended to arrange for their etc. are available from either your hotel reception or personal travel and health insurance. Registration Desk. MESSAGES EVALUATION FORMS A Notice Board will be available at the Reception Desk HTAi 2010 values your feedback on all aspects of the so delegates can leave a message for a colleague during conference. An evaluation form will be included in the conference. Any changes to the programme will be your delegate bag. Please complete and return to the posted on a daily basis. Registration Desk. MOBILE PHONES GREEN PRACTICES All attendees will be requested to switch their mobile When registering, delegates have been offered the phones to silent or turn them off during the scientifi c opportunity to offset some of their carbon footprint sessions. created from attending the conference. The funds collected will be used to purchase fuel effi cient stoves in PROGRAMME Eritrea. Please note this fi nal conference programme is correct at date of going to press. For any changes please refer to the HEALTH conference website, www.htai2010.org, for the most up Modern medical facilities and highly skilled medical to date information. practitioners are available in Ireland. PRESS HEALTH INSURANCE & HOSPITALS Please note that conference photographers and members Emergency medical services are available to residents of the accredited press will be in attendance at the of all EU member states on production of a form E111, meeting as part of routine publicity for the event. usually without payment. All visitors are advised to arrange appropriate medical insurance cover in advance PUBLIC HOLIDAY of their trip. If you are involved in an accident or other Monday 7 June is a public holiday in Ireland. Many medical emergency, call the emergency operator on 112 smaller shops and businesses, including banks, will be or 999 from any telephone, and ask for the ambulance closed. The Dublin City Women’s Mini Marathon is also service. St. Vincent’s Hospital (www.stvincents.ie) is the taking place on Monday in the vicinity of the conference closest hospital to the conference venue. venue.

8 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA 3

REGISTRATION TRAIN The DART railway stretches the full length of Dublin On-site Bay, from Malahide and Howth in north County Dublin to Greystones in County Wicklow. Sandymount HTAi Member Full €725 DART station is just a 5 mins walk from the RDS, the conference venue. For more information, log onto: www.irishrail.ie Reduced €310 GENERAL INFORMATION GENERAL VAT RECLAIMS One-day €310 Qualifying delegates i.e. any taxable person or a taxable person’s employee or agent, attending the HTAi Conference can claim back the VAT paid on their Please note: the reduced fee is reserved for students and accommodation which from Jan 1st 2010 is at 13.5%. delegates from low income countries. A list of applicable Irish companies or qualifying individual delegates will countries is available on the conference website. be able to claim the VAT back in the normal way through Because verifi cation is required, the following papers their VAT returns. must be submitted together with the registration form: Non-Irish companies/delegates can obtain refunds by • students: a letter written on offi cial letterhead and applying to the Revenue Commissioners as follows: signed by a department head or mentor and a copy of your student ID. • businesses established in the EU – under the terms • delegates from low income countries: a copy of the of the EU Eighth Directive, by submitting form delegate’s passport from a low income country or a VAT60EC to the Irish Revenue Authorities. passport from another country plus letter on headed • businesses established outside the EU –under the paper from an employer in a low income country. terms of the EU Thirteenth Directive, by submitting form VAT60OEC to the Irish Revenue Authorities. SHOPPING & SALES TAX Log onto www.revenue.ie and Ireland Inspires website, Most shops in Dublin are open from 09:00 to 18:00 www.irelandinspires.com for further details on VAT Monday to Saturday and from 12:00 until 18:00 on reclaims. Sundays. Shops stay open late Thursday evenings in the city centre and late on Friday evenings in the suburbs. HTAi ANNUAL GENERAL Many of the out-of-town shopping centres also have late opening on other nights during the week. For non-EU MEETING visitors, tax free shopping is available in many outlets The Annual Business Meeting of HTAi will take which allows you to reclaim VAT (Value Added Tax) place on Monday, 7 June from 18:00 – 19:00 in the paid. Check with the outlet before you purchase the Clyde Room, RDS Conference Centre. goods.

SPECIAL REQUIREMENTS The conference venue is wheelchair accessible. A hearing loop is available in the session rooms. If you have any special requirements, please advise the Registration Desk.

TAXI There are almost 16,000 taxis in Dublin - they can be ordered, taken from street ranks or simply hailed on approach. Three of the main taxi ranks in the city centre are located on O’Connell Street, at College Green and at St. Stephen’s Green. Tipping is at the visitor’s discretion; up to 10% is usual.

9 HTAi 7th ANNUAL MEETING DUBLIN 2010 4 Maximising the Value of HTA SOCIAL ACTIVITIES PROGRAMME

and unusual venue. The Storehouse is situated on Crane WELCOME RECEPTION Street in one of the oldest parts of Dublin in what is still part of the massive brewery, one of the biggest in the DATE: SUNDAY, 6 JUNE 2010 TIME: 19:00 world.

The evening will have exclusive use of the Storehouse where the conference dinner will be served complimented by authentic Irish sounds in the backdrop. Throughout the course of the evening guests may venture up to the Gravity Bar located on the 7th and top fl oor of the venue. Gravity is truly the VIP area of the Guinness Storehouse. This feature bar offers unparalleled views of Dublin city and is at its most impressive after darkness SOCIAL ACTIVITIES SOCIAL PROGRAMME falls. You will be treated to 360 degree views of the city and the mountains that border it.

t An invitation is extended to all delegates to attend the Welcome Reception. This informal function will be held in the Concert Hall of the RDS. It will be a great opportunity to network with old friends and new acquaintances. One ticket is included in the full registration fee.

Additional tickets: available for accompanying persons. Additional tickets: €25 per person Dress: Casual Venue: Concert Hall, RDS, Ballsbridge, Dublin 4 Tickets: €85 includes food, wine and entertainment plus transfers to and from the conference. Dress: Smart/Casual Venue: GUINNESS STOREHOUSE®, Crane Street, CONFERENCE DINNER Dublin 8 DATE: TUESDAY, 8 JUNE 2010 TIME: 19:30 Entertainment will be provided by Kíla, Ireland’s leading Irish and World music group.

The Conference Dinner is taking place in Ireland’s No.1 international visitor attraction, the GUINNESS STOREHOUSE® in the St. James’s Gate Brewery.

A successful Brewery since 1759, the Guinness Storehouse, located in the heart of Dublin, is an exciting

10 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA 5 TOURIST INFORMATION TOURIST INFORMATION TOURIST

For those returning to Dublin there will be plenty of ABOUT DUBLIN change to observe. There has been an extraordinary amount of regeneration in the last twenty years and the Dublin is one of the most popular short break City fathers take its architecture and history seriously, destinations in Europe, consistently featuring in all top with conservation of the grand Georgian squares and ten most visited cities rankings and renowned for being elegant streets now the watchword. Other pockets of one of the friendliest capitals in Europe, maintaining a Dublin have risen like the phoenix from the ashes with relaxed and intimate atmosphere. Dublin is an old city, places such as the Docklands and Smithfi eld – an old steeped in history. The Vikings were the fi rst settlers pony market – transformed into sophisticated residential in Dublin and the city began its life as two separate districts. The banks of the Liffey have been gentrifi ed on settlements, “Atha Cliath” and “Dubh Linn”. The modern both sides, with sculptures, a new walking bridge and a name of the city is derived from these two names. boardwalk. “Dublin” is the internationally recognised name of the And for all, there is plenty of craic – Ireland’s hospitality city and “Baile Atha Cliath” is the Irish translation. is legendary and Dublin is no exception. The city is renowned for its theatre and music, contemporary and Dublin is safe, dynamic and welcoming, a wonderful traditional. And the variety of pubs is phenomenal with place to visit with a compact city centre - about 3km trendy late night bars vying with traditional Victorian squared - and all attractions within walking distance. hostelries for custom. A new-found love of al fresco For fi rst-time visitors, there is plenty to see – for culture living (partly down to the smoking ban) has changed the enthusiasts the capital has all the country’s major atmosphere on the streets, with plenty of cafes and bars galleries and museums, while nature lovers can enjoy the spilling out onto the streets adding to Dublin’s ambience. city parks including St. Stephen’s Green and the Phoenix For more information visit www.visitdublin.ie Park – Europe’s largest enclosed public park. Dublin has produced, or been home to, some of the greatest literary names in history. Dublin’s most famous literary son is ACCESS TO DUBLIN James Joyce but Oscar Wilde, Samuel Beckett, W.B. Yeats, Jonathan Swift and Bram Stoker are just some Ireland‘s capital enjoys excellent access by air from all of the other famous writers who were born or lived in major European and international destinations. Over 90 Dublin. airlines serve Dublin Airport from over 150 destinations. Aer Lingus www.aerlingus.com and Ryanair www.ryanair.com are Ireland’s largest airlines. Dublin airport is only 12 kilometres (8 miles) from Dublin city centre and therefore only a short ride by bus, taxi or car. Both Dublin Bus and Aircoach have services that leave from directly outside the airport and can bring you into the city centre. Dublin Bus services cater for the bus (Busaras) and train stations (Connolly and Heuston Stations), while Aircoach caters for many of the city centre hotels. Tickets can be purchased in advance on the Aircoach website at www.aircoach.ie, thereby making it a quick and convenient option. There is a taxi rank directly outside the Arrivals Hall in Dublin Airport. Taxis into the city centre can cost approximately €25.

11 HTAi 7th ANNUAL MEETING DUBLIN 2010 6 Maximising the Value of HTA INFORMATION FOR PRESENTERS

We would like to thank all authors for submitting scientifi c contributions for consideration at the meeting and for your work preparing and delivering your presentation.

CONFIRMATION OF ABSTRACTS TUESDAY POSTER SESSION: Scientifi c contributions were confi rmed mid March 2010 Set up: Monday from 6.00pm to 8.00pm by e-mail, only to the submitting authors. Viewing: 8.00am to 4.00pm Dismantling: before 1.30pm on Wednesday ORAL PRESENTATIONS INFORMATION FOR PRESENTERS INFORMATION The Speaker’s Preparation Room is located in Dodder E Poster prizes will be awarded to the best poster presentations. and is open from 8am to 6pm Sunday to Tuesday inclusive and from 8am to 11am on Wednesday. All speakers are CME CREDITS requested to report to the Speaker’s Preparation room The Health Technology Assessment International, with their material at least 24 hours before they are due 7th Annual Meeting is accredited by the European to speak. If you are only attending the conference for one Accreditation Council for Continuing Medical Education day, please ensure you bring your material to the Speaker’s (EACCME) to provide the following CME activity for Room before 08:30 on the same day. Presentations should medical specialists. The EACCME is an institution of the be prepared in PowerPoint. If you have any videos to be European Union of Medical Specialists (UEMS), www. played, we request that you bring a copy on DVD. uems.net. The Health Technology Assessment International, 7th Annual Meeting is designated for up to 21 hours of DURATION OF PRESENTATIONS European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually For authors awarded oral presentations, a total of 15 spent in the educational activity. European Accreditation is minutes will be allocated per speaker. We recommend granted by the EACCME in order to allow participants who that you limit your presentation to a maximum of 12 attend the above-mentioned activity to validate their credits minutes to allow time for questions The Chairs of the in their own country. EACCME credits are recognised by session will signal that you have 5 minutes and 1 minute the American Medical Association towards the Physician’s of the 12 minutes remaining. For authors awarded Recognition Award (PRA). To convert EACCME credit to presentations in the HTA Policy and Practice interactive AMA PRA category 1 credit, contact the AMA. sessions, a total of 8 minutes will be allocated per speaker. For all speakers, the chair of your session will DISCLOSURE OF POTENTIAL CONFLICTS OF stop your presentation after the allocated time, in order to INTEREST ensure that there is suffi cient time for the other papers in The HTAi 2010 Local Organising Committee is committed your session. to providing an unbiased, balanced and objective educational and scientifi c programme. In accordance with POSTERS CME guidelines, all speakers at HTAi 2010 are required to Posters will be displayed in the Industries Hall and in the disclose any potential confl icts of interest or support that Serpentine Hall. There will be two poster sessions; one may cause a bias. This must be stated at the beginning of your presentation and in all printed materials. on Monday and one on Tuesday. Presenters may refer to the Abstract Book to confi rm their poster session. COMPANY LOGOS Poster presenters are requested to stand by their posters during the coffee breaks on their poster session day and Please note that it is HTAi policy, not to allow company to take note of the following schedule for poster set up, logos or any other promotional material in any of the viewing and dismantling. session rooms. All speakers should ensure these do not appear on any conference presentations.

MONDAY POSTER SESSION: PUBLICATION Set up: Sunday from 8.00am to 7.00pm Conference abstracts will be published in the Annual Viewing: Monday 8.00am to 4.30pm Meeting abstract book and also electronically in the Dismantling: All Monday’s posters should be National Library of Medicine. Therefore, published removed by 6.00pm Monday. HTAi 2010 abstracts will be citable. In accordance with HTAi guidelines, it is intended that all slides used in the oral presentations will be made available on the meeting website in a secure PDF format as soon as possible after the meeting closes. 12 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA 7 SCIENTIFIC PROGRAMME PROGRAMME AT A GLANCE

Times Sunday Monday Tuesday Wednesday 0730 0745 0800 Registration opens Registration opens 0815 Registration opens Registration opens 0830 0845

0900 SCIENTIFIC PROGRAMME Panels 0915 0930 Plenary 2 0945 Workshops Opening & Plenary 1 1000 1015 Special Session 4 & Oral 1030 Presentations Break 1045 1100 Break Break Break 1115 1130 Panels 1145 Workshops 1200 Panels 1215 Plenary 3 & Closing 1230 1245 Lunch Lunch 1300 Satellite Symposia 1315 Lunch & ISG Meetings 1330 Satellite Symposia, Closed 1345 Networking Session 2 1400 & ISG Meetings 1415 Workshops 1430 Special Session 2, Interactive 1445 Session & Oral Presentations 1500 Special Session 1, Interactive 1515 Session & Oral Presentations Break 1530 Break 1545 1600 Break 1615 Workshops 1630 Special Session 3 1645 & Oral Presentations 1700 Break Panels 1715 1730 Break 1745 Satellite Symposium and 1800 Networking Session 1 Building a Career 1815 HTAi Business Meeting in HTA Session 1830 1845 Break 1900 1930 1930 Welcome Reception VIP Sponsors Reception 2000 Conference Dinner 2030 2100

13 HTAi 7th ANNUAL MEETING DUBLIN 2010 8 Maximising the Value of HTA VENUE MAP VENUE MAP

14 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA 9 SATELLITE SYMPOSIA

different types of outcome that can be evaluated? 4) To what extent can the pharmaceutical industry collaborate with HTA bodies to agree on study design, or is it possible to agree on a common protocol across different European HTA bodies where requirements are similar? 1. Real life studies & effi ciency measurement: Moderator: SATELLITE SYMPOSIA SATELLITE Which method? Which criteria? • Mike Drummond, Professor of Health Economics, University of York, UK Speakers: Sunday 17:15 Clyde • Adrian Towse, Director, Offi ce of Health Economics Objectives: (Academic Perspective) • To understand in what circumstances European HTA • Carole Longson, Director, Health Technology bodies may ask for post launch studies Evaluation Centre, NICE (UK Perspective) • To discuss best practice and quality standards relating • Lise Rochaix, Chair, Economic and Public Health to methods used in conducting real life studies Assessment Commission, HAS ( French Perspective) • To focus on the various types of outcome that can • Finn Borlum Kristensen, Chair, EUnetHTA Executive be measured (clinical, economic, societal, patient- Committee, (EUnetHTA perspective) preference, etc) • To determine the extent to which the pharmaceutical industry can work in collaboration with HTA bodies to agree on study design • To establish the potential for agreement between different HTA bodies on a common protocol when there is a need to collect similar data 2. Harnessing Innovative Approaches to The development of drugs is becoming increasingly Improving Health amidst Economic complex especially in oncology where more and more Constraints targeted therapies for sub groups are emerging. The prices expected by Pharma are intended to express Sunday 17:15 Lansdowne the medical value of those drugs. The view is widely held that RCTs are the main scientifi c approach to Background exploring clinical value of a drug. However, Economic and Public Health stakeholders place equal weight This session will discuss attempts to maximise health on outcomes generated under real world conditions, by leveraging innovative technologies, investing in and have additional questions they wish to answer: public health research and aligning health, industrial 1) is the treatment effective in real life under non- and welfare strategies. The discussion session will try to ideal conditions? 2) Are more expensive healthcare identify ways of leveraging strategic approaches during technologies actually more effective in usual clinical times of crisis based on the belief that a totally short term practice? So, real-world research becomes critical focus may postpone or create more problems for when to demonstrate that treatments are used for the right the economic downturn recedes. patients, and deliver a similar range of benefi t as would Chairman’s Introduction be expected given results from controlled trials. In addition, observational studies can be used to evaluate Is it desirable and feasible to employ a combination of the effectiveness of a drug which can confi rm whether short and long term initiatives to optimise affordable the drug represents good value for individuals or society. health care in the coming years? In order to ensure that these observational studies Presentation 1: focus on critical HTA concerns, there are a number of “Avoiding manpower shortfalls by leveraging innovative outstanding questions which need to be discussed: 1) In technologies” what circumstances will European HTA bodies ask for post launch studies? 2) What best practice methods are It is important to take steps to increase labour being used to conduct real life studies? 3) What are the productivity in health care by leveraging innovative

15 HTAi 7th ANNUAL MEETING DUBLIN 2010 9 Maximising the Value of HTA

technologies. More information is needed on the labour effects of medical interventions and this requires investment in methods and improved data. Presentation 2: 3. Comparative effectiveness for reimbursement: “Investing in public health research to stem the tide A comparison of international policies and of chronic disease Examples from the Public Health methods

SATELLITE SYMPOSIA SATELLITE Programme from NICE, UK” Monday 13:00 Concert Hall This presentation will describe how NICE in the UK is investing in the application of HTA to support public health programmes. Research challenges and learning Comparative effectiveness practices increasingly attract from studies to date will be presented. clinicians and policy-makers who are looking for the best evidence-based information upon which to make Presentation 3: informed healthcare decisions. “Chronic Disease and Workforce participation among A rigorous approach to comparative effectiveness older Australians” practices and robust methodology is key to ensure it Many governments are promoting deferred or gradual is appropriate and ultimately to maximise its value in retirement as a solution to the effects of population supporting healthcare decisions. ageing and labour shortages on the national budget. Differing perspectives and levels of experience between The presentation will examine the relationship between jurisdictions and the introduction of new sophisticated workforce participation and long term health conditions. methods make the application of comparative Audience Q&A and Panel Discussion effectiveness research sometimes challenging. It is hoped that the international setting will help Therefore, this symposium is to help increase countries share information and learning about how to understanding of the value of comparative effectiveness achieve long term solutions without wasting time and in HTA evaluations and the methodological issues and resources. challenges. Speakers: Objectives: • Wim Groot, Maastricht University, The Netherlands • to share the expectations and perspectives from (Presentation 1) different countries / regions in term of comparative effectiveness research (CER) to support HTA • Mike Kelly, NICE Public Health Excellence, UK (Presentation 2) • to consider methodological issues in comparative effectiveness research • Deborah Schofi eld, Professor and Chair of Health • to discuss the transferability of comparative Economics, NHMRC Clinical Trials Centre and effectiveness assessment across countries from a School of Public Health, Sydney Medical School, payer and a company perspective Australia (Presentation 3) • to identify key methodological and policy research questions Symposium fl ow: The technical vision: critical assessment of Comparative Effectiveness methodologies to answer the HTA authorities needs • Defi ning CER and how it relates to HTA and reimbursement decisions • The tension between regulation and reimbursement decisions with respect to CER • Key methodological challenges in CER including quantifying net clinical benefi t, the role of sub- group analysis, transferability of evidence between jurisdictions and choice of comparators

16 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA 9

The European Vision : increasing needs in Comparative • Clifford Goodman, Vice President, The Lewin Effectiveness from European HTA authorities Group; acting Director of The Lewin Group Center for Comparative Effectiveness Research • to remind of the long-standing history of relative effectiveness in Europe • Bong-Min Yang, Professor of Economics, School of • to introduce the most recent collaborative initiatives Public Health at Seoul National University; CHP/ across HTA bodies and between HTA and regulatory PCOR Adjunct Associate -School of Public Health - Seoul National University

agencies, aiming at improving availability and best SYMPOSIA SATELLITE use of data • to discuss the future of comparative effectiveness in Europe • to consider the methodological challenges from a European perspective The US Vision: The comparative effectiveness in the US 4. Can we reliably benchmark HTA entities? today and potential directions for the future The objectives of this presentation are to present the impact of the US healthcare reform in 2009: Monday 13:00 Clyde • Comparative effectiveness: why,now in the US and how? Rationale • the consequences of the American Recovery and Reinvestment Act 2009 (more than 1 billion $ As more and more jurisdictions establish HTA entities, dedicated to research the effectiveness of certain there is a natural tendency to compare and contrast their healthcare treatments procedures and analytic processes. This raises the question of whether it is possible to establish standards of ‘best • to consider the methodological challenges from a US practice’ and to judge various entities against them. On the perspective other hand, it might be argued that such comparisons are The Asian Vision: How does comparative effectiveness diffi cult, if not impossible to make, given the diversity in fi t in HTA in Asia? the remits given to different entities and the wide variety in the fi nancing and organisation of the different healthcare The objectives of this presentation are to present an update systems to which the various entities relate. Therefore, on HTA in Asia and to address the following issues: this session will review two recent attempts to compare • how much scope is there for transferability in and contrast HTA entities and will assess whether the evidence between jurisdictions benchmarking of such organisations can be informative • how are the methodological challenges being and useful. Two speakers that have been involved in addressed in Asia? benchmarking exercises will explain their approaches and the challenges they faced. Then, two speakers associated In conclusion, Mark Sculpher will identify key messages with different HTA entities will discuss some of the coming out of the session, identify similarities and diffi culties and pitfalls of benchmarking and explore differences between the jurisdictions covered in terms whether, if appropriately conducted, such exercises can be of methods and policies and identify potential research useful. priorities. Moderator: Moderator: • Egon Jonsson, Institute of Health Economics, • Mark Sculpher, Professor of Health Economics and Edmonton,Canada (Former editor of the International Director of the Programme on Economic Evaluation Journal of Technology in Health Care) and Health Technology Assessment, University of York Speakers: Speakers: • Michael Drummond, University of York, UK. • Adrian Towse has an MA (Hons) in Politics, • Claudio Jommi, Bocconi University, Milan, Italy Philosophy and Economics, Keble College, • David Hailey, Institute of Health Economics, Oxford, an MPhil in Management Studies, from Edmonton, Canada Nuffi eld College, Oxford and the Oxford Centre for Management Studies, and is a Member of the • Irina Cleemput, Belgian Knowledge Centre and Chartered Institute of Management Accountants EUnetHTA Project

17 HTAi 7th ANNUAL MEETING DUBLIN 2010 9 Maximising the Value of HTA

5. Relative effi cacy of drugs: an emerging issue 6. From recommendation to action : views of at the interface between regulatory agencies how HTA recommendations are integrated and third party payers into decision-making and then translated into SATELLITE SYMPOSIA SATELLITE practice in various regions/countries of the Tuesday 12:30 Concert Hall world.

Drug regulatory agencies have traditionally assessed Tuesday 12:30 Clyde quality, safety, and effi cacy of drugs. The current paradigm dictates that a new drug should be licensed Evaluating the impact of recommendations based when the benefi ts outweigh the risks. In contrast, upon health technology assessment (HTA) represents a third party payers base reimbursement decisions challenge for HTA agencies, healthcare policy-makers, predominantly on a drug’s health benefi ts relative to practitioners and patients as well as industry. existing treatment options (“relative effi cacy”; RE). Over the past decade, the role of payers has become more In July 2008, the International Group for HTA prominent, and time-to-market no longer means time-to- Advancement proposed a set of fi fteen principles that licensing but time-to-reimbursement. can be used in assessing existing or establishing new HTA activities, providing examples from existing HTA Companies now have to satisfy the sometimes divergent programs (Key principles for the improved conduct of needs of both regulators and payers, and to address RE health technology assessments for resource allocation already during the pre-marketing stages. This session decisions ; International Journal of Technology will discuss the current political background to the Assessment in Health Care, 24:3 (2008), 244–25), with RE debate, present the scientifi c and methodological Key Principle 12 focusing on the need for monitoring of challenges as they relate to RE assessment, explain the the implementation of HTA fi ndings, both to ensure that impact of RE on drug development, and speculate on the original investment in conducting HTAs is valuable future developments and actions likely required from key and to ensure that fi ndings are being implemented in a players. fair and even-handed manner. Moderator: In a subsequent publication, the extent to which these • Michael Drummond : Centre for Health Economics, Key Principles are supported and used by fourteen University of York, United Kingdom selected HTA organizations worldwide was investigated. Amongst the principles receiving less widespread support Keynote Speaker were issues of being transparent on the link between HTA fi ndings and decision-making processes and monitoring • Hans-Georg Eichler: European Medicines Agency, the implementation of HTA fi ndings. London, United Kingdom During the symposium, 3 speakers, respectively Panellists associated with HTA entities from Europe, Asia and Canada, will present their views on barriers • Bengt Jonsson: Stockholm School of Economics, and incentives to implementing decision making in Stockholm, Sweden (European payer perpective) clinical practice. Because NICE is one of the more • Richard Bergstrom: Swedish Association of sophisticated and most studied HTA entities, we will the Pharmaceutical Industry, Sweden (Industry hear from a representative about whether there are any perspective) lessons for other jurisdictions as to how best to ensure intelligent dissemination of HTA recommendations to the appropriate target audiences, work nationally to encourage a supportive environment, and provide tools to support putting recommendations into practice and fi nally evaluate uptake of guidance. We will also try to understand what are the key factors infl uencing physicians’ willingness to integrate HTA recommendations into their practice and whether increased stakeholder involvement throughout the whole

18 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA 9

HTA process could result in an improved implementation in HTA research and practice, to determine its impact. of HTA fi ndings. To a certain extent, adherence is the result of patients’ involvement in health care decision making, along with Moderator: a timely exchange of information between patients • Clifford Goodman, Vice President The Lewin Group and health care professionals and a timely revision of treatment strategies and disease management.

Speakers: The aim of the symposium is to move the debate SYMPOSIA SATELLITE • Gillian Leng, Chief Operating Offi cer and Deputy from a single patient-physician setting to the broader Chief Executive, NICE - National Institute for Health HTA environment. Better patient involvement in HTA and Clinical Excellence research, assessment and decision making could have (among others) the benefi cial effect of increasing the • Muhammed Mamdani - a researcher at the Li Ka potential to adhere to the recommended treatment; thus Shing Knowledge institute and Director of Applied increasing the expected effectiveness. Health Research Centre, St. Michael’s Hospital. Member of the University of Toronto HTA group Moderator: • Isao Kamae, President of Japanease ISPOR, JPMA • Karen Facey, Chair HTAi Interest Group on Patient/ Pharmacoeconomics Program, Research Center Citizen involvement in HTA for Urban Safety and Security, Graduate School of Health Management, Keio University, Japan Speakers: • Jean Mossman, European Federation of Neurological Associations (Patient’s perspective) • Andrew Chan, St Josef-Hospital, Ruhr-University Bochum, Bochum, Germany(Health care professional perspective) 7. Role of adherence in HTAi a bridge between • Thomas Bols, Merck Serono, SA, Geneva, patients, carers and healthcare professionals? Switzerland (Industry perspective) • Francois Meyer - Director, Health Technology Assessment Division, Haute Autorite de Sante, Tuesday 12:30 Lansdowne France (HTA agency perspective)

The satellite symposium will focus on a specifi c determinant of effectiveness and cost effectiveness; that is patients’ adherence to recommended therapy. Adherence has been defi ned by the World Health Organisation as “the extent to which a person’s behaviour – taking medication, following a diet, and/ or executing lifestyle changes, corresponds with agreed recommendations from a health care provider”. A patient’s behaviour is measured from the original “agreement” (or prescription) with the health care provider. This agreement comes from understanding of the patient’s individual needs and how to meet them and so depends on clear communication between health care professionals and patients. It is intuitively clear that if a patient doesn’t take a therapy as prescribed, it may not have the intended effect. This is likely to be a particular problem when long-term treatment is given (e.g. in chronic diseases). As adherence is likely to be one determinant of effectiveness and cost effectiveness in treating chronic diseases, its causes and effects should be fully explored

19 HTAi 7th ANNUAL MEETING DUBLIN 2010 10 Maximising the Value of HTA SPECIAL SESSIONS

EUnetHTA • Kristian Lampe, FINOHTA, THL, Finland HTA Core Model Online - A new method for producing and sharing HTA information 1. European network for HTA (EUnetHTA) • Wim Goettsch, CVZ, Netherlands Joint Action work plans for 2010-12 Relative effectiveness assessment of

SPECIAL SESSIONS SPECIAL pharmaceuticals • Sun-Hae Lee Robin, HAS, France Monday 14:30 Concert Hall New technologies: information sharing and additional evidence generation This Joint Action (JA) is a response to the request by the European Commission and EU member states (MS) to • Patrice Chalon, KCE, Belgium continue fostering the development of HTA in Europe. EUnetHTA Information Management System The overarching objective of the JA on HTA including work on relative effectiveness of pharmaceuticals is to put into practice an effective and sustainable HTA Irish Medicines Board collaboration in Europe that brings added value at the European, national and regional level. 2. Early Engagement between Technology Methods: Manufacturers and Assessment Agencies The JA brings together 33 MS government appointed HTA agencies and institutional producers of HTA and Tuesday 14:00 Concert Hall assessments of pharmaceuticals in 23 EU and Norway and a large number of regional agencies. The JA builds upon the methods and tools developed by the EUnetHTA Now that decision-makers in more jurisdictions require Project. evidence on the cost-effectiveness of health technologies prior to reimbursement, manufacturers face increased The JA consists of three interrelated streams of activities. challenges in assembling the appropriate evidence In stream 1 the EUnetHTA Core Model will be expanded package. This is particularly the case for pharmaceutical to cover screening technologies. An online tool will be manufacturers, who already have to meet the stringent developed to facilitate the use of the model. In addition, evidence requirements of drug licensing agencies. It methodological guidance on relative effectiveness is increasingly becoming clear that the clinical trials assessment (REA) of pharmaceuticals will be produced undertaken to satisfy the needs of agencies such as and incorporated into the Core Model. The JA will the FDA and EMEA may not necessarily satisfy the develop a European HTA information management needs of those agencies that issue guidance on the system (IMS) allowing a single point of access to use, or reimbursement of products, such as NICE in compatible EUnetHTA tools and allowing storage and the UK, or the TLV in Sweden. Therefore, whereas exchange of information on planned and ongoing HTAs it has been customary for manufacturers to seek the on new technologies, on additional evidence generation advice of licensing agencies in evidence generation, processes and on concluded assessments. they increasingly feel the need to seek similar advice from reimbursement agencies. Several reimbursement In stream 2 the Core Model will be applied to produce agencies, such as NICE in the UK, now offer advice at least two collaborative HTAs and the methodological through ‘early engagement’ programmes. In Sweden, an guidance on REA will be tested. The IMS will be used to experiment is underway, whereby the licensing agency coordinate at least three collaborative HTAs. (MPA) and reimbursement agency (TLV) offer joint Stream 3 will develop a detailed strategy and business advice. model for sustainable collaboration. This session will discuss the issues raised by this trend. For example: Presentations and Speakers: - in what ways do the evidence requirements of • Finn Børlum Kristensen, EUnetHTA Secretariat, reimbursement agencies differ from those of National Board of Health, Denmark licensing agencies; EUnetHTA Joint Action work plans for 2010-12 - can reimbursement agencies be as defi nite as licensing agencies in the advice that they offer;

20 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA 10

- is there any prospect of reaching more agreement EuroVaQ has been funded by the European Commission on the types of evidence that should be produced to from 2007-2010. It is a collaboration of 28 researchers demonstrate both the clinical and economic value of from 10 European countries, the main aim being to new health technologies? develop more robust methods to determine the monetary value of a QALY based on surveys of the general public Moderator and also to explore the views of the public as to broader

factors that might count in healthcare priority setting (via SESSIONS SPECIAL • Pat O Mahony, Chief Executive, Irish Medicines a newer method called Q methodology). Board It is important that the results of EuroVaQ are Speakers: disseminated to the main practitioners and methodologists in HTA, especially within Europe. • Hans-Georg Eichler, Senior Medical Offi cer, Therefore, in this session, we will present results from European Medicines Agency the main EuroVaQ surveys. Two methods of deriving • Michael Wonder, Director, Global Pricing and Market a societal willingness-to-pay (WTP) based monetary Access Operations, Novartis AG, value of a QALY have been tested. Thus, as well as a project overview to begin, two presentations will follow, • Carole Longson, Director, Centre for Health outlining methods and initial results from each WTP Technology Evaluation, NICE, UK survey. A short presentation on the Q methodology part • Bengt Ljungberg, Scientifi c Director of EuroVaQ will then take place. We propose to have Pharmacotherapy, Swedish Medical Products Agency, a feedback session at the end, led by two members of Switzerland HTAi.

Speakers: • Cam Donaldson, Institute of Health & Society, EuroVaQ Newcastle University • Angela Robinson, Health, Policy and Practice, 3. EuroVaQ (European Value of a QALY): University of East Anglia preliminary results • Mark Pennington, Institute of Health & Society, Newcastle University Tuesday 16:00 Concert Hall • Job van Exel, Institute of Health Policy & Management, Erasmus University, Rotterdam (tbc) A major issue in health economic evaluation is that • Peter Littlejohns, National Institute for Health and of the value to place on a quality adjusted life year Clinical Excellence (QALY), commonly used as a measure of health care • Belen Corbacho, Andalucian Agency for the effectiveness across Europe. This has come to the fore in Evaluation of Health Technologies several European countries, resulting from the creation of national health technology and pharmaceutical assessment agencies. Such agencies were established to make recommendations on technology adoption, addressing issues of affordability and sustainability of 4. New Directions for Health Technology publicly-funded health care systems. Recommendations Assessment in Australia are most often made on the basis of QALYs produced relative to costs incurred. Methods of estimating cost per QALY, based on rigorous decision analytic models, Wednesday 10.00 Concert Hall are now very sophisticated. However, ‘threshold’ values adopted (such as £20-40,000 per QALY above or below which a new therapy will be rejected or recommended In 2009, a Review of Health Technology Assessment in for adoption in England) are essentially arbitrary, with Australia (the HTA Review) was undertaken to identify little or no economic foundation. This critical policy opportunities for reform of HTA processes undertaken issue is refl ected in the growing interest across Europe by Australian Government agencies that may have been in development of more sound methods to elicit such a poorly designed, duplicative or unnecessary, imposed value. unwarranted costs and complexity on business, or discouraged innovation. The HTA Review involved a

21 HTAi 7th ANNUAL MEETING DUBLIN 2010 10 Maximising the Value of HTA

comprehensive public consultation process, including a public submissions process, focus groups and bilateral meetings between key industry and health professional stakeholder groups, and senior government departmental offi cials. Findings were analysed, the report of the HTA Review was released by the Australian

SPECIAL SESSIONS SPECIAL Government in February 2010. The report contained 16 recommendations for change (13 of which are already being implemented), including a call for system-wide reform so that Australian HTA processes follow a set of shared objectives and principles and are part of an open, transparent and integrated system. In this special session, the background, process and fi ndings of the HTA Review will be described, the impacts of the recommended changes will be discussed, and the international implications for the future directions of HTA will be debated. Presenters from the Australian Department of Health responsible for implementing the review; from the Steering Committee of the review and State Health Departments; from industry will provide views on the impact that these reforms will have on health technology assessment in Australia. An international view of the reforms and their applicability internationally will be provided. It is intended that interactive discussion and debate will occur with the audience.

Moderator: • Brendon Kearney, Chair, Health Policy Advisory Committee on Technology in Australia. Clinician/ Manager, Australian Healthcare System

Speakers: • Brian Richards, Executive Manager, Health Technology and Medical Services Group, Australian Department of Health and Ageing. Principal Medical Advisor on Medicare policy, Australian Government • Richard King, Head of Medicine Southern Health, Monash Medical Centre Victoria, Australia • Robyn Chu, Director of Health Outcomes and Market Access, Johnson and Johnson Australia • Tammy Clifford, Chief Scientist, Canadian Agency for Drugs and Technologies in Health

22 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA 11 SCIENTIFIC PROGRAMME OVERVIEW : SUNDAY, 6 JUNE 2010

Scientific Programme Overview : Sunday, 6 June 2010 SUNDAY, 6 JUNE 2010 SUNDAY, Conference Registration 0800-1900

INDUSTRIES CONCERT CLYDE LANSDOWNE DODDER A DODDER B DODDER C DODDER D DODDER E MINERVA MERRION HALL HALL

0900 Registration Workshop 11 Workshop 3 Workshop 4 Workshop 5 Workshop 1 Workshop 6 Speaker HTAi Policy Workshop 2 - Preparation Forum 1100 Room Meeting

1100 - 1115 Coffee Break

1115 Registration Workshop 12 Workshop 3 Workshop 4 Workshop 5 Workshop 1 Workshop 6 Speaker HTAi Policy Workshop 2 - Preparation Forum 1230 Room Meeting

1230 - Lunch 1330

1330 Registration Workshop 12 Workshop 7 Workshop 10 Workshop 9 Workshop 1 Workshop 8 Speaker / Euroscan Workshop 2 - Secretariat Meeting 1530 Room

1530 - 1545 Coffee Break

1545 Registration Workshop 12 Workshop 7 Workshop 10 Workshop 9 Workshop 1 Workshop 8 Speaker Euroscan Workshop 2 - Preparation Meeting 1700 *finishes Room 17.15

Networking 1715 Registration GlaxoSmithKline Pfizer Session 1 - Satellite Satellite Int. 1845 Symposium 1 Symposium 2 Collaboration in the Mercosul

1900 - Welcome Reception in Concert Hall 2100

23 HTAi 7th ANNUAL MEETING DUBLIN 2010 11 Maximising the Value of HTA

Information in this programme is correct at time of going to press. Any changes will be notifi ed to individual presenters as soon as possible. Delegates should check the conference notice boards for updated information during the event.

SUNDAY, 6 JUNE

08:00 – 19:00 Registration Appraisal of Cost-Effectiveness Models Submitted to Reimbursement Agencies: Steve Palmer, Gavin

SUNDAY, 6 JUNE 2010 SUNDAY, Lewis, Karen Lee, Silva Zavarsek, Helen Chung, 09:00 – 17:00 Full Day Workshops James Raftery 8. HTA 101: Introduction to Health Technology Assessment: Clifford Goodman 1. Introduction to Ethics in Health Technology Assessment: INAHTA/HTAi Ethics Interest Sub 9. Methods of Meta-Analysis: Synthesis and Appraisal Group: Wija J. Oortwijn, Lorraine Caron, Tanja of Empirical Evidence: Neil Hawkins, Olivia Wu Krones, Dario Sacchini, Gert Jan van der Wilt, 10. Systematic Review of Qualitative Research: Samuli Saarni, Ilona Autti-Rämö, Annette Braunack- An Introduction to Analysing and Synthesising Mayer, Bjørn Hofmann Qualitative Research Findings: Ruth Garside, Mark 2. Optimizing Information Retrieval Methods for Pearson HTA - Towards Best Practice: Sari Ormstad, Carol Lefebvre, Julie Glanville, Shaila Mensinkai, David Kaunelis, Catherine Voutier 15:30 – 15:45 COFFEE BREAK

09:00 – 12:30 Morning Workshops 09:00 – 17:45 WHO Workshops

3. Introduction to Bayesian Methods for Health 09:00 – 10:30 Technology Assessments: Nicky Welton, Jaime Peters, Cathal Walsh 4. Maximising the Value of HTA – Closing the Loop 11. The Global Network of WHO Collaborating Centres of the Life Cycle of Technologies. Disinvestment or for HTA Annual Meeting: Janet Hatcher Roberts, Withdrawal of Technologies of Low Added Value: Peter Tugwell, Maria Benkhalti, Reiner Banken Alberto Ruano Raviña, Nora Ibargoyen Roteta, Adam Elshaug, Iñaki Gutiérrez-Ibarluzea, Sarah Gardner 11:00 – 17:15 5. Maximising the Value of HTA – the Contribution of Early Awareness and Alert Systems: EuroScan International Network: Claire Packer, Setefi lla 12. The initiation and development of HTA in developing Luengo, Linda Mundy, Sue Simpson, Brendon countries: Laura Sampietro-Colom, Adriana Kearney Velazquez, Joseph Mathew, Janet Hatcher Roberts, 6. Introduction to Economic Evaluation in Healthcare: Maria Benkhalti, Andres Pichon Riviere, Paulo Lesley Tilson, Roisin Adams, Susan Griffi n, Michael Picon, T. Lazar Mathew, Jeremy Lim, Janet Hiller Barry

17:15 – 18:45 Satellite Symposium 1 - 11:00 – 11:15 COFFEE BREAK GlaxoSmithKline: Clyde Real life studies & effi ciency measurement: Which 12:30 – 13:30 LUNCH method? Which criteria? Mike Drummond, Adrian Towse, 13:30 – 17:00 Afternoon Workshops Carole Longson, Lise Rochaix, Finn Borlum Kristensen 7. Exploring Alternative Approaches to ‘Model Busting’: Methods and Experience in the Critical

24 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA 11

Satellite Symposium 2 - Pfi zer: Lansdowne SUNDAY, 6 JUNE 2010 SUNDAY, Harnessing Innovative Approaches to Improving Health Amidst Economic Constraints Wim Groot, Mike Kelly, Deborah Schofi eld

17:15 - 18:45 Networking Session 1: Dodder B

1. International collaboration in the Mercosul region: strengthening HTA in South America Chair: Alexandre Lemgruber 1.1 HTA project results in MERCOSUL Alexandre Lemgruber Brazilian Health Surveillance Agency - Anvisa, Brasilia, Distrito Federal, Brazil 1.2 HTA subcomission IN MERCOSUL: Precedents and context Pedro Galvan Ministry Of Health Of Paraguay, Asunción, Paraguay 1.3 HTA State of Art diagnose in the MERCOSUL countries Ana Perez Ministry Of Health Of Uruguay, Montevideo, Uruguay 1.4 Capacity Building: Experiences and Challenges Flavia Elias Ministry Of Health Of Brazil, Brasilia, Distrito Federal, Brazil 1.5 HTA institutionalization and methodology: MERCOSUL countries experience Victoria Wurcel Ministry Of Health Of Argentina, Ciudad Autónoma De Buenos Aires, Argentina 1.6 Debate: Challenges in structuring cross-sectorial network for HTA development and dissemination in local and regional level Alexandre Lemgruber Brazilian Health Surveillance Agency - Anvisa, Brasilia, Distrito Federal, Brazil

19:00 – 21:00 Welcome Reception – Concert Hall

25 HTAi 7th ANNUAL MEETING DUBLIN 2010 11 Maximising the Value of HTA SUNDAY, 6 JUNE, 2010 PRE-CONFERENCE WORKSHOPS

FULL DAY WORKSHOPS 09:00 - 1700 - In situations with poor evidence how do ethical issues Workshops are open to non-HTAi members and infl uence decisions?

SUNDAY, 6 JUNE 2010 SUNDAY, those not attending the Annual Meeting. - What is the role of empirical fi ndings in ethical Pre-registration is a requirement for all workshops. analysis? WHO Workshops are free of charge. Attendees will receive copies of all course materials.

This workshop will be led and facilitated by the WS-1 INAHTA/HTAi Ethics Interest Sub Group. Faculty Introduction to Ethics in Health Technology members are: Assessment • Wija J. Oortwijn, Macro & Sector Policies, ECORYS, Netherlands Sunday 09:00 Dodder C • Lorraine Caron, Agence d’évaluation des technologies et des modes d’intervention en santé This is an introductory basic skills course. (AETMIS), Quebec, Canada This course offers a lively introduction to the role of • Tanja Krones, Clinical Ethics, Zurich University ethics in Health Technology Assessment (HTA) for those Hospital, Switzerland who are familiar with HTA, but who are not that familiar with ethics in HTA. Most importantly it provides a • Dario Sacchini, Institute of Bioethics, “A. Gemelli” number of approaches for ‘how to’ incorporate an ethical School of Medicine, Catholic University, Rome, Italy analysis into an HTA. • Gert Jan van der Wilt, University Medical Center St The course has been specifi cally developed for Radboud, Netherlands international participants and is based on recent • Samuli Saarni, National Public Health Institute, international achievements in the fi eld. It will Helsinki, Finland emphasize adapting approaches in ethics for all types of health technologies and across international settings. • Ilona Autti-Rämö, The Social Insurance Institution of Participants who attend this course will strengthen their Finland understanding and facilitate their participation in ethical • Annette Braunack-Mayer, School of Population assessment in HTA, as well as be able to participation in Health and Clinical Practice, The University of broader discussions. Adelaide, Australia This 1-day introductory course in Ethics in HTA • Bjørn Hofmann, Norwegian Knowledge Center for combines lectures, discussions and case study group the Health Services, Norway work. The Faculty who are leading this course is a group of international experts who have contributed substantially over the last several years to the WS-2 methodological development in this area. Optimizing Information Retrieval Methods for Key topics are: HTA – Towards Best Practice - Why is ethics part of HTA? What is its role and place? Sunday 09:00 Merrion - What is the relationship between technology and values? The full-day pre-conference workshop organized by - What are the basic approaches in ethics? the HTAi Information Resources Group will focus on - What are the relationships between ethical, social, systematic methods to identify studies for HTAs and economic and legal aspects? other evidence syntheses. Information retrieval for HTAs needs to be comprehensive in order to identify those - Practical approaches for ethics in HTA studies which will provide a reliable result, whilst being - What is the role of ethical analysis in the policy as effi cient as possible to avoid unnecessary expenditure decision-making process? of time and other resources.

26 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA 11

Over time various organisations have developed policies MORNING SESSIONS with respect to information retrieval and whilst there are many similarities there are also some variations across 09:00 - 12:30 organisations with respect to policy and practice. The morning session will involve presentations outlining policy and practice of the Cochrane Collaboration, WS-3 CADTH and the Norwegian Knowledge Centre for the Introduction to Bayesian Methods for Health Health Services, focusing on key issues of information Technology Assessments 6 JUNE 2010 SUNDAY, retrieval such as which sources to search, limits to searches, updating searches and reporting the search Sunday 09:00 Lansdowne process and the search strategies. These presentations will be interspersed with audience participation, refl ecting on and comparing the presentations and adding Participants may also be interested in the workshop on experience from their own organisations. Evidence Synthesis. The fi rst afternoon session will be devoted to searching Bayesian inference is a framework which allows trials registers. Trials registers, results registers and other evidence from multiple sources including expert opinion, research registers are developing quickly and provide randomised controlled trials and observational studies to challenges in terms of identifi cation, effi cient searching be combined in a formal fashion. The use of Bayesian and record management. This session will involve modelling has grown exponentially in the past decade presentations accompanied by group discussion of and a large number of Health Technology Assessments several key trials registers, and will focus on the scope of now employ these methods. the resources and approaches to structuring searches. In this workshop we introduce the Bayesian framework Health Technology Assessment agencies assessing the of inference, an overview of the decision theoretic cost-effectiveness of health care technologies need access framework will be presented, drawing on examples from to evidence from economic evaluations to identify what actual HTAs. is known about the cost-effectiveness of a technology Methods used to combine information from multiple and to fi nd information to inform models. Effi cient sources will be described, and how these can be methods to identify economic evidence will enhance the implemented in available software will be demonstrated. effi cient production and robustness of HTAs. The fi nal session will include a presentation on key economic Results from a study examining a reanalysis of existing resources and methods of searching them followed by HTAs using a Bayesian framework will also be a structured group discussion of the relative value of discussed. the key resources, additional key resources and search The workshop will be delivered by researchers approaches adopted by different teams. experienced in the use of Bayesian statistical methods who have been involved in cost effectiveness analysis This workshop will be led and facilitated by: and health technology assessment in the UK and Ireland. • Sari Ormstad, Norwegian Knowledge Center for the Health Services, Norway This workshop will be led and facilitated by: • Carol Lefebvre, UK Cochrane Centre, UK • Nicky Welton, University of Bristol, England • Julie Glanville, York Health Economics Consortium, • Jaime Peters, Peninsula Medical School, England University of York, UK • Cathal Walsh, Trinity College, Dublin, Ireland • Shaila Mensinkai, Canadian Agency for Drugs and Technologies in Health, Canada • David Kaunelis, Canadian Agency for Drugs and Technologies in Health, Canada • Catherine Voutier, Centre for Clinical Effectiveness, Australia

27 HTAi 7th ANNUAL MEETING DUBLIN 2010 11 Maximising the Value of HTA

4. Assessment WS-4 Maximising the Value of HTA – closing the loop 5. Dissemination of the life cycle of technologies. Disinvestment or withdrawal of technologies of low added This workshop will be led and facilitated by: value • Alberto Ruano Raviña, Galician agency for HTA, Avalia-T. University of Santiago de Compostela, SUNDAY, 6 JUNE 2010 SUNDAY, Sunday 09:00 Dodder A Galicia, Spain • Nora Ibargoyen Roteta, Osteba, Basque Offi ce for Health services providers and organisations have to take HTA, Basque Country. decisions on the services that are going to be introduced • Adam Elshaug, University of Adelaide, Adelaide, into the Health System, establishing at the same time Australia the limits on their funding. Bearing in mind the scarce resources in relation to the needs shortfall of the Health • Iñaki Gutiérrez-Ibarluzea, Osteba, Basque Offi ce for System, the use of a resource for specifi c conditions HTA, Basque Country prevents the same resource from being used in a different • Sarah Gardner, NICE, United Kingdom condition where it could produce equal or higher benefi ts (cost-opportunity), and unfortunately, more often than would be desirable, some health resources are invested in technologies that are not the most suitable for a given WS-5 purpose or represent a “technical” improvement in existing Maximising the Value of HTA – the Contribution technologies at a price that does not justify its acquisition, of Early Awareness and Alert Systems making it diffi cult to comply with Health Care objectives. Sometimes, the investment may not respond to priority Sunday 09:00 Dodder B needs or may involve technologies that are too complex and incompatible with existing infrastructures and Early awareness and alert systems (EAAS) also known services or require excessively expensive maintenance. as horizon scanning or early warning systems have been This, together with the irrational or inappropriate use, the implemented in many countries to aid decision making shortage of health professionals and their lack of training and to plan for the impact of new and emerging health may also lead to a wasteful use of resources, an overall technologies on health care systems. In 2009, EuroScan squandering of health services and the loss of funds - International Network launched a toolkit for the required acquiring other essential items for Health Care. identifi cation and assessment of such technologies. Recently, different agencies have promoted research in the All member agencies of EuroScan contributed fi eld of disinvestment of health technologies of low added to the toolkit to ensure that different health care value and have elaborated guidelines to aid in the process systems, contexts and methods were represented. The of delisting technologies. The workshop will present the collaborative approach resulted in a document covering methodological guidelines, experiences and the software all aspects of EAA processes as well as presenting key developed to structure the process of delisting technologies questions and offering possible solutions. The toolkit in the health care systems. At each stage practical was constructed on the basis of “one size doesn’t fi t all”, examples from agencies that have established the process utilising the heterogeneity of its members. will be presented. In addition, there will be two interactive exercises focusing on fi ltration/prioritisation of obsolete The workshop will present the toolkit and the key stages technologies and assessment of prioritised low added involved in EAA systems: value technologies. The workshop will conclude with a • Establishing an EAA system – determining needs of session on the contribution of disinvestment processes to the customer HTA. • Identifi cation of new and emerging health technologies – sources and collaboration Topics: • Filtration and prioritisation of new and emerging 1. Main issues when delisting technologies of low health technologies – developing criteria added value • Assessment and prediction of impact – information 2. Identifi cation of low added value technologies needs and the dilemma’s of early information 3. Filtration and prioritization of low added value • Dissemination – approaches used by EuroScan technologies members

28 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA 11

Practical examples from EuroScan member agencies Pharmacoeconomics in Ireland and the University of will be presented and published research on methods York in the UK. We will also include practical exercises, and recent developments drawn upon. There will be using real world examples, during the workshop. interactive exercises focusing on the fi ltration and prioritisation of important technologies, and early This workshop will be facilitated by: assessment. The workshop will conclude with a panel led discussion session on the contribution of EAASs to HTA. • Lesley Tilson, National Centre for All participants will receive a copy of the EuroScan Pharmacoeconomics, St James’s Hospital, Dublin, 6 JUNE 2010 SUNDAY, toolkit. Ireland (Workshop Leader) • Roisin Adams, National Centre for The workshop will be led and facilitated by: Pharmacoeconomics, St James’s Hospital, Dublin, Ireland • Claire Packer, National Horizon Scanning Centre, England • Susan Griffi n, Centre for Health Economics, University of York, UK • Setefi lla Luengo, AETS, Madrid, Spain • Michael Barry, National Centre for • Linda Mundy, AHTA, Adelaide, Australia Pharmacoeconomics, St James’s Hospital, Dublin, • Roberta Joppi, Italian Horizon Scanning Project, Ireland Verona, Italy • Sue Simpson, EuroScan Network Co-ordinator • Brendon Kearney, HPACT, Australia AFTERNOON SESSIONS 13:30 - 17:00 WS-6 Introduction to Economic Evaluation in Healthcare WS-7 Exploring Alternative Approaches to ‘Model Sunday 09:00 Dodder D Busting’: Methods and Experience in the Critical Appraisal of Cost Effectiveness Models This course is suitable for those with little or no Submitted to Reimbursement Agencies experience with economic evaluation. Sunday 13:30 Lansdowne This introductory workshop is designed to teach healthcare practitioners, new researchers, policy makers, industry representatives and other stakeholders the key The use of decision-analytic modelling is increasingly issues in the methodology and practice of economic considered central to the process of HTA generally, evaluation in healthcare. Participants will learn about the and it plays a key role in informing decisions on the basic aspects of conducting economic evaluations, such reimbursement of health technologies. It is now common as the different types of economic evaluations (e.g. cost that a decision model forms the core of the evidence effectiveness and cost utility analysis), costing methods, submissions to reimbursement agencies, serving to valuation of health outcomes, sensitivity analysis and synthesise data from a range of sources and facilitating decision analytic modelling approaches. There will transparency of decision making. The increased be a session on how the QALY is calculated and the emphasis on the decision model as the main vehicle of implications of using differing methods. We will also assessment has led to the development of a number of discuss some of the debate surrounding the use of the ‘good practice’ modelling guidelines and checklists both QALY. from individual reimbursement agencies and academic groups. Nevertheless, as decision models become ever Given the growing requirement for costeffectiveness more complex and sophisticated, the methods of critical data by healthcare decisionmakers, there will be a appraisal commonly need to be extended to consider discussion of requirements and the perspectives of the electronic model itself. The extension of the tasks of decisionmakers. The impact of economic evaluation on critical appraisal brings with a need to consider alternative decision-making in different countries will be addressed. approaches to ‘model busting’ and to learn from existing The lectures will be delivered by those experienced experience in undertaking these tasks. in conducting economic evaluations of drugs and healthcare interventions from the National Centre for The purpose of this workshop is to explore current

29 HTAi 7th ANNUAL MEETING DUBLIN 2010 11 Maximising the Value of HTA

methods and experience of critical appraisal and ‘model • Secondary/synthetic methods busting’ approaches from alternative perspectives (agency, • Economic analyses: CEA, QALYs, and more academic and industry) with speakers with extensive experience of working with a range of international 6) Interpreting strength of evidence reimbursement agencies (including PBAC, CADTH, 7) Priority setting, timing of assessment, and the moving NICE etc). target problem

SUNDAY, 6 JUNE 2010 SUNDAY, This workshop will be led and facilitated by: 8) A framework for conducting HTA • Steve Palmer, Centre for Health Economics, 9) Sources of evidence and expertise University of York, UK (Workshop Leader) • Bibliographic databases (peer-reviewed and gray • Gavin Lewis, Roche, UK literature) • Karen Lee, CADTH, Canada • International networks/cooperation • Silva Zavarsek, Monash University, Australia 10) Current HTA trends and emerging challenges • Helen Chung, NICE, UK • Emerging role of comparative effectiveness research • James Raftery, University of Southampton, UK • Pharmacogenomics, personalized medicine, and more WS-8 This workshop will be led and facilitated by: HTA 101: Introduction to Health Technology Assessment Clifford Goodman, Vice President The Lewin Group

Sunday 13:30 Dodder D WS-9 This course offers a lively introduction to HTA for those Methods of Meta Analysis: Synthesis and who are new to the fi eld, as well as for those who seek a Appraisal of Empirical Evidence refresher course. Developed for international participants and updated annually, this course has been a popular Sunday 13:30 Dodder B feature of HTA meetings for more than 10 years. This pre-conference workshop will strengthen understanding Meta-analysis of evidence identifi ed through a and participation in other sessions of HTAi 2010. Time systematic review is an integral part of health technology is included for questions and discussion. Attendees will assessment. In order to achieve an accurate estimate of receive copies of the workshop materials. This course average treatment effect for the purpose of determining will emphasize adapting HTA approaches for all types of clinical effectiveness or to inform economic models health technologies and across international settings. for evaluating cost effectiveness, the use of appropriate statistical methods is critical. The main topics to be covered include: 1) HTA defi nitions, purposes, and roles in health care This workshop will explore the principles and policy practice of: 2) Health technology: types, applications, lifecycle 1) Meta-analysis of data from clinical trials and 3) Factors affecting technology overuse, underuse observational studies including: 4) Properties and impacts assessed in HTA • methods of combining multiple study estimates for a variety of measures of treatment effect; • Technical performance • exploring and dealing with heterogeneity between • Health outcomes studies (choice of fi xed or random effects models, • Quality of life and functional status meta-regression and subgroup analyses); • Economic • identifying and adjusting for publication bias; and 5) HTA methods and trends • the reporting of results. • Primary methods 2) Meta-analysis of individual patient data, a

30 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA 11

methodology used to pool data of individual patients, This 3½ hour workshop aims to introduce those with instead of aggregated from different studies. little or no experience of qualitative research to methods of analysis and synthesis of qualitative research. It 3) Network meta-analysis, a developing methodology will focus on how to understand a qualitative research used to go beyond pairwise comparisons in report; identifying and categorising the fi ndings; comparing multiple treatment options. These methods and their analysis and synthesis using frameworks allow the combination of complex networks of trial or meta-ethnography. Presentations will illustrate

evidence in a single statistical analysis. 6 JUNE 2010 SUNDAY, and demonstrate these issues but the majority of the Meta-analysis is a key component in health technology workshop will involve individuals and small groups assessment and a complex area of active research. working through the steps of a synthesis. Therefore, a fi rm understanding of the basic principles 1) Why qualitative research? Ruth Garside (Why use and the emerging methodologies of this discipline of qualitative research? What can it offer? Why review statistical analysis is essential to those who are active in and synthesise?) assessing health technologies. In addition, this workshop complements the existing basic skills workshops, and in 2) What’s this paper about? Mark Pearson (Identifying particular, provides a natural progression for participants aims, methods, infl uences and theories in qualitative who attended courses on ‘economic evaluations’ and papers) ‘systematic reviews’. 3) Identifying the fi ndings in qualitative research reports. Mark Pearson. (Identifying and categorising Presentations: types of fi ndings in a qualitative paper, data vs. • Meta-analysis methodology, Olivia Wu fi ndings, 1st order & 2nd order concepts.) • Meta-analysis of individual patient data, Neil 4) Analysis and synthesis of qualitative research Hawkins fi ndings. Ruth Garside (Mechanisms of analysis and synthesis based on types of fi ndings in papers, • Network meta-analysis, Neil Hawkins examples of framework analysis and meta- • Some further practical examples, Olivia Wu ethnography)

This workshop will be led and facilitated by: This workshop will be led and facilitated by: • Neil Hawkins, Director, Oxford Outcomes Ltd, • Ruth Garside, Senior Research Fellow, PenTAG, Oxford, UK Peninsula Medical School, University of Exeter. • Olivia Wu, Reader in Health Economics, University • Mark Pearson, Research Fellow, PenTAG, Peninsula of Glasgow, UK. Medical School, University of Exeter.

WS-10 Systematic Review of Qualitative Research: An Introduction to Analysing and Synthesising Qualitative Research Findings

Sunday 13:30 Dodder A

There is increasing interest in broadening the evidence base in systematic reviews to address not just the “does it work?” questions well served by RCTs, but also “how does it work?”, “why?” and “will it work around here?” This may be particularly the case where, for example, the focus is on complex interventions; understanding facilitators and inhibitors of success is vital; or where patient or health professional understandings are sought. Qualitative research may be particularly well placed to address such questions, and several approaches to synthesising fi ndings across more than one study have been developed.

31 HTAi 7th ANNUAL MEETING DUBLIN 2010 11 Maximising the Value of HTA SUNDAY, 6 JUNE, 2010 PRE-CONFERENCE WHO WORKSHOPS

MORNING AND AFTERNOON SESSIONS 09:00 – 17:45

WS-11 WS-12

SUNDAY, 6 JUNE 2010 SUNDAY, The Global Network of WHO Collaborating HTA in Developing Countries: where are we and Centres for HTA Annual Meeting where do we go?

Sunday 09:00 – 10:30 Clyde Sunday 11:00 – 17:15 Clyde

The Global Network of WHO Collaborating Centres The initiation and development of HTA in developing (WHOCC) for HTA was launched during HTAi 2009 countries is challenged by numerous factors, among in Singapore and its current secretariat is the WHOCC which include lack of awareness among stakeholders, for Knowledge Translation and HTA in Health Equity resource constrains, existing decision-making based at the Centre for Global Health at the University of systems and resistance to change; are contributory. Ottawa. The Network aims to link WHOCCs and others Recognizing these challenges, individuals, institutions across the world involved directly or indirectly in HTA and organizations have been working together to work to promote dialogue and collaboration and to strengthen with or around them. The World Health Organization, existing projects. We also aim to work in synergy with especially through its Collaborating Centres (WHO CCs) other HTA organizations and individuals in order to has been making progress in this direction over the past galvanize the HTA community as a whole. The workshop few years. HTAi, in particular through the Interest Sub is intended as the annual meeting of the Global Network Group on Developing Countries (HTAi DC ISG) has of WHO Collaborating Centres for HTA. This meeting is been active in this fi eld for a considerable period of time. geared for members of the network as well as potential It is but natural for the two organizations to join hands members, which could be not only Collaborating in the common aim of supporting HTA in developing Centres but also other HTA organizations or individuals countries. interested in HTA. Discussions will be led by organizers Janet Hatcher Roberts, co-director, with Peter Tugwell, This workshop is jointly organized by the WHO, WHO of the WHOCC for Knowledge Translation and HTA CCs and HTAi DC ISG. It includes presentations on the in Health Equity and Maria Benkhalti, coordinator of current status of HTA in developing countries across the WHOCC and secretariat of the Network. The focus the continents and regions. The WHO Collaborating will be on reporting on last year’s activities, upcoming centres will project their presence in these countries planned activities and in depth discussions on how the and summarize the work done so far. The HTAi DC secretariat and the network overall can meet the needs ISG will highlight unique challenges to HTA from the of its members and to strengthen HTA in their respective perspective of developing countries. The background contexts. Other invited speakers and participants include presentations on “current status” will be followed by case World Health Organization coordinator of Diagnostic studies of how some countries across three continents Imaging and Medical Devices and Essential Health have managed to overcome the challenges and initiated Technologies, Adriana Velazquez and advisor to the HTA activities, addressing the unique problems relevant Network, Reiner Banken. to the local health-care setting. This will be followed by a brain-storming session among the WHO, WHO CCs, This workshop will be led and facilitated by: HTAi and participants to determine how each willing stakeholder can help towards the overall goal of fostering • Janet Hatcher Roberts, WHOCC co-director a culture of evidence-informed decision-making in (Moderator) developing countries. • Peter Tugwell, WHOCC for Knowledge Translation An added highlight of the workshop will be the and HTA in Health Equity presentation of brief but concrete, feasible action plans • Maria Benkhalti, WHOCC coordinator and (on behalf of WHO, HTAi and developed country secretariat of the Network partners) to be undertaken within the subsequent 12 months, to achieve the overall goal. • Adriana Velazquez, WHO coordinator of Diagnostic Imaging and Medical Devices and Essential Health Thus this workshop will benefi t all interested individuals, Technologies institutions and organizations- sharing the common goal of enhancing health-care systems in developing • Reiner Banken, advisor to the Network countries, through appropriate HTA.

32 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA 11

This workshop will be led and facilitated by amongst others: • Laura Sampietro-Colom, MD PhD, HTAi President. Deputy Director for Innovation at the Hospital Clinic, Barcelona (Moderator) • Adriana Velazquez, WHO coordinator of Diagnostic Imaging and Medical Devices and Essential Health 6 JUNE 2010 SUNDAY, Technologies • Dr Joseph Mathew, Chair, HTAi Interest Sub-Group on HTA in Developing Countries • Jan Hatcher Roberts, WHOCC co-director

33 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

PROGRAMME OVERVIEW - MONDAY

Scientific Programme Overview : Monday, 7 June 2010

Conference Registration 0730-1900

11 0900 - Opening & Plenary 1 1100 Maximising the Value of HTA to Decision-makers (Chair Michael Barry) Concert Hall

1100 - 1130 Coffee Break & Poster Session 1

INDUSTRIES SERPENTINE CONCERT CLYDE LANSDOWNE DODDER A DODDER B DODDER C DODDER D DODDER E MINERVA MERRION HALL HALL HALL

1130 Registration Poster Panel 1 Panel 2 Panel 6 Panel 5 Speaker Panel 3 Panel 4 - & Session 1 Preparation 1300 Poster Session Room 1

1300 MONDAY, 7 JUNE 2010 MONDAY, - Lunch 1430

Networking 1300 Registration Poster Sanofi Aventis Lilly Session 2 Coverage with Hospital Ethics ISG Patient /Citizen Speaker - & Session 1 Satellite Satellite Efficiency & Evidence Based HTA Involvement Preparation 1430 Poster Session Symposium Symposium role of HTA Development ISG in HTA ISG Room 1 3 4 Agencies ISG

Policy & 1430 Registration Poster EUnetHTA Practice Oral Oral Oral Oral Oral Speaker - & Session 1 Special Interactive Presentation Presentation Presentation Presentation Presentation Preparation 1600 Poster Session Session 1 Session 1 1 2 3 4 5 Room 1

1600 - 1630 Coffee Break & Poster Session 1

1630 Registration Poster Panel 7 Panel 8 Panel 12 Panel 11 Panel 13Speaker Panel 9 Panel 10 - & Session 1 Preparation 1800 Poster Session Room 1

1800 - HTAi Business Meeting in Clyde Room 1900

1900 - 2030 VIP Sponsor’s Reception in President’s Room

34 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

MONDAY PLENARY SESSION the adoption of all non-drug health technologies. Dr. Levin initiated the Cancer Care Ontario evidence SPEAKERS based cancer guidelines initiative and was instrumental in creating an evidence–based provincial cancer drug Chair: Michael Barry program. He has published in evidence based analysis, and cancer research. Dr. Levin is a Professor in the Department of Medicine, University of Toronto and is a senior consultant in 11 medical oncology at the Princess Margaret Hospital. He is a member of the HTA Council of ISPOR and the Medical Advisory Panel of Blue Cross Blue Shield (U.S.A.).

Michael Scanlan

Dr Barry is Medical Director of the National Centre for Pharmacoeconomics, Consultant Pharmacologist at St James’s Hospital and a Senior Lecturer in Trinity College Dublin. He is also a former Board member of the Health 7 JUNE 2010 MONDAY, Information and Quality Authority. Research areas of interest include economic evaluation, health technology assessment as well as pricing and reimbursement strategies. Dr. Barry has published widely on the costeffectiveness of medicines in the Irish healthcare setting. He was co-chair of the ISPOR 10th Annual European Congress in Dublin 2007. He is President of Secretary General of the Department of Health and ISPOR 2009-2010. Children. Michael Scanlan was appointed Secretary General of the Department of Health and Children in April 2005. Les Levin He was educated in Templeogue College and joined the civil service as an Executive Offi cer in 1973. He has spent most of his career in the former Department of the Public Service and in the Department of Finance. He was Secretary to the “Gleeson” and “Buckley” Review Bodies on public sector remuneration. Later he dealt with overall public service pay policy including pay policy within the health sector. Michael was promoted to Assistant Secretary in December 2000. He was responsible for overall public expenditure policy, the expenditure aspects of the Sustaining Progress social partnership agreement and Government’s decentralisation programme. Dr. Les Levin is the Senior Medical, and Health As an Assistant Secretary, Michael was also responsible Technology Advisor to the Ministry of Health and for public expenditure policy within the health sector Long-Term Care [MOHLTC] and Head of the Medical and worked closely with the Department of Health Advisory Secretariat [MAS] which provides evidentiary and Children on the health sector structural reform platforms for policy decision making. Dr. Levin works programme, including the establishment of the Health closely with the leadership of Academic Health Science Service Executive, and on a number of major health Centres, academia, and industry. He was instrumental policy issues. in creating the Ontario Health Technology Advisory Committee (OHTAC) which advises the MOHLTC on

35 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

Sean Tunis Karen Facey

11

Sean Tunis, MD, MSc. is the Director for the Center Karen Facey is a Chartered Statistician, Honorary for Medical Technology Policy (CMTP) in Baltimore, Member of the Faculty of Public Health, Fellow of Maryland, USA. CMTP is an independent non-profi t the Royal Society of Medicine and Honorary Senior (non-governmental organisation) that convenes health Research Fellow at the University of Glasgow. Karen has care stakeholders to collaborate on comparative worked in senior statistical roles in the pharmaceutical effectiveness research, with a focus on priority setting, industry and the UK government agency responsible methods development, protocol design, and study for regulating pharmaceuticals. In 2000, Karen became MONDAY, 7 JUNE 2010 MONDAY, implementation. The Center also advises numerous Chief Executive of the Health Technology Board for public and private organisations on medical technology Scotland (HTBS), responsible for providing authoritative policy, evidence based medicine and health technology advice on the clinical and cost effectiveness of health assessment. interventions to the National Health Service in Scotland (NHS Scotland). Since October 2003, Karen has Through September of 2005, Dr. Tunis was the been consulting on all matters related to international Chief Medical Offi cer at the Centers for Medicare evidence-based assessment of health interventions. and Medicaid Services (CMS), where he had lead Karen is a Non Executive Member of her local health responsibility for clinical policy for the Medicare and board (provider/payer for 300,000 people). She chaired Medicaid programs. Previously he served as the Director a Scottish Government committee that created the new of the Health Program at the Congressional Offi ce of funding formula for NHS Scotland that was implemented Technology Assessment and as a health policy advisor to last year. She is a member of the UK Committee on the U.S. Senate, where he worked on pharmaceutical and Safety of Devices and on the editorial boards of IJTAHC device policy issues. and The Patient. Karen is the past chair of the HTAi Dr. Tunis trained at the University of California in Los Policy Forum and the chair of the HTAi Interest Group Angeles and the University of Maryland in Internal for Patient/Citizen involvement in HTA. Medicine and Emergency Medicine, and holds adjunct faculty positions at the Center for Health Policy at Stanford University and the Department of Internal Medicine at the Johns Hopkins School of Medicine.

36 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

MONDAY, 7 JUNE

07:30 – 19:00 REGISTRATION

09:00 – 09:30 CONFERENCE OPENING

Mary Harney TD, Minister for Health and Children Department of Health and Children 11 09:30 – 11:00 PLENARY SESSION 1 Concert Hall

PL1 Maximising the value of HTA to decision makers Chair: Michael Barry National Centre for Pharmacoeconomics, Ireland PL1-1 Engaging government and hospital stakeholders in the Ontario HTA programme Les Levin Ministry of Health and Long Term Care, Ontario, Canada PL1-2 HTA – A view from the Department of Health and Children Michael Scanlan

Secretary General, Department of Health and Children, Ireland 7 JUNE 2010 MONDAY, PL1-3 Strategies for engaging decision makers in comparative effectiveness research Sean Tunis Centre for Medical Technology Policy, Baltimore, MD, US PL1-4 A Policy Forum perspective on maximizing the value of HTA in decision making Karen Facey HTAi Policy Forum Past Chair

11:00 – 11:30 COFFEE BREAK & POSTERS

11:30 – 13:00 PANEL SESSIONS 1-6

PP-1 Monday 11.30 Clyde

Closing the Loop: HTA, Evidence Gaps, and Recommendations for New Research 1.1 Mind the (Evidence) Gap: Why HTA is Not Enough Steven Pearson Institute for Clinical and Economic Review, Boston, MA, US & Harvard Medical School, Boston, MA, US 1.2 Engaging stakeholders in prioritizing research recommendations Sean Tunis Centre for Medical Technology Policy, Baltimore, MD, US 1.3 Identifying important research gaps, the role of HTA and decision makers Jean Slutsky Agency for Healthcare Research and Quality, Washington, DC, US 1.4 Linking HTA to Future Research: The UK Experience Susan Griffi n University of York , UK

37 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

PP-2 Monday 11.30 Lansdowne

Real world experience with access with evidence development (AED): Learning from partial successes 2.1 Access to Disease Modifying Therapies – the Multiple Sclerosis Risk-sharing scheme in the United Kingdom 11 Cindy Cooper University of Sheffi eld, UK 2.2 Challenges in estimating real-world (cost-)effectiveness to satisfy the Outcomes Research requirement of the Dutch conditional reimbursement policy for expensive inpatient medicines Margreet Franken Erasmus University, Rotterdam, Netherlands 2.3 Public and private sector efforts to implement coverage with evidence development (CED) in the United States Raj Sabharwal Centre for Medical Technology Policy, Baltimore, MD, US

MONDAY, 7 JUNE 2010 MONDAY, 2.4 Highlights from the 2009 Banff Summit on AED Christopher McCabe University of Leeds, UK

PP-3 Monday 11.30 Minerva

Demand forecasting and early modelling in medical technology development - from theory to maximised value of HTA in practice 3.1 Maarten IJzerman University of Twente, Enschede, Netherlands 3.2 Mark Sculpher University of York, UK 3.3 Jan Pietzsch Stanford University, US & Wing Tech Inc., Menlo Park, US 3.4 Lotte Steuten University of Twente, Enschede, Netherlands & Care Innovations Research and Consultancy, Maastricht, Netherlands Centre for Medical Technology Policy, Baltimore, MD, US

38 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

PP-4 Monday 11.30 Merrion

HTA to optimize health technology utilization - Perspectives on discussions held at the HTAi Policy Forum Meeting 2009 4.1 Using implementation initiatives and monitoring processes in optimizing health technology utilization Katrine Frønsdal 11 Norwegian Knowledge Centre for the Health Services (NOKC) Oslo, Norway 4.2 Use of registries to optimize health technology utilization – the Kaiser Permanente joint replacement registry Liz Paxton Southern California Permanente Medical Group (SCPMG), San Diego, CA, US 4.3 Optimizing health technology utilization – tailoring outputs to meet the needs of different decision makers Carole Longson National Institute for Health and Clinical Excellence (NICE), London, UK 4.4 Optimal technology use in complex health care systems Clare McGrath 7 JUNE 2010 MONDAY, Pfi zer, Tadworth, UK

PP-5 Monday 11.30 Dodder B

Maximizing the value for money. Delisting technologies, current approaches and methodological guidance Chair: Iñaki Gutierrez-Ibarluzea, Osteba, Basque Offi ce for HTA 5.1 A methodological guide for the detection, prioritisation and assessment of obsolete health technologies. The fi rst methodological guide and software on prioritisation Alberto Ruano-Raviña Avalia-T, Galician Agency for HTA, Santiago de Compostela (Galicia), Spain & University of Santiago de Compostela, Spain 5.2 How to guide the process of delisting technologies in different health care settings. The GuNFT tool. A software and a tool for managing delisting technologies Nora Ibargoyen-Roteta Osteba, Basque Offi ce for HTA, Vitoria-Gasteiz (Basque Country), Spain 5.3 Practical examples on disinvestment in health technologies. From theory to practice. The Australian experience Adam Elshaug University of Adelaide, Australia & ANZHSN, Adelaide, Australia 5.4 Obsolete health technologies. NICE experience and future perspectives Sarah Gardner NICE, London, UK

39 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

PP-6 Monday 11:30 Dodder A

Health technology assessment: what additional methodologies can we offer decision makers 6.1 Setting the Scene Mel Walker (Chair) 11 University of Wales, Cardiff, UK & GlaxoSmithKline R&D, London, UK 6.2 Health Investment model Mark Connolly GMA Solutions, ST-Prex, Switzerland & University of Groningen, Netherlands 6.3 Budget optimization model Nadia Demarteau GSK Biologicals, Wavre, Belgium 6.4 Dynamic budget impact approach Olivier Ethgen University of Liege, Belgium & GSK Biologicals, Wavre, Belgium MONDAY, 7 JUNE 2010 MONDAY, 13:00 – 14:30 LUNCH

13:00 – 14:30 Satellite Symposium 3 – Sanofi Aventis Concert Hall

Comparative effectiveness for reimbursement: A comparison of international policies and methods. Mark Sculpher Adrian Towse Clifford Goodman Bong-Min Yang

13:00 – 14:30 Satellite Symposium 4 – Lilly Clyde

Can we reliably benchmark HTA entities? Egon Jonsson Michael Drummond Claudio Jommi David Hailey Irina Cleemput

40 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

13:00 – 14:30 NETWORKING SESSION 2

Monday 13:00 Lansdowne

Effi ciency and role of HTA Agencies in Middle Income Countries 2.1 Interactive tool – Serbia 11 Krzysztof Landa & Alexandre Lemgruber Central and Eastern European Society of Technology Assessment in Health Care, Krakow, Poland 2.2 AHTAPol and HTA Guidelines Wojciech Matusewicz & Iga Lipska Polish HTA Agency, Warsaw, Poland 2.3 Mirror Discussion Andrea Rappagliossi GlaxoSmithKline, Belgium MONDAY, 7 JUNE 2010 MONDAY, 14:30 – 16:00 Special Session 1 – EUnetHTA Concert Hall

European network for HTA (EUnetHTA) Joint Action work plans for 2010-12 Finn Boerlum Kristensen, Kristian Lampe, Wim Goettsch, Sun-Hae Lee-Robin, Patrice Chalon

14:30 – 16:00 HTA POLICY AND PRACTICE INTERACTIVE SESSION 1 (8x8 mins)

IPS1 Monday 14:30 Clyde

Chair:Tammy Clifford, Canada Chair: Michael Barry, Ireland IPS1-1 A novel process for the phased introduction of a new interventional procedure with simultaneous enhancement of the evidence base Hannah Patrick Transcatheter aortic valve implantation steering group, England, United Kingdom IPS1-2 A ‘fail-safe' approach to coverage with evidence development: Investment and disinvestment double Paul Fennessy1, Kylie Mayo1, Richard King1 ,2 1Victorian Department of Health, Melbourne, Victoria, Australia, 2Southern Health, Melbourne, Victoria, Australia

41 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

IPS1-3 Development of quality indicators to assess a new healthcare model for the prevention of high risk colorectal cancer Victoria Serra-Sutton1,2, Mireia Espallargues1 ,2, Sonia Alomar1, Leslie Barrionuevo3, Lola Sanz4, Michael Herdman4 1Catalan Agency for Health Technology Assessment and Research, Barcelona, Catalonia, Spain, 2CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, 3Hospital de Bellvitge, 11 Barcelona, Spain, 4Insight Consulting and Research, Barcelona, Spain IPS1-4 Finding ways to make outcomes assessments effective in risk-sharing agreements Lisbet Coulton5, Abdulkadir Keskinaslan2, Lieven Annemans3 ,4, Jill Javier1 1United BioSource Corporation, Bethesda, MD, United States, 2Novartis Pharma AG, Basel, Switzerland, 3Ghent University, Ghent, Flanders, Belgium, 4Vrije Universiteit Brussel, Brussels, Belgium, 5United BioSource Corporation - Europe, London, United Kingdom IPS1-5 Successful implementation of coverage with evidence development (CED) - 14 years of Swiss experience Maya Züllig1, Sylvie Bailat1, Kathrin Peter2, Felix Gurtner1 1Federal Offi ce of Public Health, Medical Technologies Unit, Berne, Switzerland, 2health-evaluation gmbh, Berne, Switzerland MONDAY, 7 JUNE 2010 MONDAY, IPS1-6 Impact of introducing a DRG reimbursement system in an acute inpatient hospital setting: A literature review Urs Brügger, Klaus Eichler Winterthur Institute of Health Economics, Winterthur, Switzerland IPS1-7 Examining the impact of decision irreversibility in HIV/AIDS programme prioritization in the context of the global economic crisis: A case study of Malawi Paul Revill, Steve Thomas Trinity College Dublin, Ireland IPS1-8 A targeted review of Factor V Leiden and prothrombin 20210G>A testing in women with recurrent pregnancy loss (RPL) Linda Bradley1, Glenn Palomaki1, Joan Scott2 1Women & Infants Hospital/Alpert Medical School of Brown University, Providence, RI, United States, 2Genetics and Public Policy Center, Washington, DC, United States

42 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

14:30 – 16:00 ORAL PRESENTATION SESSIONS 1-5 (6X15MINS)

OP1 Monday 14:30 Lansdowne

HTA in Context – Disinvestment and System Issues Chair: Iñaki Gutierrez-Ibarluzea, Spain 11 Chair: Mairin Ryan, Ireland OP1-1 To be or not to be - A fi ve country comparison of funding policies for assisted reproductive technologies Janet Hiller1 ,3, Adam Elshaug1 ,3, Amber Watt1, Annette Braunack-Mayer2, John Moss2, Heather Buchan4, Janet Wale5, and the ASTUTE Health Study Group1 ,2 1Adelaide Health Technology Assessment (AHTA), School of Population Health and Clinical Practice, The University of Adelaide, Adelaide, SA, Australia, 2Discipline of Public Health, The University of Adelaide, Adelaide, SA, Australia, 3Hanson Institute, Institute of Medical and Veterinary Science (IMVS), Adelaide, SA, Australia, 4National Institute of Clinical Studies (NICS), NHMRC, Melbourne, VIC, Australia, 5Cochrane Collaboration Consumer Network, Melbourne, VIC, Australia

OP1-2 Increasing HTA input to decision-making with tools from political science: The veto player approach 7 JUNE 2010 MONDAY, Rainer Thiel, Karl A. Stroetmann empirica Communication and Technology Research GmbH, Bonn, Germany

OP1-3 HTA may need to consider broader issues around implementation to ensure that interventions identifi ed as cost effective can be adopted Martin Flattery1, Ann Delany1, Kevin O'Carroll1, Deirdre Mulholland1, Caroline Waldron1, Nick Mapstone2, Mary Teeling3, Mary-Jo McAvin3, Laura McCullagh4, Mairin Ryan1 1Health Information and Quality Authority, Cork, Ireland, 2Audit Commission, England, United Kingdom, 3Centre for Advanced Clinical Therapeutics, St James's Hospital, Ireland, 4National Centre for Pharmacoeconomics, St James's Hospital, Ireland OP1-4 Development and application of a framework for real world Health Technology Assessment Janneke Grutters1, Shanly Seferina2, Vivianne Tjan-Heijnen2, Roel Van Kampen2, Wim Goettsch3, Manuela Joore2 ,1 1Maastricht University, Maastricht, Netherlands, 2Maastricht University Medical Centre, Maastricht, Netherlands, 3Health Care Insurance Board, Diemen, Netherlands OP1-5 Determining the value of new technologies. A descriptive review of the supplementary ‘end of life' advice issued by the National Institute of Health and Clinical Excellence Rebecca Trowman, Janet Robertson, Carole Longson National Institute for Health and Clinical Excellence, Manchester/London, United Kingdom OP1-6 Health technology disinvestment in Australia: policy, process and practice Paul Fennessy1, Claire Harris2, Richard King1,2, Kylie Mayo1 1Department of Health, Melbourne, Victoria, Australia, 2Southern Health, Melbourne, Victoria, Australia

43 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

OP2 Monday 14:30 Dodder A

Portability of HTA – Challenges and Opportunities Chair: Andres Pichon-Riviere, Argentina Chair: Ciaran O’Neill, Ireland 11 OP2-1 Health informatics evaluation and health technology assessment: lessons and warnings Don Juzwishin1, Christian Nohr1, Elizabeth Borycki1, Andre Kushniruk1 1Alberta Health Services, Edmonton, Alberta, Canada, 2Aalborg University, Aalborg, Denmark, 3University of Victoria, Victoria, British Columbia, Canada, 4University of Victoria, Victoria, British Columbia, Canada OP2-2 Controlling for treatment switching in NICE technology appraisals Nicholas Latimer1, Rebecca Trowman2 1University of Sheffi eld, Sheffi eld, United Kingdom, 2National Institute for Health and Clinical Excellence, Manchester, United Kingdom OP2-3 Is standardization of processes in health economic evaluation a dead end? Marion Danner, Schwalm Anja, Fabian Volz, Astrid Seidl, Andreas Gerber, Charalabos-Markos

MONDAY, 7 JUNE 2010 MONDAY, Dintsios Institute for Quality and Effi ciency in Health Care, Cologne, Germany OP2-4 Harnessing the evidence gaps: a European database of uncertainties in the management of cancer Sarah Garner, Moni Choudhury, Clifford Middleton NICE, London, United Kingdom OP2-5 The Australian HTA review: are we moving towards harmonisation of process? Sally Wortley1, Samara Lewis2 1University of Sydney, NSW, Australia, 2NHMRC Clinical Trials Centre, Camperdown, Australia OP2-6 The transferabiltiy of valuing lost productivity across jurisdications: Differences between national pharmacoeconomic guidelines Saskia Knies, Johan Severens, Andre Ament, Silvia Evers Maastricht University, Maastricht, Netherlands

OP3 Monday 14:30 Dodder B

HTA in Context: Ethical and other Considerations Chair: Bjorn Hoffman, Norway Chair: Tracey Cooper, Ireland OP3-1 The health and economic impact of switching from atorvastatin to generic simvastatin in the Netherlands Danny Liew1, Kate Webb2, Willem Jan Meerding3 1The University of Melbourne, Melbourne, Australia, 2Pfi zer Limited, Surrey, United Kingdom, 3Pfi zer bv, Capelle a/d IJssel, Netherlands

44 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

OP3-2 Formatting cost-effectiveness fi ndings for multiple stakeholders: The comparative value evidence table Daniel Ollendorf, Marc Silverstein, Steven Pearson Institute for Clinical and Economic Review, Boston, Massachusetts, United States OP3-3 The effi ciency frontier of antiviral hepatitis C treatment – A pilot and feasibility study commissioned by IQWiQ Uwe Siebert1 ,3, Nikolai Muehlberger1, Annette Conrads-Frank1, Ruth Schwarzer1 11 1UMIT – University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria, 2ONCOTYROL – Center of Personalized Cancer Medicine, Innsbruck, Austria, 3Harvard School of Public Health, Boston, United States, 4Harvard Medical School, Boston, United States OP3-4 The ethical assessment in HTA reports: An Italian experience Dario Sacchini1, Walter Ricciardi2, Giuseppe La Torre3, Pietro Refolo1, Antonio G. Spagnolo1 1Institute of Bioethics, Catholic University of the Sacred Heart, Rome, Italy, 2Institute of Hygiene, Catholic University of the Sacred Heart, Rome, Italy, 3Clinical Medicine and Public Health Unit, Sapienza University, Rome, Italy OP3-5 Contribution of bioethics to health technology assessment, an illustration with growth hormones (GH) in non-GH-defi cient short children

Clémence Thébaut, Stéphanie Barré, Françoise Hamers, Olivier Scemama 7 JUNE 2010 MONDAY, French National Health Authority (Haute Autorité de Santé), Saint-Denis, France OP3-6 The role of senior health service managers in technology adoption John Hutton1, Tesha Cardow1, Jen Kruger1, Colin Callow2 1York Health Economics Consortium, York, United Kingdom, 2NHS Institute for Innovation and Improvement - NHS Technology Adoption Centre, Manchester, United Kingdom

OP4 Monday 14:30 Dodder C

Summarising the Evidence Chair: Kathy Cargill, Switzerland Chair: Cathal Walsh, Ireland OP4-1 Biologic drugs for the treatment of rheumatoid arthritis: Challenges in metaanalysis of older and new drugs Valentin Brodszky1, Katalin Érsek1, Petra Baji1, Márta Péntek1 ,2, László Gulácsi1 1Corvinus University of Budapest, Budapest, Hungary, 2Flor Ferenc County Hospital, Kistarcsa, Hungary OP4-2 Cumulative meta-analysis - When to “stop fl ogging dead horses” Louise Dent1, James Raftery1, Rod Taylor3, Kate Jolly2 1Wessex Institute, School of Medicine, University of Southampton, Southampton, Hampshire, United Kingdom, 2University of Birmingham, Birmingham, Warwickshire, United Kingdom, 3PenTAG, Peninsula Medical School, Exeter, Devon, United Kingdom OP4-3 Empirical validity check of methods for indirect comparisons Dagmar Lühmann1, Ben Schoettker2, Heiner Raspe1 1University of Lübeck, Lübeck, Germany, 2German Cancer Research Center, Heidelberg, Germany

45 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

OP4-4 HTA when there are no direct comparative effectiveness data: PARTS J. Jaime Caro1 ,2, Zeba Khan1 1United BioSource Corporation, Lexington, MA, United States, 2McGill University, Montreal, Quebec, Canada, 3Celgene Corporation, Summit, NJ, United States OP4-5 The effectiveness of the heptavalent pneumococcal vaccine: A systematic review and meta-analysis of 11 post-marketing studies Chiara de Waure1, Giuseppe La Torre1 ,2, Admir Malaj1, Silvio Capizzi1, Walter Ricciardi1 1Research Center of Health Technology Assessment, Institute of Hygiene, Catholic University of the Sacred Heart, Rome, Italy, 2Clinical Medicine and Public Health Unit, Sapienza University of Rome, Rome, Italy OP4-6 A mixed treatment comparison of paracetamol and selective and non-selective anti-infl ammatory drugs (NSAIDS) for the reduction of morphine related side-effects after major surgery Stephen Rice, Catriona McDaid, Nerys Woolacott, Emma Maund Centre for Reviews and Dissemination, University of York, York, United Kingdom

OP5 Monday 14:30 Dodder D

MONDAY, 7 JUNE 2010 MONDAY, Clinical Reviews – Devices, Imaging and Therapies Chair: Jean-Michel Dubernard, France Chair: Patricia Harrington, Ireland OP5-1 Holium laser enucleation of the prostate for BPH patients: A systematic review Ryeojin Ko1, So-hee Kim1, Tchun Yong Lee3, Jin Seon Cho4, Sang Jin Yoon5, Sang Keun Park6 1Health Technolodgy Assessment Department, Health Insurance Review & Assessment Service, Seoul, Republic of Korea, 2Health Technolodgy Assessment Department, Health Insurance Review & Assessment Service, Seoul, Republic of Korea, 3Department of Urology, Hanyang University College of Medicine, Seoul, Republic of Korea, 4Department of Urology, College of Medicine, Hallym University, Kyeongi, Republic of Korea, 5Department of Urology, Gachon University Gil Hospital, Incheon, Republic of Korea, 6Department of Neurosurgery, Inje University Paik Hospital, Seoul, Republic of Korea, OP5-2 Rapid-HTA: Robot-assisted gait therapy for hemiplegic stroke patients Shao Chuen Tong1, Yee Sien Ng2, Peter Lim2, Chek Wai Bok2, Wai Leng Chow1 1SingHealth Centre for Health Services Research, Singapore Health Services Pte Ltd., Singapore, Singapore, 2Department of Rehablitation Medicine, Singapore General Hospital, Singapore, Singapore OP5-3 Effi cacy of the Da Vinci Surgical System in abdominal surgery compared to that of laparoscopy: A systematic review and meta-analysis Sergio Maeso1, Mercedes Reza1, Julio Mayol2, Juan Antonio Blasco1, Mercedes Guerra1, Elena Andradas3 1Health Technology Assessment Unit (UETS), Madrid, Spain, 2Hospital clínico San Carlos, Madrid, Spain, 3Laín Entralgo Agency, Madrid, Spain

46 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

OP5-4 Systematic review and meta-analysis of photodynamic diagnosis of bladder cancer compared with white light cystoscopy Graham Mowatt1, James N’Dow2, Shihua Zhu1, Mary Kilonzo3, Charles Boachie1, Cynthia Fraser1, Ghulam Nabi4, Jonathan Cook1, Luke Vale1 ,3, T.R. Leyshon Griffi ths5 1Health Services Research Unit, University of Aberdeen, Aberdeen, United Kingdom, 2Academic Urology Unit, Department of Surgery, University of Aberdeen, Aberdeen, United Kingdom, 3Health Economics Research Unit, University of Aberdeen, Aberdeen, United Kingdom, 4University of 11 Dundee, Dundee, United Kingdom, 5University of Leicester, Leicester, United Kingdom OP5-5 Percutaneous pulmonary and aortic valve insertion in Belgium: Conditional reimbursement or waiting for further evidence? Mattias Neyt, Hans Van Brabandt, Imgard Vinck Belgian Health Care Knowledge Centre (KCE), Brussels, Belgium OP5-6 Assessing the longer - term clinical effectiveness of pulmonary rehabilitation David Hailey Institute of Health Economics, Edmonton, Alberta, Canada

16:00 – 16:30 COFFEE BREAK & POSTERS MONDAY, 7 JUNE 2010 MONDAY,

16:30 – 18:00 PANEL SESSIONS 7-13

PP-7 Monday 16.30 Clyde

What are the challenges of assessing public health technologies for policy making? Chair: Ken Stein, PenTAG, Peninsula Medical School, University of Exeter, UK 7.1 The role of modelling for producing public health guidance Jim Chilcott ScHARR, University of Sheffi eld, UK 7.2 Synthesis of qualitative research in assessing public health technologies Ruth Garside PenTAG, Peninsula Medical School, University of Exeter, UK 7.3 Policy, practice and theoretical challenges associated with producing public health guidance Mike Kelly Centre for Public Health Excellence, National Institute for Health and Clinical Excellence, London, UK 7.4 Identifying appropriate literature to appraise public health technologies Suzy Paisley ScHARR, University of Sheffi eld, UK

47 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

PP-8 Monday 16.30 Lansdowne

Adding value? HTAs and systematic reviews of health economic evidence. The value of performing systematic reviews of previously published and unpublished health economic evidence. Chair: Mike Drummond, University of York, UK 11 8.1 The role of economic perspectives and evidence in systematic review Rob Anderson Peninsula Medical School, University of Exeter, UK 8.2 Evaluation of economic outcomes in systematic reviews Louis Niessen Johns Hopkins University, Baltimore, United States 8.3 Use of GRADE evidence profi les in decision models to inform clinical practice guidelines Ian Shemilt University of East Anglia, Norwich, UK 8.4 Implications for HTA and future research

MONDAY, 7 JUNE 2010 MONDAY, Luke Vale University of Aberdeen, UK

PP-9 Monday 16.30 Minerva

Prospective observational data collection to support health care technology assessment(HTA) where the existing evidence base is inadequate. Chair: Bruce Campbell, National Institute for Health and Clinical Excellence, London, UK 9.1 Quality of data from prospective cohort studies Nancy Dreyer Outcome Sciences Inc., Cambridge, MA, US 9.2 Relevant Case Studies Roberto Grilli Regional Agency for Health and Social Care, Bologna, Spain 9.3 Relevant Case Studies Sean Tunis Center for Medical Technology Policy, Baltimore, MD, US

PP-10 Monday 16.30 Merrion

Supporting implementation of our guidance - what can the HTA community and the guideline community learn from each other? 10.1 Jean Slutsky Guidelines International Network, Berlin, Germany & AHRQ, Rockville, US

48 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

10.2 Najoua Mlika-Cabanne Guidelines International Network, Berlin,Germany & HAS, Paris, France 10.3 Keng Ho Pwee Ministry of Health, Singapore

PP-11 Monday 16.30 Dodder B 11

Value in HTA in medical devices – What are the expectations from decision making authorities? Chair: Peter Kolominsky-Rabas, Centre for HTA & Public Health (IZPH), University of Erlangen- Nurnberg, Germany 11.1 The question is: Whether and When – not How – should medical devices be evaluated Matthias Perleth Head of Department, Abteilung Fachberatung Medizin, Gemeinsamer Bundesausschuss (GBA), Berlin, Germany 11.2 Clinical data for medical devices: are HTA bodies requirements adequate? Francios Meyer MONDAY, 7 JUNE 2010 MONDAY, Health Technology Assessment Division, Haute Authorite de Sante (HAS), Paris, France 11.3 Challenges and opportunities for the evaluation of innovative medical technologies Pascale Brasseur Health Economics and Reimbursement, Cardiovascular, Medtronic International SA, Tolochenaz, Switzerland 11.4 Medical devices – better and more reliable market access? Stephan Feldhaus Senior Vice President Communications, Siemens AG Healthcare Sector, Erlangen, Germany

PP-12 Monday 16.30 Dodder A

Supporting tough decision in healthcare – the link between HTA and priority setting. Chair: Berit Mørland, Norwegian Knowledge Centre for the Health Services, Oslo, Norway 12.1 An equitable choice – clarifying effi ciency: equity trade-offs in healthcare priority setting Dan Chisholm Department of Health Systems Financing, Health Systems and Services, World Health Organization, Switzerland 12.2 Using comparative effectiveness research to identify “marginal medicine” Steven Pearson Institute for Clinical and Economic Review (ICER) at Harvard Medical School, Boston, US 12.3 The link between HTA and national priority setting – the case of Norway Ånen Ringard Norwegian Knowledge Centre for the Health Services, Oslo, Norway

49 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

12.4 Strengths and weaknesses of HTA as a tool for decision making support – applied to priority setting Per Carlsson National Centre for Priority Setting in Health Care, Linkøping, Sweden

PP-13 Monday 16.30 Dodder D

11 Maximising the social value and impact of health technology innovations Chair: Janet Hiller 13.1 Does innovation benefi t low and middle income countries? Björn Fahlgren World Health Organisation, Geneva, Switzerland 13.2 Patients perspectives on medical technology innovation Maarten IJzerman University of Twente, Enschede, Netherlands 13.3 Bench to Benefi ciary: Product Pipelines for Global Health Technology Solutions Michael Free MONDAY, 7 JUNE 2010 MONDAY, PATH, Seattle, US 13.4 Societal value of medical technology: balancing access and innovation Ashoke Bhattacharjya Johnson & Johnson Asia-Pacifi c, Delhi, India

18:00 – 19:00 HTAi Business Meeting Clyde

19:00 – 20:30 VIP Sponsor’s Reception President’s Room

50 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

PROGRAMME OVERVIEW - TUESDAY

Scientific Programme Overview : Tuesday, 8 June 2010

Conference Registration 0800-1900

0900 - Plenary 2 1030 Maximising the Value in conducting HTAs (Chair Mke Drummond) Concert Hall

1030 - 1100 Coffee Break & Poster Session 2

INDUSTRIES SERPENTINE CONCERT CLYDE LANSDOWNE DODDER A DODDER B DODDER C DODDER D DODDER E MINERVA MERRION HALL HALL HALL

1100 Registration Poster Panel 14 Panel 15 Panel 19 Panel 18 Speaker Panel 16 Panel 17 - & Session 2 Preparation 1230 Poster Session Room 2

1230 - Lunch 11 1400

EFPIA / Medtronic PhRMA Merck Serono 1230 Registration Poster Satellite Developing Information Surrogate Speaker Satellite Satellite - & Session 2 Symposium Countries ISG Resources Outcomes Preparation Symposium Symposium 1400 Poster Session 6 7 ISG ISG Room 2 5

Engagement Policy & between 1400 Registration Poster Practice Oral Oral Oral Oral Oral Speaker Manufacturers - & Session 2 Interactive Presentation Presentation Presentation Presentation Presentation Preparation & Agencies 1530 Poster Session Session 2 6 7 8 9 10 Room 2 Special Sess.

1530 - 1600 Coffee Break & Poster Session 2

1600 Registration Poster EuroVaQ Oral Oral Oral Oral Oral Oral Speaker / 8 JUNE 2010 TUESDAY, - & Session 2 Special Presentation Presentation Presentation Presentation Presentation Presentation Secretariat 1730 Poster Session Session 3 11 12 13 14 15 16 Room 2

1745 - Building a Career in HTA Session in Dodder A 1845

1930 - Conference Dinner – Guinness Storehouse 0000

51 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

TUESDAY PLENARY SESSION Guy Maddern SPEAKERS

Chair: Mike Drummond

Professor Guy Maddern is the RP Jepson Professor of Surgery at the University of Adelaide, Director of Surgery at The Queen Elizabeth Hospital and Director of the Basil Hetzel Institute for Medical Research in Professor Drummond is Professor of Health Economics Adelaide. He was appointed inaugural Surgical Director and was Director of the Centre for Health Economics, of ASERNIP-S in October 1997 and since that time has University of York from December 1995 to September been involved in developed the ASERNIP-S program for 11 2005. His particular fi eld of interest is in the economic the Royal Australasian College of Surgeons. He is past evaluation of health care treatments and programmes. He President of INAHTA and current Secretary of HTAi. has undertaken evaluations in a wide range of medical fi elds including care of the elderly, neonatal intensive care, immunisation programmes, services for people with Carole Longson AIDS, eye health care and pharmaceuticals. He is the author of two major textbooks and more than 500 scientifi c papers, has acted as a consultant to the World Health Organization and was Project Leader of a European Union Project on the Methodology of Economic Appraisal of Health Technology. He has served on the Board of Directors of the International Society of Technology Assessment in Health Care and is a past president of the International Society TUESDAY, 8 JUNE 2010 TUESDAY, for Pharmacoeconomics and Outcomes Research. He participated in a workshop at HTAi 2007 in Barcelona. He was co-chair of the ISPOR 10th Annual European Congress in Dublin 2007. Carole is Director of the Centre for Health Technology Evaluation at NICE. She has a doctorate in Pharmacology and spent 8 years at GlaxoSmithKline Research working on the development of novel pharmaceuticals. She has also undertaken many academic secondments including research at The Institute of Molecular Biology in Geneva and the University of California in Irvine, USA. Carole has previously been involved in health technology assessment as Director of the Evidence Research Unit. She contributes to a number of international policy forums, including the WHO advisory group on Priority Medical Devices and Health Technology Assessment International. Her research interests lie in the methodologies and processes of health technology assessment in the context of health policy decision making.

52 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

Albert Jovell Uwe Siebert

Albert J. Jovell (Barcelona, 1962), is a MD specialized Prof. Uwe Siebert, MD, MPH, MSc, ScD, Professor of in Preventive Medicine and Public Health. He holds the Public Health, is the Chair of the Department of Public degrees of Master of Public Health in Epidemiology, Health, Information Systems and Health Technology Master of Science in health Policy and Management and Assessment at UMIT - University for Health Sciences, Doctor in Public Health from Harvard University; and a Medical Informatics and Technology in Austria and Master of Arts in Social and Political Sciences from the Division Director in the ONCOTYROL – Center for University Autonomous of Barcelona and a Doctor in Personalized Cancer Medicine. He is also Adjunct Sociology from the University of Barcelona. Currently , Professor of Health Policy and Management (Harvard 11 he is the General Director of the Josep Laporte Library Univ.) and Director of the Cardiovascular Research Foundation; Associate Professor of Preventive Medicine Program at the Institute for Technology Assessment, and Public Health at the University Autonomous of Massachusetts General Hospital, Harvard Medical Barcelona, President of the Spanish Patients’ Forum School, Boston. and Director of Patients’ University. He is academic His research interests include applying evidence-based of the Royal Academy of Medicine of Catalonia and quantitative methods from public health, epidemiology, ASHOKA fellow; He has several appointments in outcomes research, economic evaluation and decision Executive Boards, Committees and Commissions and has sciences in the framework of health technology got several awards and honorary acknowledgements. He assessments (HTA) as well as in the clinical context of is author of several books including a novel and writes routine health care. regularly in several newspapers. He fi elds of expertise are health policy and management. He has been fi ghting He was a member of the International Expert Committee cancer since 2001. Advising IQWiG on the Methods for Economic Evaluations of Health Care Interventions and he has TUESDAY, 8 JUNE 2010 TUESDAY, worked with several HTA and Government Agencies (e.g., DAHTA@DIMDI/Germany, IQWiG/Germany, NICE/UK, ANVISA/Brazil, CADTH/Canada, LBI-HTA/ Austria, GOEG/Austria). He has authored more than 200 publications including HTA reports, textbook chapters, scientifi c articles, and editorials.

53 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

TUESDAY, 8 JUNE

08:00 – 19:00 REGISTRATION

09:00 – 09:05 Recognition of Jill Sanders Concert Hall

Laura Sampietro-Colom, Marjukka Makela

09:05 – 10:35 PLENARY SESSION 2 Concert Hall

PL2 Maximising the value in conducting HTAs Mike Drummond University of York, UK PL2-1 Rapid versus full systematic reviews: fi nding the balance Guy Maddern Professor of Surgery, University of Adelaide; Surgical Director, Australian Safety and Effi cacy 11 Register of New Interventional Procedures Surgical (ASERNIP-S) PL2-2 Pros and cons of relying on reviews of industry submissions in HTAs for decision-making Carole Longson Director, Health Technology Evaluation Centre, NICE, UK PL2-3 Making the involvement of patients in HTA both effective and effi cient Albert Jovell Associative Professor of Preventative Medicine and Public Health, University of Barcelona; President of the Spanish Patients’ Forum, Spain PL2-4 Complex versus simple decision models – Assessing what is fi t for purpose Uwe Siebert Department of Public Health, Medical Decision Making and Health Technology Assessment, UMIT

TUESDAY, 8 JUNE 2010 TUESDAY, - University for Health Sciences, Medical Informatics and Technology, Hall i.T, Austria, Institute for Technology Assessment and Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, USA, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA, Division of Public Health Decision Modelling, Health Technology Assessment and Health Economics, ONCOTYROL – Center for Personalized Cancer Medicine, Innsbruck, Austria

10:35 – 11:00 COFFEE BREAK & POSTERS

54 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

11:00 – 12:30 PANEL SESSIONS 14-19

PP-14 Tuesday 11.00 Clyde

Evidence development schemes in Europe: Recent experience and future potential – ‘The use of coverage with evidence development’ Chair: Andrew H Briggs, University of Glasgow 14.1 Conditional Reimbursement in The Netherlands Ties Hoomans Maastricht University, Maastricht, Netherlands 14.2 Evidence Development Schemes in the UK Kalipso Chalkidou National Institute for Clinical Excellence, London, UK 14.3 Methodology for evidence development schemes Elisabeth Fenwick University of Glasgow, UK 14.4 An industry perspective on evidence development schemes across Europe Clare McGrath 11 Pfi zer, Tadworth, UK

PP-15 Tuesday 11.00 Lansdowne

How do we use results of comparative and/or relative effectiveness assessments of pharmaceuticals across the world? Chair: Bert Boer, Health Care Insurance Board (CVZ) Diemen, Netherlands 15.1 How do we use results of relative effectiveness assessment in Europe with a special focus on the Netherlands? Wim Goettsch

Health Care Insurance Board (CVZ), Diemen, Netherlands 8 JUNE 2010 TUESDAY, 15.2 How do we use results of comparative effectiveness assessment of pharmaceuticals in the USA? Jean Slutsky Center for Outcomes and Evidence Agency for Healthcare Research and Quality, Rockville, MD, US 15.3 How do we use results of comparative effectiveness assessment of pharmaceuticals in Australia? Andrew Mitchell Pharmaceutical Evalution Branch of the Australian Government, Dept of Health and Ageing, Canberra, Australia 15.4 How do we use results of comparative and/or relative effectiveness assessments of pharmaceuticals in Korea? Jeonghoon Ahn National Evidence-based healthcare Collaborating Agency (NECA), Seoul, Republic of Korea

55 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

PP-16 Tuesday 11.00 Minerva

Health technology assessment of new interventional procedures in different countries: maximising the potential for mutual learning and international collaborations Chair: Georgios Lyratzopoulos, National Institute for Health and Clinical Excellence, UK 16.1 The appraisal of interventional procedures in the UK Bruce Campbell National Institute for Health and Clinical Excellence, UK 16.2 The appraisal of interventional procedures in Australia Guy Maddern ASERNIP-S, Adelaide, Australia 16.3 The appraisal of interventional procedures in Washington State, USA Gary Franklin HTA Programme, Seattle, US 16.4 The appraisal of interventional procedures in France Sun-Hae Lee-Robin 11 HAS, Paris, France

PP-17 Tuesday 11.00 Merrion

Payer versus societal perspective: whose costs should count in cost-effectiveness analysis? Chair: Mark Sculpher 17.1 Alternative perspectives for economic evaluation: what’s at stake? Mark Sculpher University of York, UK 17.2 Arguments for a social perspective

TUESDAY, 8 JUNE 2010 TUESDAY, Bengt Jonsson Stockhold School of Economics, Sweden 17.3 Appropriate perspectives for health care decisions Karl Claxton University of York, UK 17.4 Comment & Discussion Peter Littlejohns National Instiute for Health and Clinical Excellence, London, UK Måns Rosén Swedish Council on Technology Assessment in Health Care, Stockholm, Sweden Les Levin Ontario Ministry of Health, Toronto, Canada

56 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

PP-18 Tuesday 11.00 Dodder B

Valuing health: From conventional QALYs to subjective well-being 18.1 From cost-utility analysis to cost happiness analysis Paul Dolan Imperial College, London, UK 18.2 Uneven fl oors, broken ceilings, and other problems with describing health Henry Lee Imperial College, London, UK 18.3 Always on my mind: Insights from analyses of new data health and wellbeing Robert Metcalfe Merton College, Oxford, UK

PP-19 Tuesday 11 :00 Dodder A

Can social networking and the web provide patients’ perspectives to inform rapid HTAs? Chair: Karen Facey, Chair HTAi Interest Group Patient/Citizen Involvement in HTA 11 19.1 Obtaining patients’ views in rapid HTAs at the Scottish Medicines Consortium Ken Patterson Scottish Medicines Consortium, Glasgow, UK 19.2 Understanding patients’ perspectives from Message Board and Twitter Tania Stafi nski University of Alberta, Edmonton, Canada 19.3 Blogs and on-line discussion forums to elicit community views on health technologies Jackie Street University of Adelaide, Australia

19.4 Making the most of the information patient organizations can gather 8 JUNE 2010 TUESDAY, Judy Birch Pelvic pain support network, UK

12:30 – 14:00 LUNCH

12:30 – 14:00 Satellite Symposium 5 - efpia and PhRMA Concert Hall

Relative effi cacy of drugs: an emerging issue at the interface between regulatory agencies and third party payers Mike Drummond, Hans-Georg Eichler, Bengt Jonsson, Richard Bergstrom

57 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

12:30 – 14:00 Satellite Symposium 6 - Medtronic Clyde

From recommendation to action : views of how HTA recommendations are integrated into decision- making and then translated into practice in various regions/countries of the world. Clifford Goodman, Gillian Leng, Muhammed Mamdani, Isao Kama

12:30 – 14:00 Satellite Symposium 7 – Merck Serono Lansdowne

Role of adherence in HTA: a bridge between patients, carers and healthcare professionals? Karen Facey, Jean Mossman, Andrew Chan, Thomas Bols, 11 Francois Meyer

14:00 – 15:30 Special Session 2 – Irish Medicines Board Concert Hall

Early Engagement between Technology Manufacturers and Assessment Agencies. Pat O Mahony, Hans-Georg Eichler, Michael Wonder, Carole Longson, Bengt Ljungberg TUESDAY, 8 JUNE 2010 TUESDAY, 14:00 – 15:30 HTA POLICY AND PRACTICE INTERACTIVE SESSION 2 (8X8MINS)

IPS2 Tuesday 14:00 Clyde

Chair: Brendon Kearney, Australia Chair: Dolores Quinn, Ireland IPS2-1 HTA and policy decision making in South Korea Seon Heui Lee Health Insurance Review & Assessment Service, Seoul, Republic of Korea IPS2-2 Capacity building for Health Technology Assessment in India following the guidance of EUnetHTA Work Package 8 and existing European good practices Abinaya Rajan1 1Universidad de Deusto, Bilbao, Spain, 2OSTEBA, Vitoria-Gasteiz, Spain

58 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

IPS2-3 Policy makers' views on diffusion and use of health technologies in Iran Mohammad Palesh2, Carol Tishelman1 5, Sten Fredrikson1, Hamidreza Jamshidi3, Goran Tomson1, Azita Emami4 1Karolinska Institutet, Stockholm, Sweden, 2Kermanshah University of Medical Sciences, Kermanshah, Iran, Islamic Republic of, 3Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic of, 4Seattle University, Seattle, United States, 5University of Manchester, Manchester, United Kingdom IPS2-4 Analysis of current approaches to HTA in the Mexican Health Care System Fabiola Martínez-Licona, Miguel Cadena Méndez, Joaquin Azpiroz-Leehan Universidad Autónoma Metropolitana-Iztapalapa, Mexico, D.F., Mexico IPS2-5 Implementation of assessment of medical technology in the Republic of Kazakhstan Kulsara Rustemova, Evgeniya Pak, Lyazzat Kosherbaeva, Laura Kozhageldieva Healthcare development institute, Astana, Kazakhstan IPS2-6 Screening - The work of a political committee in Denmark Tine Andresen, Louise Nordvig, Mette Kjoelby Department of HTA, Institute of Public Health, Aarhus University, Denmark, Århus, Denmark IPS2-7 Patient, citizen and public involvement in topic selection at NICE 11 Emma Chambers, Laura Norburn, Lizzie Amis National Institute for Health and Clinical Excellence, London, United Kingdom IPS2-8 Novel methods of patient, citizen and public involvement at NICE Lizzie Amis, Laura Norburn, Emma Chambers National Institute for Health and Clinical Excellence, London, United Kingdom TUESDAY, 8 JUNE 2010 TUESDAY,

59 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

14:00 – 15:30 ORAL PRESENTATION SESSIONS 6-10 (6X15MINS)

OP6 Tuesday 14:00 Lansdowne

Economic Analyses I Chair: Mark Sculpher, UK Chair: Loretto Lacey, Ireland OP6-1 Long-term effectiveness and cost-effectiveness of primary HPV testing for cervical cancer screening in Germany. A Health Technology Assessment commissioned by DAHTA@DIMDI Gaby Sroczynski1, Petra Schnell-Inderst1, Nikolai Muehlberger1, Katharina Lang2, Pamela Aidelsburger2, Jürgen Wasem3, Thomas Mittendorf4, Jutta Engel5, Peter Hillemanns6, Karl Ulrich Petry7, Alexander Krämer8, Uwe Siebert1 ,9 1Department of Public Health, Information Systems and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i. T., Austria, 2Carem GmbH, Sauerlach, Germany, 3Institute for Health Care Management, University of Duisburg-Essen, Essen, Germany, 4Institute for Health Economics, University of Hanover, Hanover, Germany, 5Munich 11 Cancer Registry of the Munich Cancer Centre, Clinic Grosshadern,Ludwig-Maximilians-University, Munich, Germany, 6Department of Obstetrics and Gynecology, Hanover Medical School, Hanover, Germany, 7Department of Obstetrics and Gynecology, Teaching Hospital Wolfsburg, Wolfsburg, Germany, 8School of Public Health, University of Bielefeld, Bielefeld, Germany, 9Center for Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, United States, 10Institute for Technology Assessment and Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, United States OP6-2 The HPV-DNA test as primary screening test for cervical cancer screening Guglielmo Ronco1, Paolo Giorgi Rossi2, NTCC Working Group1 1Centro per la Prevenzione Oncologica, Torino, Italy, 2Laziosanità - Agency for Public Health, Rome, Italy OP6-3 Effi cacy of human papillomavirus detection tests in cervical cancer screening: A systematic review

TUESDAY, 8 JUNE 2010 TUESDAY, and meta-analysis Ana López-Polín1, Mercedes Reza1, Daniel Callejo1, Tirso Pérez2, Maria José López-Pedraza1, Elena Andradas3 1Health Technology Assessment Unit (UETS), Madrid, Spain, 2Hospital Puerta de Hierro, Madrid, Spain, 3Laín Entralgo Agency, Madrid, Spain OP6-4 The cost effectiveness of opportunistic screening for Chlamydia trachomatis in Ireland Paddy Gillespie1, Elisabeth Adams4, Katy Turner4, Deirdre Vaughan1, Diarmuid O’Donovan1, Ruairi Brugha2, Catherine Fleming1, Martin Cormican1, Margaret Fitzgerald3, Emer O’Connell1, Myles Balfe2, Claire Coleman1, Ciaran O’Neill1 1NUI Galway, Galway, Ireland, 2RCSI, Dublin, Ireland, 3HSE, Dublin, Ireland, 4HPA, London, United Kingdom OP6-5 The cost-effectiveness of monitoring stable glaucoma patients in shared care: An economic evaluation alongside a randomized controlled trial K.M. Holtzer-Goor1, E. van Sprundel2, H.G. Lemij2, T. Plochg3, N.S. Klazinga3, M.A. Koopmanschap1 1Erasmus University Rotterdam, Rotterdam, Netherlands, 2Rotterdam Eye Hospital, Rotterdam, Netherlands, 3Academic Medical Center, Amsterdam, Netherlands

60 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

OP6-6 Are adverse effects incorporated in economic models? A survey of current practice Dawn Craig, Catriona McDaid, Tiago Fonseca, Christian Stock, Steven Duffy, Nerys Woolacott CRD, University of York, York, United Kingdom

OP7 Tuesday 14:00 Dodder A

Methods – Model Development / Expected Value of Information Chair: Karl Claxton, UK Chair: Jenny Hughes, Ireland OP7-1 Informing research decisions using the expected value of information: Application to enhanced external counterpulsation for angina Claire McKenna, Karl Claxton, Neil Hawkins, Mark Sculpher Centre for Health Economics, University of York, York, United Kingdom OP7-2 Prioritising further research when there are multiple competing health technologies Nicky Welton, AE Ades University of Bristol, Bristol, United Kingdom 11 OP7-3 Being defi nitive about decision problems: HTA as policy evaluation and the implications for decision model development Rob Anderson, Martin Pitt, Jaime Peters, Martin Hoyle, Rod Taylor, Ken Stein PenTAG, Peninsula Medical School, Exeter, United Kingdom OP7-4 An interactive and graphical meta-analysis module for the Transparent Interactive Decision Interrogator (TIDI) interface Monica Lai1, Sylwia Bujkiewicz1, Nicola Cooper1, Keith Abrams1, Neil Hawkins4 ,3, Hayley Jones2, David Spiegelhalter2, Alex Sutton1 1University of Leicester, Leicester, United Kingdom, 2University of Cambridge, Cambridge, United Kingdom, 3Oxford Outcome, Oxford, United Kingdom, 4University of York, York, United Kingdom OP7-5 Historical lifetimes of drugs in England: Application to value of information and cost-effectiveness analyses 8 JUNE 2010 TUESDAY, Martin Hoyle Universities of Exeter and Plymouth, Exeter, United Kingdom OP7-6 Public Health Genomics European Network (PHGEN II) and evaluation of genome-based technologies: Is there a need for a new analytic framework? Karla Douw1, HIndrik Vondeling1, Elfriede Swinnen2, Jean Jacques Cassiman1 1University of Twente, Enschede, Netherlands, 2University of Leuven, Leuven, Belgium

61 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

OP8 Tuesday 14:00 Dodder B

Valuing Outcomes Chair: Leonor Maria Pacheco Santos, Brazil Chair: Aisling O’Leary, Ireland OP8-1 A revised scoring system for the EQ-5D produces a change in preference-based utility score, which is closer to disease measures in infl ammatory arthritis Roisin Adams1, Benjamin Craig4, Cathal Walsh2 ,1, Douglas Veale3, Barry Bresnihan3, Oliver FitzGerald3, Michael Barry1 1National Centre for Pharmacoeconomics, Dublin 8, Ireland, 2Department of Statistics, Trinity College Dublin, Dublin 2, Ireland, 3St.Vincents University Hospital, Dublin 4, Ireland, 4H. Lee Moffi tt Cancer Center &, Tampa, Florida, United States OP8-2 Quality Adjusted Life Years (QALYs) as an outcome measure in the economic evaluation of health technologies in Spain: A review of the literature (2003-2009) Paloma Gonzalez1, Jose Manuel Rodriguez4, Silvia Paz2, Luis Lizan2 ,3, Enrique Anton1, Desire Rodriguez1 1Medtronic, Madrid, Spain, 2OUTCOMES’10, Castellon, Spain, 3Jaume I University, Castellon, Spain, 11 4Johnson and Johnson, Madrid, Spain OP8-3 Using QALYs in cancer: What are the methodological limitations? Koonal Shah1, Martina Garau1, Anne Mason2, Qing Wang3, Adrian Towse1, Mike Drummond2 1Offi ce of Health Economics, London, United Kingdom, 2CHE, University of York, York, United Kingdom, 3Bristol-Myers Squibb, Uxbridge, United Kingdom OP8-4 Does Adjusting for HRQoL Matter in Cost-Effectiveness Analysis? A Comparison of Cost/Life-year and Cost/QALY Estimates Dan Greenberg1 ,2, Joshua T. Cohen2, Chi-Hui Fang2, Peter J. Neumann2 1Ben-Gurion University of the Negev, Beer-Sheva, Israel, 2Tufts Medical Center, Boston, MA, United States OP8-5 Estimation of decreases in health-related quality of life associated with diabetes-related complications TUESDAY, 8 JUNE 2010 TUESDAY, for patients with type 2 diabetes in Ontario, Canada Daria O’Reilly1 ,2, Feng Xie1 ,2, Eleanor Pullenayegum1 ,3, Hertzel Gerstein1 ,4, Janet Greb2, Gord Blackhouse1 ,2, Jean-Eric Tarride1 ,2, James Bowen1 ,2, Ron Goeree1 ,2 1Programs for Assessment of Technology in Health (PATH) Research Institute, St. Joseph’s Healthcare Hamilton, Hamilton, Ontario, Canada, 2Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada, 3Centre for Evaluative Medicines, Hamilton, Ontario, Canada, 4Department of Medicine and the Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada OP8-6 How much good do new medicines do - A valuable role for HTA? Andrew Walker2, Corinne Booth1, Ailsa Brown1, Kenneth Paterson1 1Scottish Medicines Consortium, Glasgow, United Kingdom, 2University of Glasgow, Glasgow, United Kingdom

62 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

OP9 Tuesday 14:00 Dodder C

Economic Analyses II Chair: Susan Griffi n, UK Chair: Ann Dee, Ireland OP9-1 Is it worth thinking about HIV vaccine and at what cost? An economic evaluation of HIV vaccine in Thailand Pattara Leelahavarong1, Yot Teerawattananon1, Pitsaphun Werayingyong1, Chutima Akaleephan2, Nakorn Premsri3, Chawetsan Namwat3, Viroj Tangcharoensathien2 1Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand, 2International Health Policy Program (IHPP), Nonthaburi, Thailand, 3Department of Disease Control, Mimistry of Public Health, Nonthaburi, Thailand OP9-2 The costs of sentinel lymph node biopsy and axillary lymph node dissection in Canada: A cost- minimization analysis Bryan J Wells1, May Lynn Quan3, Peter Coyte2 1University of Toronto, Department of Surgery, Toronto, Ontario, Canada, 2University of Toronto, Department of Health Policy, Management and Evaluation, Toronto, Ontario, Canada, 3University of Calgary, Department of Surgery, Foothills Medical Centre, Calgary, Alberta, Canada 11 OP9-3 The introduction of the 13-valent pneumococcal vaccine in Italy: The Health Technology Assessment in practice Giuseppe La Torre1 ,2, Chiara de Waure1, Maria Lucia Specchia1, Silvio Capizzi1, Flavia Kheiraoui1, Admir Malaj1, Alessandro Zollo3, Giuseppe Bunone3, Roberto Di Virgilio3, Pietro Refolo4, Lorenzo Mantovani5, Walter Ricciardi1 1Research Center of Health Technology Assessment, Institute of Hygiene, Catholic University of the Sacred Heart, Rome, Italy, 2Clinical Medicine and Public Health Unit, Sapienza University of Rome, Rome, Italy, 3Wyeth Italy Dept, Rome, Italy, 4Institute of Bioethics, Catholic University of the Sacred Heart, Rome, Italy, 5University of Naples “Federico II”, Naples, Italy OP9-4 Willingness to pay for voluntary community-based health insurance in Malaysia Asrul Shafi e, Mohamed Hassali TUESDAY, 8 JUNE 2010 TUESDAY, Universiti Sains Malaysia, Penang, Malaysia OP9-5 Cost-effectiveness of interventions for the prevention of casualties on the road: Transport economics meets health economics Jaime Peters, Rob Anderson Peninsula Medical School, Exeter, United Kingdom OP9-6 Service innovation in care homes for older people: What are the costs and benefi ts of providing an in-reach clinical team? Ala Szczepura1 ,2, Deidre Wild2 ,1, Sara Nelson2 1University of Warwick, Coventry, United Kingdom, 2University of the West of England, Bristol, United Kingdom

63 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

OP10 Tuesday 14:00 Dodder D

Clinical Reviews: Imaging and Screening Chair: Claire Packer, UK Chair: Colette Bonner, Ireland OP10-1 Estimation of overdiagnosis by new technologies for cancer screening Chisato Hamashima, Hiroshi Saito, Tomotaka Sobue National Cancer Center, Tokyo, Japan OP10-2 Is a high risk strategy cost-effective in a general population? The Inter99 study Torben Jørgensen, Charlotta Pisinger Research Centre for Prevention and Health, Glostrup, Denmark

OP10-3 Clinical practice guideline (CPG) on osteoporosis and prevention of fragility fractures: A tool for the decision makers Maria-Dolors Estrada1, Anna Kotzeva1, María Graciela Rodríguez1, Dolors Benítez1 1Catalan Agency for Health Technology Assessment and Research (CAHTA). Catalan Health Service. Catalan Department of Health, Barcelona, Catalonia, Spain, 2CIBER epidemiology and public Health 11 (CIBERESP), Barcelona, Spain OP10-4 Impact assessment of biomedical computer simulations: The Osteoporotic Virtual Physiological Human Project Rainer Thiel1, Karl A. Stroetmann1, Veli N. Stroetmann1, Marco Viceconti2 1Empirica Communication and Technology Research GmbH, Bonn, Germany, 2Laboratorio di Tecnologia Medica, Istituti Ortopedici Rizzoli, Bologna, Italy OP10-5 Appropriate use of ultrasonography and diagnostic imaging technologies in breast pathology Sofía Escalona1, Juan Antonio Blasco1, Nerea Fernández de Larrea1, Beatriz Valentín1, Elena Andradas2 1Health Technology Assessment Unit (UETS), Madrid, Spain, 2Laín Entralgo Agency, Madrid, Spain OP10-6 Prostate cancer screening through prostate-specifi c antigen (PSA) and digital rectal exam (DRE) TUESDAY, 8 JUNE 2010 TUESDAY, Mariana Pineda, Rosa Maria Ceballos CENETEC, México, D.F., Mexico

15:30 – 16:00 BREAK & POSTERS

16:00 – 17:30 Special Session 3 – EuroVaQ Concert Hall

EuroVaQ (European Value of a QALY): preliminary results Cam Donaldson, Angela Robinson, Mark Pennington, Job van Exel, Peter Littlejohns, Belen Corbacho

64 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

OP11 Tuesday 16:00 Clyde

Contribution and Impact of HTA Chair: Carole Longson, UK Chair: Pat McGrath, Ireland OP11-1 Modelling resource use and health outcomes as an aid to decision making between multiple cost- effective interventions: The example of colorectal cancer screening in Ireland Linda Sharp1, Lesley Tilson2, Sophie White3, Alan Ó Céilleachair1, Cathal Walsh4, Cara Usher2, Paul Tappenden3, Jim Chilcott3, Anthony Staines5, Harry Comber1, Michael Barry2 1National Cancer Registry, Cork, Ireland, 2National Centre for Pharmacoeconomics, Dublin, Ireland, 3School for Health and Related Research, University of Sheffi eld, Sheffi eld, United Kingdom, 4Dept. of Statistics, Trinity College Dublin, Dublin, Ireland, 5School of Nursing, Dublin City University, Dublin, Ireland OP11-2 Manufacturer’s response to cost-effectiveness information: Societal consequences of price changes of disposables for renal transplantation using pulsatile machine perfusion Henk Groen1, C. Moers2, J.M. Smits3, J. Treckmann4, D. Monbaliou5, A. Rahmel3, A. Paul4, J. Pirenne5, R.J. Ploeg2, E. Buskens1 1University Medical Center Groningen, Dept. of Epidemiology, Groningen, Netherlands, 2University 11 Medical Center Groningen, Dept. of Surgery, Groningen, Netherlands, 3Eurotransplant International Foundation, Leiden, Netherlands, 4University Hospital Essen, Abdominal and Transplant Surgery, Essen, Germany, 5University Hospital Leuven, Abdominal and Transplant Surgery, Leuven, Belgium OP11-3 Organization and fi nancing of chronic dialysis in Belgium Irina Cleemput, Chris De Laet Belgian Health Care Knowledge Centre, Brussels, Belgium OP11-4 Key decision makers’ and experts’ perspectives on the present and future of the assessment of health technologies in Spain: A naturalistic, two phases study Enrique Anton1, Silvia Paz2, Luis Lizan2,3, Jose Manuel Rodriguez4, Paloma Gonzalez1, Desire Rodriguez1

1Medtronic, Madrid, Spain, 2OUTCOMES’10, Castellon, Spain, 3Jaume I University, Castellon, Spain, 8 JUNE 2010 TUESDAY, 4Johnson and Johnson, Madrid, Spain OP11-5 Which health care settings for interventional care? Michele Morin - Surroca, Fabienne Quentin, Denis Jean David, Sun Hae Lee – Robin French National Authority for Health, Saint Denis La Plaine, France

OP11-6 The status of adoption of electronic medical records (EMR) in USA and in Europe: The role and the impact of HTA evaluations Giuseppe Turchetti1, Elie Geisler2 1Scuola Superiore Sant’Anna, Pisa, Italy, 2Illinois Institute of Technology, Chicago, United States

65 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

OP12 Tuesday 16:00 Lansdowne

HTA in Coverage Decision Making Chair: Jens Grueger, UK Chair: Valerie Walshe, Ireland OP12-1 Health technology assessment and the management of methicillin resistant staphylococcus aureus (MRSA) in Scotland - the sequel. A coverage with evidence development project Karen Ritchie1, Jacqui Reilly1 ,2, Sally Stewart1 ,2 1NHS Quality Improvement Scotland, Glasgow, United Kingdom, 2Health Protection Scotland, Glasgow, United Kingdom OP12-2 Establishing a National Framework for the assessment of Patient Access Schemes in NHS Scotland Marion Bennie, Victoria Cairns, Sharon Hems, Janet Richardson, Sue Stobie National Medicines Utilisation Unit, Information Services Division, NHS National Services Scotland, Scotland, United Kingdom OP12-3 Patient access schemes in NICE technology appraisals Helen Knight, Helen Chung, Meindert Boysen, Carole Longson 11 National Institute for Health and Clinical Excellence, Manchester/London, United Kingdom OP12-4 Dynamics in daily practice challenge real-world pharmacoeconomics: Clinical practice of bortezomib in relapsed or refractory multiple myeloma Margreet Franken1, Jennifer Gaultney1, Peter Huijgens2, Ken Redekop1, Carin Uyl-de Groot1 1Institute for Medical Technology Assessment, Erasumus University Rotterdam, Rotterdam, Netherlands, 2Department of Haematology, VU University Medical Center, Amsterdam, Netherlands OP12-5 CED, OIR, risking sharing or patient access scheme?: A framework for policy choice Simon Walker, Karl Claxton, Steve Palmer, Mark Sculpher University of York, York, United Kingdom

OP12-6 Collecting primary data to support policy decision making in Ontario: Why do we need different processes for diffused and non-diffused technologies?

TUESDAY, 8 JUNE 2010 TUESDAY, James M. Bowen1 ,2, Daria J. O’Reilly1 ,2, Jean-Eric Tarride1 ,2, Feng Xie1 ,2, Gord Blackhouse1 ,2, Lisa L. Patterson1 ,2, Robert B. Hopkins1 ,2, Natasha Burke1 ,2, Ron Goeree1 ,2 1PATH Research Institute, St. Joseph’s Healthcare Hamilton, Hamilton, Ontario, Canada, 2Dept. of Clinical Epidemiology & Biostatistics, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada

OP13 Tuesday 16:00 Dodder A

Methods in Systematic Reviews / Training and Capacity Building Chair: Alvaro Atallah, Brazil Chair: Martin Donnelly, Northern Ireland OP13-1 Objectivised development of search strategies - A new methodological approach for practical application Elke Hausner1, Siw Waffenschmidt1, Michael Simon2, Thomas Kaiser1 1Institute for Quality and Effi ciency in Health Care, Cologne, Germany, 2University of Kansas Medical Center, Kansas City, United States

66 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

OP13-2 Comparing AMSTAR to a QUOROM-based scoring system for evaluating the quality of systematic reviews and meta-analyses on treatment of paediatric obesity Pierre Dagenais, Linda Pinsonneault, Jolianne Renaud Agence d’évaluation des technologies et modes d’intervention en santé du Québec (AETMIS), Montreal, Québec, Canada OP13-3 ViHTA: Value in Health Technology Assessment. Results of an Italian experience Alessandro Agostinelli1, Giuseppe La Torre2, Americo Cicchetti3, Pietro Derrico4, Francesca Patarnello5, ViHTA Project Team* *Maria Avolio; Amalia Biasco; Silvio Capizzi; Antonio Giulio de Belvis; Chiara De Waure; Stefania Donno; Francesco Faggiano; Maria Rosaria Gualano; Flavia Kheiraoui; Francesco Maddalena; Alice Mannocc1, Walter Ricciardi1 1Health Technology Assessment Research Centre - Institute of Hygiene of the Catholic University of the Sacred Hearth, Rome, Italy, 2Clinical Medicine and Public Health Unit, Sapienza University, Rome, Italy, 3Health Technology Assessment Unit – Teaching Hospital “Agostino Gemelli”, Rome, Italy, 4Clinical Engineering Services, Pediatric Hospital “Bambino Gesù”, Rome, Italy, 5GlaxoSmithKline, Verona, Italy OP13-4 HTA Online - The fi rst German e-learning course tailored to HTA Annette Zentner, Christine Hoffmann, Reinhard Busse Berlin University of Technology, Dep. Healthcare Management, Berlin, Germany OP13-5 Collaborative HTA Capacity Building in Developing Countries: What works and what doesn’t? 11 (Lessons from the SIGNET Project) Joseph L. Mathew1, Lazar Mathew Thalakkotur3, Jeremy Lim2, Shin Yuh Ang2 1Postgraduate Institute of Medical Education And Research, Chandigarh, India, 2Singapore Health Services, Singapore, Singapore, 3VIT University, Vellore, India OP13-6 Health economic evaluation at the coal face - supporting therapeutic decision making in London NHS hospital trusts Michael A. Scott, Anthony M. Grosso University College London Hospital, Pharmacy Department, London, United Kingdom

OP14 Tuesday 16:00 Dodder B TUESDAY, 8 JUNE 2010 TUESDAY, Positron Emission Tomography (PET) Chair: Hans Peter Dauben, Germany Chair: Jon Billings, Ireland OP14-1 Forecasting the need for PET in Norway: Extending the range and impact of HTA. A report provided by the Norwegian Knowledge Centre for the Health Services Elisabeth Jeppesen, Inger N. Norderhaug, Bjørn Anton Graff, Espen Movik Norwegian Knowledge Centre for the Health Services, Oslo, Norway OP14-2 Positron emission tomography (PET) for assessment of axillary lymph node metastases in breast cancer: Systematic review Katy Cooper1, Susan Harnan1, Yang Meng1, Sue Ward1, Patrick Fitzgerald1, Diana Papaioannou1, Lynda Wyld2 ,1, Christine Ingram2 ,1, Iain Wilkinson1 ,2, Eleanor Lorenz2 ,1 1University of Sheffi eld, Sheffi eld, United Kingdom, 2Sheffi eld Teaching Hospitals, Sheffi eld, United Kingdom

67 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

OP14-3 Positron emission tomography for lymphoma - Findings from an Australian systematic review Stephanie Schoeppe, Luke Marinovich, Sally Wortley University of Sydney, NHMRC Clinical Trials Centre, Sydney, NSW, Australia

OP14-4 Big ticket technologies, indications and recommendations on use of PET-CT in radiation oncology treatment planning Eunate Arana-Arri1, Iñaki Gutiérrez-Ibarluzea2, Natalia Lekerika-Royo1, Pedro Bilbao- Zulaica1, Elsira Boveda-Carro1, J.M. Peña1 1Cruces Hospital, Barakaldo, Bizkaia/Basque Country, Spain, 2Osteba, Basque Offi ce for HTA, Vitoria-Gasteiz/Basque Country, Spain OP14-5 A systematic review of PET, PET/CT and conventional imaging in the detection of recurrent breast cancer: A case study of the use of direct and indirect test accuracy comparisons Mary Pennant1, Yemisi Takwoingi1, Clare Davenport1, Lucy Pennant1, Anne Fry-Smith1, Anne Eisinga2, Jon Deeks1, Chris Hyde3 1University of Birmingham, Birmingham, United Kingdom, 2UK Cochrane Centre, Oxford, United Kingdom, 3Universities of Exeter and Plymouth, Exeter, United Kingdom OP14-6 Meta-analysis as a method to optimize policy impact of health technology assessment: A French study on virtual colonoscopy. 11 Dominique Tessier1, Pascal Potier1, Michel Cucherat2, Denis-Jean David1, Sun-Hae Lee Robin1 1French National Authority for Health (HAS), Saint-Denis La Plaine, France, 2Faculty of Medical Sciences, Lyon, France

OP15 Tuesday 16:00 Dodder C

Data Quality and Handling of Uncertainty Chair: Uwe Siebert, Austria Chair: Lesley Tilson, Ireland OP15-1 The Catalan Arthroplasty Register (RACat): First years of experience and results (2005-2008) Mireia Espallargues1 ,2, Vicky Serra-Sutton1 ,2, Olga Martinez1, Alejandro Allepuz3 ,2, Francesc 4 TUESDAY, 8 JUNE 2010 TUESDAY, Palliso 1Catalan Agency for Health Technology Assessment and Research, Barcelona, Spain, 2CIBER Epidemiology & Public Health, CIBERESP, Barcelona, Spain, 3Primary Health Service Alt Penedes- Garraf, Catalan Health Institute, Barcelona, Spain, 4Hospital Santa Maria Lleida, Lleida, Spain OP15-2 Registries as supplementary evidence sources for HTAs: Their uses and abuses Sue O’Malley1 1Medical Intelligence, Sydney, NSW, Australia, 2Macquarie Graduate School of Management, Sydney, NSW, Australia OP15-3 Can multiple N-of-1 trials produce reliable evidence of clinical effectiveness of drugs for rare diseases? A systematic review of their quality of reporting Corinne Eisma1, Juul van den Reek1, Jaap Deinum2, Hans Groenewoud1, Gea Drost3, Gert Jan van der Wilt1 1Radboud University Medical Centre, Dept. of Epidemiology, Biostatistics and HTA, Nijmegen, Netherlands, 2Radboud University Medical Centre, Dept. of General Internal Medicine, Nijmegen, Netherlands, 3Radboud University Medical Centre, Dept. of Neurology, Nijmegen, Netherlands

68 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

OP15-4 Capturing the uncertainty of surrogate outcomes in cost-effectiveness models Kent Johnson1, Marissa Lassere1 1University of Newcastle, Newcastle, NSW, Australia, 2University of New South Wales, Sydney, NSW, Australia OP15-5 Creating realistic scenarios for sensitivity analysis in economic evaluation - applying parameter data from a different setting: a case study on chlamydia testing Jenni Hislop1, Zahidul Quayyum2 1Health Services Research Unit, University of Aberdeen, Aberdeen, United Kingdom, 2Health Economics Research Unit, University of Aberdeen, Aberdeen, United Kingdom OP15-6 Structural differences in NorCaD - Huge potential impact on cost-effectiveness Torbjørn Wisløff1 ,2, Ivar Sønbø Kristiansen2 1NOKC, Oslo, Norway, 2University of Oslo, Oslo, Norway

OP16 Tuesday 16:00 Dodder D

Methods – Assessment of Devices, Diagnostics and Technologies Chair: Sun-Hae Lee-Robin, France 11 Chair: Deirdre Mulholland, Ireland OP16-1 Myths and methods in economic evaluation of medical devices Cynthia P Iglesias Urrutia University of York, York, United Kingdom OP16-2 Assessment of diagnostic test performance study quality: A back to basics approach Andrea C Skelly, Joseph R Dettori Spectrum Research, Inc, Tacoma, Washington, United States OP16-3 Cochrane reviews of diagnostic test accuracy: progress and implications for HTA of diagnostics Chris Hyde1, 2 1Peninsula College of Medicine and Dentistry, University of Exeter, Exeter, United Kingdom, TUESDAY, 8 JUNE 2010 TUESDAY, 2University of Birmingham, Birmingham, United Kingdom OP16-4 “Linked evidence” Weighting of diagnostic accuracy criteria to state non-inferiority of an index test compared to a gold standard Katharina Biester1, Michaela Eikermann1, Guido Skipka1, Ulrich Grouven1, Alric Ruether1, Dagmar Luehmann1 ,2, Stefan Lange1 1Institute for Quality and Effi ciency in Health Care, Cologne, Germany, 2Universitätsklinikum Schleswig-Holstein, Institut für Sozialmedizin, Luebeck, Germany OP16-5 OP16-5 There is a lack of evidence concerning the evaluation of dental prosthesis. How to overcome this situation and establish evidence-based prosthodontics? Ch.-Markos Dintsios, Sigrid Droste, Annegret Herrmann-Frank Institute for Quality and Effi ciency in Health Care, Cologne, Germany OP16-6 Approaches to evaluate rehabilitation and fi rst steps towards pay for performance Brigitte Piso Ludwig Boltzmann Institute for Health Technology Assessment, Vienna, Austria

69 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

17:45 – 18:45 Building a Career in Health Technology Assessment Dodder A

This informal session is specially designed for students, or those just embarking on a career in HTA. Senior colleagues from a national HTA agency, a consulting group, the pharmaceutical industry and academia will outline what it takes to be successful in their fi eld. The presentations will be brief and there will be plenty of time for questions and discussion. In keeping with the informality of the occasion, wine, soft drinks and light refreshments will be provided Chair: Michael Barry Tammy Clifford, CADTH, Canada, Michael Drummond, University of York, UK Cliff Goodman, The Lewin Group, USA Jens Grueger, Pfi zer Inc., UK and USA

19:30 – 00:00 Conference Dinner Guinness Storehouse 11 Buses will leave the Conference Centre from 7.00pm for the Guinness Storehouse. TUESDAY, 8 JUNE 2010 TUESDAY,

70 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

PROGRAMME OVERVIEW - WEDNESDAY

Scientific Programme Overview : Wednesday, 9 June 2010

Conference Registration 0800-1330

INDUSTRIES SERPENTINE CONCERT CLYDE LANSDOWNE DODDER A DODDER B DODDER C DODDER D DODDER E MINERVA MERRION HALL HALL HALL

0830 Registration Panel 20 Panel 21 Panel 24 Panel 23 Speaker / Panel 22 - Secretariat 1000 Room

New Oral Oral Oral Oral Oral Oral 1000 Registration Directions Speaker / Presentation Presentation Presentation Presentation Presentation Presentation - for HTA in Secretariat 17 18 19 20 21 22 1100 Australia Room Special Session

1100 - Break 1130

Plenary 3 1130 - Maximising the Value through International Collaboration (Chair Máirín R yan) Concert Hall 1330 Presentation of Awards and Closing Ceremony

1330 Conference closed

11 WEDNESDAY, 9 JUNE 2010 WEDNESDAY,

71 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

WEDNESDAY PLENARY Andres Pichon Riviere SPEAKERS

Chair: Máirín Ryan

Prof. Andres Pichon-Riviere is a Physician, graduated from the University of Buenos Aires. He has a Master of Sciences in Clinical Epidemiology from Harvard University and a PhD in Public Health from the Dr Ryan is the Director of Health Technology Assessment University of Buenos Aires. Prof. Pichon-Riviere is the in the Health Information and Quality Authority and Executive Director and Director of Health Technology is a Lecturer in Pharmacoeconomics in the Dept of Assessment and Economic Evaluations from the Institute Pharmacology and Therapeutics, Trinity College Dublin. for Clinical Effectiveness and Health Policy (IECS – Prior to this position she was Chief I Pharmacist at the www.iecs.org.ar), a Latin American HTA Agency based National Centre for Pharmacoeconomics where she in Buenos Aires, Argentina, and member of INAHTA worked since its inception in 1998, and was a senior since 2005. Andres is Professor of Public Health at clinical pharmacist in HIV medicine in St James’s the University of Buenos Aires and Director of the Hospital. She holds a PhD from Trinity College and a HTA e-learning course. He is one of the Directors of Diploma in Health Economics from the University of INAHTA. In 2008 he was awarded the Global Health York. She also holds a Diploma in Clinical Pharmacy Leadership Award to promote Health Technology from the University of Derby. Her research interests Assessment in Latin America. include: cost data generation in the Irish setting, economic incentives in pharmaceutical policy in Ireland, trial based Jasmine Raoh Fang Pwu economic evaluation, economic analyses of HIV treatment and care delivery strategies in the resource limited setting. She is the principal investigator on a number of pharmacoeconomic analyses of HIV interventions in 11 African countries. She was co-chair of the Contributed Research Review Committee of the ISPOR 10th Annual European Congress in Dublin 2007.

Dr. Pwu is currently the Acting Director of Health Technology Assessment Division, Center for Drug Evaluation, Taiwan. She is also an adjunct Assistant Professor in Taipei Medical University. Dr. Pwu has been doing research in economic evaluation for nearly 20 years. Her division (CDE/HTA) is working closely WEDNESDAY, 9 JUNE 2010 WEDNESDAY, with the Bureau of National Health Insurance on reimbursement and pricing decisions. She has also been involved in several research projects of assessment to aid health policy decision-making – including anti- HBV treatment, cervical cancer screening, and HPV vaccination, etc.

72 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

Iga Lipska Laura Sampietro-Colom

Dr Lipska has been the Head of the HTA Department She has over 19 years of experience in evaluative in AHTAPol for 4 years. During this period she has research, specifi cally in HTA. She was partly responsible been responsible for building and managing the team for the development of the fi rst international project of research analysts (starting from 3, now up to 30 undertaken by INAHTA, and has collaborated actively in analysts). She has also been responsible for the position several other HTA European Projects, leading some areas of the Agency on the international scene via networking of action. She has been temporary advisor of United with professional organisations and institutions (HTAi, Nations Agencies (WHO, PAHO, World Bank). She has EUnetHTA, ISPOR, INAHTA). She is a member of been in several leading positions at the Catalan Ministry the EUnetHTA Executive Committee. She has great of Health dealing with planning and evaluation of health experience in international project management (mostly care services. Overall, her work has focused on the EU-funded projects). She has over 10 years experience in evaluation of health care technologies, the identifi cation, Polish public administration in health care sector. In 2004 management and transference of information to improve she was nominated by Minister of Health to represent the decision-making process, and in evidence-based Poland in the European Commission (the Audit Board planning healthcare services. She is currently the HTAi dealing with health care costs and international issues President. in health care, e.g negotiating bilateral agreements with Member States).

11 WEDNESDAY, 9 JUNE 2010 WEDNESDAY,

73 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

WEDNESDAY, 9 JUNE

08:00 – 11:00 REGISTRATION

08:30 – 10:00 PANEL SESSIONS 20-24

PP-20 Wednesday 08:30 Clyde

Risk-sharing approaches and patient access schemes: translating concepts into real world settings Chair: Mel Walker 20.1 Setting the Scene Mel Walker University of Wales, Cardiff, UK – GlaxoSmithKline R&D, London, UK 20.2 Introduction to Risk-sharing and Overview of Schemes Adrian Towse Offi ce of Health Economics (OHE), London, UK 20.3 Risk-sharing Analytics: Practical and Modelling Approach Olivier Ethgen University of Liege, Belgium & GlaxoSmithKline Biologicals, Wavre, Belgium 20.4 Broad HTA Perspectives on Risk-sharing and Patient Access Schemes Ad Schuurman Dutch Health Care Insurane Board (CVZ) Diemen, Netherlands & Medicine Evaluation Committee (MEDEV), Diemen, Netherlands 20.5 Practical Challenges of implementing Patient Access Schemes in the UK NHS Meindert Boysen National Institute for Health and Clinical Excellent (NICE), Manchester, UK

11 PP-21 Wednesday 08:30 Lansdowne

Informing research decisions: the role of economic analysis? 21.1 How and why value of information methods can be used to meet the needs of research funders and improve research prioritisation decisions Susan Griffi n University of York, UK 21.2 How and why value of information methods can be used to meet the needs of research funders and improve research prioritisation decisions Lotte Steuten University of Twente, Enschede, Netherlands 21.3 How and why value of information methods can be used to meet the needs of research funders and

WEDNESDAY, 9 JUNE 2010 WEDNESDAY, improve research prioritisation decisions Alan Brennan University of Sheffi eld, UK

74 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

21.4 Are value of information analyses useful in research prioritisation? A research funders perspective Tom Walley National Institute for Health Research, Southampton, UK – University of Liverpool, UK 21.5 Are value of information analyses useful in research prioritisation? A research funders perspective Carolyn Clancy Agency for Healthcare Research and Quality, Rockville, Maryland, US – George Washington University School of Medicine, Washington, D.C., US

PP-22 Wednesday 08:30 Minerva

Emerging and evolving methods for ethics in HTA 22.1 Ethical approaches in HTA: An overview Bjørn Hofmann Norwegian Knowledge Center for the Health Services, Oslo, Norway & University College of Gjøvik, Gjøvik, Norway 22.2 Can there be a hierarchy of ethical approaches or values, as in the fi eld of study design? What end points and quality criteria are relevant for ethics approaches in HTA? Gert Jan van der Wilt University Medical Center St Radboud, Nijmegen, Netherlands 22.3 Advantages and limitations for different approaches Annette Braunack-Mayer The University of Adelaide, Adelaide, Australia 22.4 To what extent does the method frame the message? Do methods have affi nities for conclusions? Annette Braunack-Mayer The University of Adelaide, Adelaide, Australia 22.5 Public opinion and public engagement: what is its role in ethics in HTA? Yvonne Bombard Faculty of Medicine, University of Toronto, Canada 11

PP-23 Wednesday 08:30 Dodder B

HTA contribution in the decision making process at hospital level 23.1 Marco Marchetti HTA Unit, “A. Gemelli” Teaching Hospital, Catholic University of Sacred Heart, Rome, Italy 23.2 Lennart Jivegard HTA - Centrum - Sahlgrenska University Hospital, Göteborg, Sweden 23.3 Claudia Wild LBI of HTA - Ludwig Boltzmann Institut für Health Technology Assessment, Wien, Austria

23.4 Jean-Blaise Wasserfallen 9 JUNE 2010 WEDNESDAY, University Hospital of Lausanne in French: Centre Universitaire: Hospitalier Vaudois / CHUV, Lausanne, Switzerland

75 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

23.5 Americo Cicchetti Catholic University of Sacred Heart, Rome, Italy

PP-24 Wednesday 08:30 Dodder A

Patients’ and citizens’ perspectives in Health Technology Assessments. How to use scientifi c methodology? Chair: Helle Ploug Hansen 24.1 Which methods are relevant in primary research for incorporating patients’/citizens’ views and perspectives? Helle Ploug Hansen The University of Southern Denmark, Institute of Public Health, Odense, Denmark 24.2 How to understand the processes of knowledge production? Julie Grew National Board of Health, Copenhagen, Denmark 24.3 How to generate robust research based evidence for assessments of patients’/citizens’ views and perspectives? Javier Gracia San Román Health Technology Assessment Unit (UETS), Agencia Laἱn Entralgo, Madrid, Spain

10:00 – 11:00 Special Session 4 Concert Hall

New Directions for Health Technology Assessment in Australia Brendon Kearney, Brian Richards, Richard King, Robyn Chu, 11 Tammy Clifford WEDNESDAY, 9 JUNE 2010 WEDNESDAY,

76 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

10:00 – 11:00 ORAL PRESENTATION SESSIONS 17-22 (4X15MINS)

OP17 Wednesday 10:00 Clyde

Patients as Stakeholders in HTA Chair: Karen Facey, UK Chair: Mary Vasseghi, Ireland OP17-1 Deliberative inclusive processes for community engagement in HTA and policy development: Fanfare or fi reworks? Jackie Street1, Annette Braunack-Mayer1, Janet Hiller1 ,2 1University of Adelaide, School of Population Health and Clinical Practice, Adelaide, SA, Australia, 2University of Adelaide, Adelaide Health Technology Assessment, Adelaide, SA, Australia OP17-2 Value of patient training in health technology assessment Durhane Wong-Rieger1, Elisabeth Fowler1 1Institute for Optimizing Health Outcomes, Toronto, Ontario, Canada, 2World Health Advocacy, Ottawa, Ontario, Canada OP17-3 From the experience in patient involvement in clinical practice guidelines to the patient-based health technology assessment Petra Diaz del Campo, Raquel Luengo, Beatriz Nieto, Javier Gracia, Fatima Izquierdo, Juan Antonio Blasco Lain Entralgo Agency, Health Technology Assessment Unit, Madrid, Spain OP17-4 HTAinSite: Analysis of an on-line database of all NICE submissions and decisions Christie Niziol, Simon Howard, Pamela Poppe Abacus International, Bicester, Oxfordshire, United Kingdom

OP18 Wednesday 10:00 Lansdowne 11 Health and social services: Common challenges Chair: Guy Maddern, Australia Chair: Martin Flattery, Ireland OP18-1 Adherence to international guidelines on vancomycin prescription in hospitalized children: A systematic review Carmen Bouza, Alfredo Borda-Olivas, Teresa López-Cuadrado Instituto de Salud Carlos III, Madrid, Spain OP18-2 Health and social services: Common challenges Jean-Pierre Duplantie, Reiner Banken AETMIS, Montreal, Quebec, Canada

OP18-3 Study quality and reporting bias in reviews of public health interventions 9 JUNE 2010 WEDNESDAY, Mark Pearson, Jaime Peters Peninsula Medical School, Exeter, United Kingdom

77 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

OP18-4 Integrating new technologies in the health services: Use of the Normalization Process Model to assess impact of complex intervention. The example of robotic surgery Luciana Ballini, Roberto Grilli Agenzia Sanitaria e Sociale Regionale - Regione Emilia-Romagna, Bologna, Italy

OP19 Wednesday 10:00 Dodder A

Horizon Scanning / Research to Inform Topic Selection Chair: Janet Hiller, Australia Chair: Mairead O Driscoll, Ireland OP19-1 What is the value of NIHR HTA Programme funded research in informing UK health care funding decisions? Tannaze Tinati, Marina Malaffo, Andrew Cook NETSCC HTA, Southampton, United Kingdom OP19-2 Horizon scanning system (HSS) in oncology: identifi cation and early assessment of new and emerging oncologic drugs Anna Nachtnebel1, Katharina Hintringer1 ,2, Sabine Geiger-Gritsch1 ,2 1Ludwig Boltzmann Institute for Health Technology Assessment, Vienna, Austria, 2Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Information Systems and Health Technology Assessment, UMIT - University for Health Sc, Hall i.T., Austria OP19-3 Testing the feasibility of KNOW ESSENTIALS – An algorithm for informed decision-making in the absence of formal HTA Joseph L. Mathew Postgraduate Institute of Medical Education And Research, Chandigarh, India OP19-4 Out with the old, in with the new: Identifying health technologies for disinvestment - Can early awareness and alert systems play a part? Adebowale Osinowo1, Sue Simpson2 1Department of Public Health, Epidemiology & Biostatistics, University of Birmingham, Birmingham, 11 West Midlands, United Kingdom, 2National Horizon Scanning Centre, University of Birmingham, Birmingham, West Midlands, United Kingdom

OP20 Wednesday 10:00 Dodder B

HTA Guidelines and Standardisation of Process Chair: Mike Drummond, UK Chair: Alan Smith, Ireland OP20-1 Comparison of international HTAs on new and established cardiac rhythm device therapies Pascale Dequen1, Kathy Cargill2, Liesl Birinyi-Strachan2 1London School of Economics, London, United Kingdom, 2Medtronic International Trading Sarl,

WEDNESDAY, 9 JUNE 2010 WEDNESDAY, Tolochenaz, Switzerland

78 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

OP20-2 A KM Framework to support a multinational network Patrice Chalon KCE, Brussels, Belgium

OP20-3 How can HTA guidelines be directed to make the greatest policy impact? The use and misuse of an infl uential set of guidelines for cost-effectiveness analysis Sara Khor1 ,2, Dilfuza Djalalova1 ,2, Jeffrey Hoch1 ,2 1Cancer Care Ontario, Toronto, Ontario, Canada, 2St. Michael’s Hospital, Toronto, Ontario, Canada OP20-4 Assessment and appraisal. Time for a re-appraisal Gert Jan van der Wilt Radboud University Medical Centre, Nijmegen, Netherlands

OP21 Wednesday 10:00 Dodder C

Clinical Reviews Chair: Tom Walley, UK Chair: Joe Devlin, Ireland OP21-1 Assessment of drug-eluting-stents Emmanuelle Schapiro-Dufour, Fabienne Midy, Elodie Velzenberger, Hubert Galmiche, Catherine Denis, Catherine Rumeau-Pichon HAS, La Plaine Saint Denis, France OP21-2 A meta-analysis and meta-regression analysis of recent data on INR management using portable prothrombin systems Monica Cepoiu-Martin, Sarah Rose, Diane Lorenzetti, Ken Fyie, Tom Noseworthy, Lloyd Sutherland University of Calgary, Calgary, Alberta, Canada OP21-3 A systematic review comparing paracetamol, non-steroidal anti-infl ammatory drugs (NSAIDs) and COX-2 inhibitors for the reduction of morphine-related side-effects in the 24 hours following major surgery Catriona McDaid1, Emma Maund1, Stephen Rice1, Kath Wright1, Brian Jenkins2, Nerys 11 Woolacott1 1Centre for Reviews and Dissemination, University of York, United Kingdom, 2School of Medicine, University of Wales, United Kingdom OP21-4 The potential cardiovascular consequences of switching from atorvastatin to generic simvastatin in the Netherlands Danny Liew1, Kate Webb2, Willem Jan Meerding3 1The University of Melbourne, Melbourne, Australia, 2Pfi zer Limited, Surrey, United Kingdom, 3Pfi zer bv, Capelle a/d IJssel, Netherlands WEDNESDAY, 9 JUNE 2010 WEDNESDAY,

79 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

OP22 Wednesday 10:00 Dodder D

Local Applications of HTA Chair: Laura Sampietro-Colom, Spain Chair: Shaun Flanagan, Ireland OP22-1 CEDIT: 27 years of experience of a hospital-based HTA agency - Evolutions in missions and organisation Anne-Florence Fay, Emmanuel Charpentier, Bruno Frachet, Hélène Gilardi, Jean-Yves Fagon Assistance Publique- Hopitaux de Paris, Paris, France OP22-2 Potential future impact of price control mechanisms on the community drug schemes in Ireland Lesley Tilson, Cara Usher, Michael Barry National Centre for Pharmacoeconomics, St. James’s Hospital, Dublin 8, Ireland

OP22-3 Bibliometric impact of the production of the Spanish HTA agencies Antoni Parada1, Iñaki Gutiérrez-Ibarluzea2, Mercedes Guerra3, Beatriz Duque4, Lorea Galnares2, Rocio Rodriguez5, Maria Sobrido6, Marta Millaret1, Montserrat Salas7, Raimundo Alcazar8 1AATRM, Catalan Agency for HTA, Barcelona, Catalonia, Spain, 2Osteba, Basque Offi ce for HTA, Vitoria-Gasteiz, Basque Country, Spain, 3UETS, Lain Entralgo, Madrid, Spain, 4Canary Island Health Service, Canarias, Spain, 5AETSA, Andalusian Agency for HTA, Sevilla, Spain, 6AValia-T, Galician Agency for HTA, Santiago, Spain, 7ICS, Aragon, Zaragoza, Spain, 8AETS-ISCIII, Madrid, Spain OP22-4 Did reimbursement decisions in Israel maximize the value of cost against benefi t for cancer technologies? Ifat Abadi-Korek, Alice Lowenstein-Kadori, Einav Horowitz, Ariela Freudenstein-Dan, Joshua Shemer Gertner Institute, Ramat Gan, Israel

11:00 – 11:30 COFFEE BREAK 11 WEDNESDAY, 9 JUNE 2010 WEDNESDAY,

80 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

11:30 – 13:30 Plenary 3, Presentation of Awards and Closing Ceremony Concert Hall

PL3 Maximising the value of HTA through international collaboration Chair: Mairin Ryan Health Information and Quality Authority PL3-1 South-South and North-South HTA transferability in Latin-America and the Caribbean Andres Pichon-Riviere IECS, University of Buenos Aires, Argentina PL3-2 Adapting HTAs conducted in another setting for local use Jasmine Raoh-Fang Pwu Division of Health Technology Assessment, CDE, Taiwan PL3-3 The role of staff exchanges in promoting international collaboration Iga Lipska AHTAPol, Poland PL3-4 HTAi’s role in promoting international collaboration Laura Sampietro-Colom Hospital Clinic Barcelona, HTAi President

13:30 CONFERENCE CLOSED

11 WEDNESDAY, 9 JUNE 2010 WEDNESDAY,

81 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

ANCILLARY MEETINGS

Sunday

09:00 HTAi Policy Forum Meeting – Minerva Room 14:00 Brazilian ISPC Meeting – President’s Room 14:00 EuroScan Meeting – Minerva Room

WELCOME MESSAGES Monday

13:00 Coverage with Evidence Development ISG – Dodder A 13:00 Hospital Based HTA ISG – Dodder B 13:00 Ethics ISG – Dodder C 13:00 Patients/Citizen Involvement in HTA ISG – Dodder D

18:00 HTAi Business Meeting – Clyde Room 19:00 IJTAHC Editorial Board – Lansdowne Room

Tuesday

12:30 Developing Countries ISG – Dodder A 12:30 Information Resources ISG – Dodder C 12:30 Surrogate Outcomes ISG – Dodder D

Wednesday

14:00 EUnetHTA Stakeholder Forum – Lansdowne Suite, Herbert Park Hotel

82 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010 1

Poster Sessions WELCOME MESSAGES Monday& Tuesday

83 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

POSTER SESSIONS Monday

M1-05 M1 - Clinical Effectiveness of psychological treatments based on Mindfulness Meditation to treat anxiety and depression M1-01 Lilisbeth Perestelo-Perez1 ,2, Jeanette Perez-Ramos1 ,3, Socio-ethical Analysis of Health Methodologies and Amado Rivero-Santana1 ,3, Marien Gonzalez-Lorenzo1 ,3, Technologies Used in Assessing Pesticide Poisoning Mayte Miro-Barrachina4 among Farmers- A Continuing Study 1Evaluation and Planning Unit. Canary Islands Health JInky Leilanie Lu Service, Tenerife, Spain, 2CIBER de Epidemiologia y Salud National Institutes of Health, UNiv of the Philippines, Publica (CIBERESP), Tenerife, Spain, 3Canarian Foundation Manila, Philippines of Health and Research (FUNCIS), Tenerife, Spain, 4Department of Personality, Evaluation and Psychological M1-02 Treatment. University of La Laguna, Tenerife, Spain Type of occupational health services for 21st century hazards in industrial productions system M1-06 JInky Leilanie Lu The group psychotherapy as therapeutic technique in National institutes of Health, Univ of the Philippines Manila, people with schizophrenia Manila, Philippines Lilisbeth Perestelo-Perez1 ,2, Marien Gonzalez-Lorenzo1 ,3, Jeanette Perez-Ramos1 ,3, Amado Rivero-Santana1 ,3, Lina 4 4 M1-03 Tost-Pardell , Cecilio Hernandez-de Sotomayor , Manuel 5 4 ,6 Cesarean delivery among women in Brazil: The role of Gonzalez-de Chavez , Francisco Rodriguez-Pulido , Angeles Rodriguez-Garcia4 socio-economic level in a national population based study 1 Gilberto Kac, Fernanda Rebelo, Camilla Da Rocha, Evaluation and Planning Unit. Canary Islands Health Service, Tenerife, Spain, 2CIBER de Epidemiologia y Salud Juliana Vaz, Michael Maia Publica (CIBERESP), Tenerife, Spain, 3Canarian Foundation Federal University of Rio de Janeiro, Josué de Castro of Health and Research (FUNCIS), Tenerife, Spain, Institute of Nutrition, Rio de Janeiro/Rio de Janeiro, Brazil 4Assertive Community Equip of the Canary Islands Health Service, Tenerife, Spain, 5Mental Health Service. University M1-04 Hospital Gregorio Marañón, Madrid, Spain, 6Medicine Evidence-based practice for children with cerebral palsy Department. University of La Laguna, Tenerife, Spain (CP) Ilona Autti-Rämö1 ,7, Heidi Anttila4, Katja Kanelisto5, M1-07 Ira Jeglinsky3, Leena Haataja2 ,8, Helena Mäenpää6 ,7, Salvage cryotherapy for recurrent or persistent prostate Marjukka Mäkelä4 cancer after radiotherapy 1The Social Insurance Institution, Department of Research, Zhaohui Liufu, Skye Newton, Janet Hiller, Tracy Merlin Helsinki, Finland, 2The Turku University Hospital, Adelaide Health Technology Assessment, School of Departmen of Pediatric Neurology, Turku, Finland, Population Health and Clinical Practice, the University of 3Arcada University of Applied Sciences, Helsinki, Finland, Adelaide, Adelaide, South Australia, Australia 4National Institute of Health and Welfare, Helsinki, Finland, 5The University of Jyväskylä, faculty of Sport and Health M1-08 Sciences, Department of Health Sciences, Jyväskylä, Systematic review of the endoscopic cryotherapy of lung Finland, 6The Helsinki University Hospital, Department tumors Seon heui Lee, Kaung Ju Park, won Jung Choi of Pediatric neurology, Helsinki, Finland, 7University of 8 Health Insurance review & Assessment Service, Seoul, 12 Helsinki, Faculty of Medicine, Helsinki, Finland, University Korea, Republic of of Turku, Faculty of Medicine, Turku, Finland M1-09 True non-surgical spinal decompression system Noormah Mohd Darus, Rugayah Bakri Malaysian Health Technology Assessment Section, Ministry of Health, Putrajaya, Malaysia POSTERS

84 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

M1-10 M1-16 Maggot debridement therapy Evaluating the effectiveness of anti-müllerian hormone Noormah Mohd Darus, Rugayah Bakri [ELISA], through a systematic literature review Malaysian Health Technology Assessment Section, Ministry Hae-Won Shin1, Jung-Ae Ko1, Eung-Gi Min2, Seung- of Health, Putrajaya, Malaysia Ryong Kim3, Chung-Hoon Kim4, Seung-Soo Sheen5, Sun- Hee Lee1 M1-11 1Department of Health Technology Assessment, Health Effectiveness of employment strategies and competitive Insurance Review & Assessment Service, Seoul, Korea, therapeutic intervention for people with disabilities by Republic of, 2Department of Obstetrics and Gynecology, severe and persistent mental health disorder College of Medicine, Dongguk University Ilsan Hospital, 3 Lilisbeth Perestelo-Perez1 ,2, Amado Rivero-Santana1 ,3, Ilsan, Korea, Republic of, Department of Obstetrics and Marien Gonzalez-Lorenzo1 ,3, Jeanette Perez-Ramos1 ,3, Gynecology, College of Medicine, Guri-Si, Korea, Republic 4 Francisco Rodriguez-Pulido4 ,5, Elena Tallo-Valdana6 of, Department of Obstetrics and Gynecology, College of 1Evaluation and Planning Unit. Canary Islands Health Medicine, University of Ulsan Asan Medical Center, Seoul, Korea, Republic of, 5Department of Pulmonary and Critical Service, Tenerife, Spain, 2CIBER de Epidemiologia y Care Medicine Ajou University School of Medicine, Su-Won, Salud Publica (CIBERESP), Tenerife, Spain, 3Canarian Korea, Republic of Foundation of Health and Research (FUNCIS), Tenerife, 4 Spain, Assertive Community Equip of the Canary Islands M1-17 Health Service, Tenerife, Spain, 5Medicine Department. Long term effect of injection therapy on low back pain University of La Laguna, Tenerife, Spain, 6Individual Support BoHyoung Jang1, So-Young Park2, Hyun Jin Choi2, Hee- Employment Unit (SIMPROMI), Tenerife, Spain Jeong Son1, Sang-Moo Lee1, SeoKyung Hahn2 1National Evidence-based Healthcare Collaborating Agency, 2 M1-12 Seoul, Korea, Republic of, Seoul National University, Seoul, Korea, Republic of Assessment tools for risk prediction of cardiovascular diseases M1-18 Vitali Gorenoi, Matthias P. Schönermark, Anja Hagen Health Technology Assessment for preventing patient Hannover Medical School, Hannover, Germany falls in hospitals Anne-Kirstine Dyrvig Nielsen M1-13 Odense University Hospital, Odense, Region of Southern Molecular testing for myeloproliferative disease: Denmark, Denmark The conundrum of an imperfect reference standard Elizabeth Buckley, Tracy Merlin, Linda Mundy, Janet M1-19 Hiller Interventions for the primary prophylaxis of retinal University of Adelaide, Adelaide, South Australia, Australia detachment in Stickler Syndrome: A systematic review Christopher Carroll, Diana Papaioannou, Sue Harnan M1-14 University of Sheffi eld, Sheffi eld, United Kingdom Enhanced recovery after surgery (ERAS) or fast-track surgery - What is the evidence? M1-20 Lana Sturm, Alun Cameron, Wendy Babidge Effectiveness of a school-based tobacco prevention ASERNIP-S, Royal Australasian College of Surgeons, programme Adelaide, South Australia, Australia Yolanda Ramallo Fariña1 ,2, Antonio Torres Lana2, Juan 10 Manuel Ramos Goñi1 ,2, Ana Morales Nuñez2, Renata M1-15 Linertová1 ,2, Beatriz Duque González1 ,2 Autologous fat transfer for cosmetic and reconstructive 1Foundation for Health and Research, FUNCIS, Tenerife/ breast augmentation 2 1 1 Canary Island, Spain, Canary Islands Health Service, Deanne Leopardi , Prema Thavaneswaran , Keith Tenerife/Canary Island, Spain Mutimer2, Norman Olbourne3, Guy Maddern1 ,4 1ASERNIP-S, Royal Australasian College of Surgeons, M1-21 Adelaide, South Australia, Australia, 2Brighton Plastic Effectiveness of Continuous Subcutaneous Insulin Surgery Centre, Melbourne, Victoria, Australia, 3Sydney 12 Infusion (CSII) in Type 2 Diabetes: Rapid HTA Institute of Plastic Surgery, Sydney, New South Wales, 1 2 2 Australia, 4Department of Surgery, The Queen Elizabeth Aung Soe Tin , Daphne Su-Lyn Gardner , Su-Yen Goh , 1 Hospital & Adelaide University, Adelaide, South Australia, Wai Leng Chow 1 Australia SingHealth Centre for Health Services Research, Singapore Health Services Pte Ltd, Singapore, Singapore, 2Department of Endocrinology, Singapore General Hospital, Singapore, Singapore POSTERS

85 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

M1-22 M1-28 Sugammadex for routine or rapid reversal of Is there a preferred gliptin for the treatment of type 2 neuromuscular block: A systematic review diabetes? Fiona Paton1, Duncan Chambers1, Nerys Woolacott1, Nadia Bahmad, Anne D’Andon, François Meyer Jennifer Hunter2, Morag Heirs1 Haute Autorité de Santé, Saint Denis, France 1University of York, York, United Kingdom, 2University of M1-29 Liverpool, Liverpool, United Kingdom HTA of alternative medicine: Bioresonance therapy - Clinical effectiveness and safety M1-23 Katharina Hintringer Comparative effectiveness of peginterferon 2a and 2b for Ludwig Boltzmann Institute for Health Technology chronic hepatitis C in a public health setting in Brazil Assessment, Vienna, Austria Karine Medeiros Amaral2 ,1, Candice Treter Gonçalves2 ,1, 2 ,1 3 ,2 Simara Artico , Norberto Campos Martins , Mathias M1-30 3 1 ,3 Bressel , Paulo Dornelles Picon Effectiveness and safety of probiotics for treating acute 1 Public Health State Secretariat of Rio Grande do Su, Porto diarrhea in children: A systematic review 2 Alegre, Brazil, Hospital Sanatório Partenon, Porto Alegre, Martin Bussières, Marc Rhainds, Brigitte Larocque, 3 Brazil, Hospital de Clinicas de Porto Alegre, Porto Alegre, Mélanie Hamel Brazil UETMIS, Centre hospitalier universitaire de Québec, Québec, Canada M1-24 Effectiveness of HLA DQ2 and DQ8 determination in M1-31 diagnosing Celiac´s Disease: A systematic review. New oral device (Thornton Adjustable Positioner®- TAP) Alicia Díaz-Redondo2, Zuleika Saz-Parkinson1, Luis for the treatment of obstructive sleep apnea syndrome Menchén3, Javier P Gisbert4 (OSAS) 1 ,2 2 2 1Instituto de Salud Carlos III, Madrid, Spain, 2Hospital La Abinaya Rajan , Setefi lla Luengo , Mar Polo 1 2 Paz, Madrid, Spain, 3Hospital Gregorio Marañón, Madrid, Universidad de Deusto, Bilbao, Spain, AETS, Madrid, Spain Spain, 4Hospital La Princesa, Madrid, Spain M1-32 M1-25 Pharmacovigilance of the treatment of chronic hepatitis Helmet therapy for children with deformational C as part of a effectiveness public health program: A plagiocephaly comparative study in Brazil Setefi lla Luengo-Matos, Mar Polo-DeSantos, Zuleika Candice Goncalves1, Karine Amaral1, Simara Artico1, Saz-Parkinson, Raimundo Alcazar-Alcazar, Antonio Suhelen Caon1, Paulo Picon2 Sarria-Santamera 1Hospital Sanatório Partenon, Porto Alegre, Rio Grande do Institute of health Carlos III, Madrid, Spain Sul, Brazil, 2Public Health State Secretariat, Rio Grande do Sul, Brazil M1-26 Data synthesis of ibandronate in persons with osteoporosis M1-33 or osteopenia: A meta-analysis of randomized controlled Systematic reviews on interventions to reduce mother- trials child mortality (Catirina Project) Haesun Suh, Min-Kyung Hyun, Younhee Kim, Sunyoung Taís Galvão, Maurício Pereira Park, Jooyeon Park, Jeonghoon Ahn, Minkyung Hong Universidade de Brasília Faculdade de Medicina, Brasília, National Evidence-based Collaborating Agency, Seoul, Korea, Distrito Federal, Brazil Republic of M1-34 M1-27 Surveillance of the ADR reporting system in Mongolia, How to stop drug users dying from an overdose: PART 1 A systematic review of treatment and prevention Zuzaan Zulzaga, Enkhzaya Shiiter Department of Health - Implementing agency of the 12 interventions government of Mongolia, Ulaanbaatar, Mongolia Bridie Evans1, Helen Snooks1, Daphne Russell1, Christine Brown2, Akshey Nair2, Chris Moore3, Alan Lewis4 1Swansea University, Swansea, United Kingdom, 2ABM University NHS Trust, Swansea, United Kingdom, 3Welsh Ambulance Service Trust, Cardiff, United Kingdom, 4Welsh Assembly Government, Cardiff, United Kingdom POSTERS

86 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

M1-35 M1-39 A systematic review: Palliative radiotherapy for bone The effi cacy of cholinesterase inhibitor and memantine metastasis for vascular dementia Sangjin Shin1, Hak Jae Kim3, Sang Min Yoon4, Woong Yoonjae Lee, Heeyoung Lee, Yeongchull Choi, Hee-jeong Sub Koom5, Hee Chul Park6, Sang Wook Lee4 ,1, Seung Son, In-sun Hwang Soo Sheen7 ,1, Yoon Jae Lee1, Jin Hee Kim1, Ji-ae Park1, National Evidence-based Healthcare Collaborating Agency, Yong Chan Ahn2 ,1 Seoul, Korea, Republic of 1National Evidence-based Healthcare Collaborating Agency, Seoul, Korea, Republic of, 2Dept of Radiation Oncology, M1-40 SungKyunKwan Univ., Seoul, Korea, Republic of, 3Dept of School scoliosis screening programme Radiation Oncology, Seoul National Univ, Seoul, Korea, Junainah Sabirin, Saidatul Norbaya Buang Republic of, 4Dept of Radiation Oncology, Univ of Ulsan, Ministry of Health, Putrajaya, Malaysia Seoul, Korea, Republic of, 5Dept of Radiation Oncology, Yonsei Univ., Seoul, Korea, Republic of, 6Dept of Radiation Oncology, M1-41 Samsung Medical Center, Seoul, Korea, Republic of, 7Dept of Validity of RMI (risk malignancy index) in Pre-operative Pulmonary, Ajou Univ., Suwon, Korea, Republic of evaluation of ovarian tumors Saera Afghan, Shazia Ali, Farhat Perveen M1-36 Maternal and Child Health Centre Pims., Islamabad, Pakistan Evaluating the effectiveness of the human papilloma virus E6/E7 mRNA test, [real-time nucleic acid sequence- M1-42 based amplifi cation (real-time NASBA)], through a Safety and effectiveness of transnasal upper systematic literature review gastrointestinal endoscopy: A systematic review So-hee Kim1, Tae-jin Kim2, Tae-hyun Um3, Seung-su Sin4, Ah Ram Sul1, Hyun Ho Kong2, Sang Woo Kim3, Kwang- Won-jeong Choi1, Jae-won Kim5 Jae Lee4, Young-Soo Rho5, Seon-Heui Lee1 1Department of Health Technology Assessment, Health 1Department of Health Technology Assessment, Health Insurance Review & Assessment Service, Seoul, Korea, Insurance Review & Assessment Service, Seoul, Korea, Republic of, 2Department of Obstetrics and Gynecology, Republic of, 2Kong’s Internal Medicine Clinic, Seoul, Cheil General Hospital and Women’s Healthcare Center, Korea, Republic of, 3Department of Internal Medicine, Kwandong University College of Medicine, Seoul, Korea, College of Medicine, Catholic University of Korea, Seoul, Republic of, 3Department of Laboratory Medicine, Ilsan Korea, Republic of, 4Department of Gastroenterology, Ajou Paik Hospital, Inje University College of Medicine, Goyang, University School of Medicine, Suwon, Korea, Republic of, Korea, Republic of, 4Department of Pulmonary and Critical 5Department of Otorhinolaryngology-Head & Neck Surgery, Care Medicine, Ajou University School of Medicine, Hallym University College of Medicine, Seoul, Korea, Suwon, Korea, Republic of, 5Department of Obstetrics and Republic of Gynecology, Seoul National University College of Medicine, Seoul, Korea, Republic of M1-43 A systematic literature review on tonsillectomy and M1-37 adenoidectomy with coblation Effects of a weight management program on Gaeun kim, D.I. Sun, S.H. Kim anthropometric indices and body fat Health Insurance Review & Assessment Service, seoul, 10 Fitriya Hartono, Celia Tan, Yong-Hao Pua Korea, Republic of Singapore General Hospital, Singapore, Singapore M1-44 M1-38 Occupational health and hydration status assessment Systematic review of human placental extracts among workers in a developing country HeeYoung Lee1, Ji-Eun Park1, Yoon-Jae Lee1, Byung- Rajan P. Bhandari1, Padam Prasai1 Cheul Shin2, Eun-Hwan Oh3, Sun-Young Jung1, Jeong- 1Jagadamba Pvt. Ltd, Ktm, Nepal, 2Community Health and Hyun Cho1, Na-Rae Leee1, Jong-Myon Bae1 Environmental Society Nepal, Ktm, Nepal 1National Evidence-based Healthcare Collaborating Agency, 12 Seoul, Korea, Republic of, 2Pusan National University, M1-45 School of Korean Medicine, Pusan, Korea, Republic of, Magnetic navigation in arrhythmia ablation, 3Hyupsung University, Department of Health Management, percutaneous coronary intervention, cardiac Hwaseong, Korea, Republic of resynchronized therapy Youjin Jung, Min Lee Health Insurance Review & Assessment Service, Seoul, Korea, Republic of

POSTERS

87 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

M2-07 M2 - Economics Budget impact analysis of natalizumab use in Ireland Anne Dee3, Shaun Flanagan1, Michael Hutchinson2, M2-01 Davida De la Harpe1 Model development for cost-effectiveness analysis of 1Health Service Executive, Dublin, Ireland, 2St. Vincents surgical site infection prevention strategies in total hip University Hospital, Dublin, Ireland, 3Heaslth Service arthroplasty Executive, Limerick, Ireland Katharina Merollini1, Nicholas Graves1 ,2, M2-08 Ross Crawford1 ,3 An application of value of information analysis to 1Institute of Health and Biomedical Innovation, Queensland decrease uncertainty University of Technology, Brisbane, Queensland, Australia, Laura McCullagh1, Cathal Walsh1 ,2, Michael Barry1 2The Centre for Healthcare Related Infection Surveillance 1National Centre for Pharmacoeconomics, St James’s and Prevention, Queensland Health, Brisbane, Queensland, Hospital, Dublin 8, Ireland, 2Department of Statistics, Trinity Australia, 3Orthopaedic Research Unit, Prince Charles College Dublin, Dublin 2, Ireland Hospital, Brisbane, Queensland, Australia M2-09 M2-02 Assessing the cost-effectiveness of an intervention to Manufacturer pricing of cardiac point of care testing prevent bath water scalds (POCT) within a publicly funded national healthcare Ceri Phillips1, Denise Kendrick2, Jane Stewart3, Mike system as a means of meeting reimbursement policy Hayes5, David Stone5, Lesley Nish7, Carol Coupland2, issues 4 2 1 Francis FitzGibbon1, David Huckle2, Brian Meenan1 Elizabeth Towner , S Smith , Ioan Humphreys 1 1University of Ulster, MATCH Programme, Jordanstown Co. Swansea University, Swansea, United Kingdom, Antrim Northern Ireland, United Kingdom, 2Adams Business 2University of Nottingham, Nottingham, United Kingdom, Associates, High Wycombe Bucks, United Kingdom 3Nottinghamshire County Teaching Primary Care Trust, Nottingham, United Kingdom, 4University West of England, M2-03 Bristol, United Kingdom, 5Child Accident Prevention Trust, Economic consequences of home hospitalization of London, United Kingdom, 6University of Glasgow, Glasgow, chronic obstructive pulmonary disease patients United Kingdom, 7Glasgow Housing Association, Glasgow, 1 2 Iben Fasterholdt , Mickael Bech United Kingdom 1Odense University Hospital, Odense, Denmark, 2University of Southern Denmark, Odense, Denmark M2-10 M2-04 Piloting the development of a cost-effective evidence- Cost effectiveness of lapatinib for previously treated informed hypertension guideline for primary care in metastatic breast cancer in Ireland Jordan Sandra Redmond1, Tom Delea2 Nour Obeidat1, Kalipso Chalkidou2, Joanne Lord3, 1GlaxoSmithLine, Dublin, Ireland, 2Policy Analyis Inc, Ibrahim Al-Abbadi5, Rania Bader6, Ayman Momani4, Brookline, MA, United States Lara Qatami7, Rachel O’Mahony9, Andrew Stanley8 1King Hussein Institute for Biotechnology and Cancer, M2-05 Amman, Jordan, 2National Institute for Clinical Excellence Cost-effectiveness analysis of the genetic screening for International, London, United Kingdom, 3Brunel University, predisposition to venous thromboembolism (VTE) in the London, United Kingdom, 4PharmaNet, Amman, Jordan, Italian context 5 6 1 1 2 University of Jordan, Amman, Jordan, Department for Amelia Compagni , Alessia Melegaro , Stefania Boccia , Walter Ricciardi2, Rosanna Tarricone1 International Development MeTA project, Amman, Jordan, 7 8 1Bocconi University, Milan, Italy, 2Catholic University, King Hussein Cancer Center, Amman, Jordan, University Rome, Italy Hospitals of Leicester NHS Trust, Leicester, United Kingdom, 9National Clinical Guidelines Centre for Acute and M2-06 Chronic Conditions, London, United Kingdom Handling side effects of 5alpha-reductase inhibitors: 12 Impact on the cost-effectiveness of chemoprevention for M2-11 prostate cancer Remember not to forget integration of local context 1 ,2 1 ,2 1 Shelby Reed , Charles Scales , Suzanne Stewart , when extrapolating HTA from developed to developing Jielin Sun3, Judd Moul1, Kevin Schulman1 ,2, Jianfeng Xu3 1 countries Duke University Medical Center, Durham, NC, United 1 2 1 2 Joseph L. Mathew , Regina El Dib , Preethy J. Mathew States, Duke Clinical Research Institute, Durham, NC, 1 United States, 3Wake Forest University School of Medicine, Postgraduate Institute of Medical Education And Research, 2 Durham, NC, United States Chandigarh, India, Fomerly at McMaster University, Hamilton, Canada POSTERS

88 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

M2-12 M2-19 Is it cost-effective? It depends on whom you ask Spinal cord stimulation in the treatment of failed back Dan Greenberg1 ,2, Allison B. Rosen3, Peter J. Neumann2 surgery syndrome: Cost effectiveness in the United States 1Ben-Gurion University of the Negev, Beer-Sheva, Israel, Rod Taylor1, Richard North3, Jane Shipley4, Anthony 2Tufts Medical Center, Boston, MA, United States, 3University Bentley2 of Michigan, Ann Arbor, MI, United States 1Peninsula Medical School, University of Exeter, Exeter, United Kingdom, 2Abacus International, Bicester, United M2-13 Kingdom, 3The Sandra and Malcolm Berman Brain & Spine Can magnetic resonance imaging be used to screen Institute, Sinai Hospital of Baltimore, Baltimore, United women at high risk for breast cancer? A mini-HTA States, 4The Neuromodulation Foundation, Inc., Baltimore, Vivian Wang1, Wai Leng Chow1, Su Ming Tan2 United Kingdom 1SingHealth Centre for Health Services Research, Singapore, Singapore, 2Changi General Hospital, Singapore, Singapore M2-20 Cost-effectiveness of radio-frequency ablation in M2-14 paroxysmal atrial fi brillation: implications for future Cost and cost-effectiveness of spinal cord stimulation reimbursement policies (SCS) for failed back surgery syndrome: An Paul Gross1, Nick Graves2, Jonathon Kalman3, John observational study in a workers’ compensation Hayes6, Cameron Singleton4, Stuart Thomas5, Kristy population Hardy7, Sarah Griffi n8 William Hollingworth1, Judith Turner2, Nicky Welton1, 1Health group Strategies Pty Ltd, Balgowlah Heights, NSW, Bryan Comstock2, Rick Deyo3 Australia, 2Queensland University of Technology, Brisbane, 1University of Bristol, Bristol, United Kingdom, 2University Queensland, Australia, 3Department of Cardiology, of Washington, Seattle, United States, 3Oregon Health and Royal Melbourne Hospital and Department of Medicine, Science University, Portland, United States University of Melbourne, Victoria, Australia, Melbourne, Victoria, Australia, 4Department of Cardiology, Flinders M2-15 Medical Centre, Bedford Park, South Australia, Australia, An alternate low cost method of vacuum assisted wound 5Department of Cardiology Westmead Hospital, Westmead management NSW, Australia, 6St Andrews War Memorial Hospital, Spring Tanwir Khaliq, M HameedUddin, Ali Akhtar Hill Queensland, Australia, 7Johnson and Johnson Medical Pakistan Institute of Medical Sciences, Islamabad, Pakistan Pty Ltdl, North Ryde NSW, Australia, 8St Jude Medical Australia Pty Ltd, Lane Cove NSW, Australia M2-16 Cost-utility analysis of tiotropium for the treatment of M2-21 COPD under real-world conditions in Belgium Are the healthcare expenditures of morbidly obese Mattias Neyt, Stephan Devriese, Nancy Thiry, Ann Van patients higher before or after bariatric surgery? den Bruel Silvana Bruschi Kelles1 ,2, Sandhi Barreto3, Henrique Belgian Health Care Knowledge Centre (KCE), Brussels, Guerra3 Belgium 1Unimed-BH, Belo Horizonte, Minas Gerais, Brazil, 2Federal University of Minas Gerais (NATS/HC/UFMG), National M2-17 Institute of Science and Technology for Health Technology Five-year evolution of drug prescribing in a university Assessment (IATS), Belo Horizonte, Minas Gerais, Brazil, 10 adult intensive care unit 3Program of Post-graduation on Adults Health in the Faculty Jean-Blaise Wasserfallen1 ,2, Christine Carron2, Pierre of Medicine, Federal University of Minas Gerais, Belo Voirol1, Philippe Eggimann1 ,2, René Chioléro1 ,2, André Horizonte, Minas Gerais, Brazil Pannatier1 ,3 1Lausanne University Hospital (CHUV), Lausanne, M2-22 Switzerland, 2Lausanne University (UNIL), Lausanne, Direct costs of deferasirox incorporation by Brazilian Switzerland, 3Geneva University (UNIGE), Geneva, Switzerland Public Health System (BPHS) for the treatment of heavily iron-overloaded patients M2-18 Silvana Bruschi Kelles1 ,2, Carlos Amaral1 ,2, Antonio Luiz 12 Cost-utility analysis of cholinesterase inhibitors in the Ribeiro1 ,2, José Luiz Nogueira1 ,2 treatment of mild to moderate alzheimer’s disease 1Heath Technology Assessment Nucleus, Hospital das 1 ,2 1 ,2 Saowalak Turongkaravee , Usa Chaikledkaew , Yot Clínicas, Federal University of Minas Gerais (NATS/HC/ Teerawattananon1 UFMG) National Institute of Science and Technology for 1Health Intervention and Technology Assessment Program Health Technology Assessment (IATS) – C, Belo Horizonte, (HITAP), Nonthaburi, Thailand, 2Department of Pharmacy, Brazil, 2National Institute of Science and Technology for Faculty of Pharmacy, Mahidol University, Bangkok, Thailand Health Technology Assessment (IATS) – CNPq/Brazil, Belo Horizonte, Brazil POSTERS

89 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

M2-28 M2-23 Economic evaluation of photodynamic diagnosis and Five leading causes of mortality and its impact on urinary biomarkers for detection and follow-up of economy in Mongolia bladder cancer Munkh-Erdene Luvsan2, Zoljargal Erdenechimeg1, Mary Kilonzo1, Luke Vale1 ,2, Shihua Zhu2, Graham Byambatseren Jambaljav1, Sevjid Natsagdorj1 Mowatt2, Charles Boachie2, James N’Dow3, T.R.L. 1Department of Health - Implementing Agency of the Griffi ths4, Jonathan Cook2, Ghulam Nabi3, Government of Mongolia, Ulaanbaatar, Mongolia, 2School Cynthia Fraser2 of Public Health, Health Sciences University of Mongolia, 1Health Economics Research Unit, University of Aberdeen, Ulaanbaatar, Mongolia Aberdeen, United Kingdom, 2Health Services Research Unit, University of Aberdeen, Aberdeen, United Kingdom, M2-24 3Academic Urology Unit, Department of Surgery, University Experiences of using a spreadsheet decision-tree tool with of Aberdeen, Aberdeen, United Kingdom, 4Department of non-professional health economists Cancer Studies and Molecular Medicine, University of John Crowe, Michael Craven, Bo Lu, Steve Morgan Leicester, Leicester, United Kingdom MATCH, University of Nottingham, Nottingham, United Kingdom M2-29 Screening for Prostate Cancer: A Decision Analysis M2-25 Julio López Bastida1, Franco Sassi2, Begoña Bellas3 Economic evaluation of a universal childhood rotavirus 1Evaluation and Planning Unit. Canary Islands Health vaccination programme in Ireland Service, Tenerife/Canary Island, Spain, 2London School of Lesley Tilson1, Cathal Walsh2, Suzanne Schmitz2, Mark Economics and Political Science, Londres, United Kingdom, Jit3, Michael Barry1 3Canary Islands University Hospital. Canary Islands Health 1National Centre for Pharmacoeconomics, St James’s Service, Tenerife/Canary Island, Spain Hospital, Dublin 8, Ireland, 2Department of Statistics, Trinity College Dublin, Dublin 2, Ireland, 3Modelling and M2-30 Economics Unit, Centre for Infections, Health Protection Reimbursement of Lantus in Poland: A budget impact Agency, Health Protection Agency, London, London, United analysis Kingdom Kaja Kostrzewska1, Robert Plisko1, Przemyslaw Rys1, Joanna Lis2 1 2 M2-26 HTA Consulting, Kraków, Poland, Sanofi -Aventis, Transcatheter aortic valve implantation (TAVI) Warszawa, Poland evaluation in a regional setting: the experience of Veneto, M2-31 Italy Screening for gestational diabetes mellitus: The impact Chiara Filippi1, Anna Fratucello1, Paola Marini1, of estimating patient level risk compared with population Francesca Bassotto1, Valentina Fantelli1, Corrado 2 2 3 risk Vassanelli , Flavio Ribichini , Gino Gerosa , Mara 1 2 3 4 4 1 Jeff Round , Paul Jacklin , Magdalena Wladysiuk Vezzani , Teresa Gasparetto , Giovanna Scroccaro 1University of Leeds, Leeds, United Kingdom, 2National 1 Drug effectiveness evaluation unit of the Regional Reference Collaborating Centre for Women’s and Children’s Health, Centre for pharmaceutical agents (UVEF) - Department London, United Kingdom, 3HTA Consulting, Poland of Pharmacy of Civile Maggiore Hospital, Verona, Italy, 2Department of Cardiology - Civile Maggiore Hospital, M2-32 Verona, Italy, 3Department of Cardiac Surgery – Padova Safety and cost-effectiveness of off-pump coronary artery Hospital, Padova, Italy, 4Regional Pharmaceutical Service of by-pass surgery in elderly patients. A randomized study Veneto, Venice, Italy of 900 patients above 70 years Kim Houlind1 ,10, Bo Juul Kjeldsen2, Britta Bjerrum3, M2-27 Susanne Madsen4, Kristian Kidholm5, Bodil S 12 Cost-utility of cataract surgery Rasmussen6, Søren P Johnsen7, Susanne Holme8, Poul Julio López Bastida2, Yolanda Ramallo Fariña1 ,2, Pedro Erik Mortensen2, Lars Ehlers9 Serrano Aguilar2, Jose María Cabrera Hernández2 1Dept. of Vascular surgery, Viborg Hospital, Viborg, 1Foundation for Health and Research, FUNCIS, Tenerife/ Denmark, 2Dept. of Cardiothoracic Surgery, Odense Canary Island, Spain, 2Canary Islands Health Service, University Hospital, Odense, Denmark, 3Dacehta,

Tenerife/Canary Island, Spain National Board of Health, Copenhagen, Denmark, 4Dept. of Cardiothoracic Surgery, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark, 5Health Technology Assessment, Odense University Hospital, POSTERS

90 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

Odense, Denmark, 6Dept. of Anaesthesia, Aalborg Hospital, M2-37 aarhus University Hospital, Aalborg, Denmark, 7Dept. of Unattended sleep studies in the diagnosis of obstructive Clinical Epidemiology, Aarhus University Hospital, Aarhus, sleep apnoea Denmark, 8Dept. of Cardiothoracic Surgery, Gentofte Tracy Merlin, Zhaohui Liufu, Shuhong Wang Hospitral, Gentofte, Denmark, 9Health Economics and Adelaide Health Technology Assessment (AHTA), School Management, Aalborg University, Aalborg, Denmark, of Population Health and Clinical Practice, University of 10Biomedical Engineering, Clinical Institute, Aarhus Adelaide, Adelaide, South Australia, Australia University Hospital, Aarhus, Denmark M2-38 M2-33 Use of an economic threshold analysis to inform infection Costs of producing single and multiple technology control decision making assessment reports for National Institute for Health and Kate Halton1 ,2, Nicholas Graves1 Clinical Excellence (NICE) appraisals 1Queensland University of Technology, Brisbane, Australia, Catherine Meads, Linda Briscoe, David Moore 2Centre for Healthcare Related Infection Surveillance and Department of Public Health, Epidemiology and Prevention, Brisbane, Australia Biostatistics, University of Birmingham, Birmingham, United Kingdom M2-39 Analysis of incremental effectiveness range for economic M2-34 evaluation in Korea What are the most cost-effective statins in France? Hyunjin Song1, Younhee Kim1, Sangjin Shin1, Sunyoung Emmanuelle Cohn-Zanchetta1, Nathalie Preaubert- Park1, Jooyeon Park1, Eunyoung Bae2, Jeonghoon Ahn1 Hayes2, Anne D’andon1, Catherine Rumeau-Pichon1 1National Evidence-based Healthcare Collaborating 1Haute Autorité de Santé, Saint Denis, France, 2CHU Agency, Seoul, Republic of Korea, 2Sangji University, Wonju, Bordeaux, Bordeaux, France Republic of Korea

M2-35 M2-40 Oral anticoagulation therapy testing in developing A systematic review of economic methods to measure countries: Implications of self-testing patients and public perspectives in Health Technology Syed Ghulam Sarwar Shah1, Andre Wajner2 ,3, Salman Assessment Adil4, Carolina da Fonte Pithan5 ,6, Tanwir Khaliq7 Erika Daza1, Marie-Pierre Gangon2, Anis Benabdeljelijl2 1Multidisciplinary Assessment of Technology Centre for 1ICESI University, Cali, Colombia, 2Laval University, Healthcare, Brunel University, Uxbridge, Middlesex, Quebec, Canada United Kingdom, 2Hospitalist of Hospital Nossa Senhora da Conceição and Hospital, Municipal Getúlio Vargas, Brazil, M2-41 3Preceptor of Internal Medicine Residency of Hospital Nossa Bevacizumab for age-related macular degeneration and Senhora da Conceição, Porto Alegre/RS, Brazil, 4Aga Khan diabetic retinopathy University & Hospital, Karachi, Sindh, Pakistan, 5Hospital Izzuna Mudla Mohamed Ghazali, Noormah Mohd Moinhos de Vento e Hospital Nossa Senhora da Conceição, Darus, Mohd Said Morad, Rugayah Bakri Porto Alegre, Brazil, 6Preceptor of Hematology Residency MaHTAS, Putrajaya, Malaysia of Hospital Nossa Senhora da Conceição, Porto Alegre/RS, 10 Brazil, 7Pakistan Institute of Medical Sciences, Islamabad, M2-42 Pakistan HIV infection screening among the general population in France M2-36 Olivier Scemama, Anne-Isabelle Poullié Comparative analysis of HTAs of Endovascular Haute Autorité de Santé, Saint Denis La Plaine, France Abdominal Aortic Aneurysm Repair (EVAR) Pascale Brasseur1, Pascale Dequen2 M2-43 1Medtronic International Trading Sarl, Tolochenaz, A priori evaluation of expanding the French national 12 Switzerland, 2London School of Economics, London, United neonatal screening programme to one or more inborn Kingdom errors of metabolism using tandem mass spectrometry Françoise Hamers, Clémence Thébaut, Olivier Scemama Haute Autorité de Santé, Saint-Denis, France POSTERS

91 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

M2-44 M2-48 Health Technology Assessment report on the new Paying for health care of communicable diseases among Pneumococcal Non-Typeable Haemophilus infl uenzae women and children: economic value with application to Protein D Conjugate Vaccine in Italy developing country, Nepal Maria Rosaria Gualano1, Giuseppe La Torre1 ,7, Flavia Shambhu D. Joshi1, Rajan P. Bhandari1 Kheiraoui1, Paolo Castiglia2, Stefano Capri3, Eugenio 1Primary Health Cener, Kailali, Nepal, 2Community Health 4 5 6 Anessi Pessina , Dario Sacchini , Alessia Marocco , Alice and Environmental Society Nepal, Community Health and 1 1 6 Mannocci , Nicola Nicolotti , Francesco Bamfi , Federico Environmental Society Nepal, Nepal Marchetti6, Francesca Patarnello6, Walter Ricciardi1 1 Research Centre of Health Technology Assessment, Institute M2-49 of Hygiene, Catholic University of the Sacred Heart, Rome, Economic evaluation of smoking cessation medications in Italy, 2Institute of Hygiene, University of Sassari, Sassari, Thailand Italy, 3Institute of Economics, Cattaneo LIUC-University Kednapa Thavorn, Nathorn Chaiyakunapruk of Castellanza, Castellanza, Italy, 4Institute of Economics, University of Toronto, Toronto, Canada Catholic University of the Sacred Heart, Rome, Italy, 5 Institute of Bioethics, Catholic University of the Sacred M2-50 Heart, Rome, Italy, 6GlaxoSmithKline S.p.a., Italy, Verona, Economic evaluation of dasatinib for the treatment of Italy, 7Clinical Medicine and Public Health Unit, Sapienza chronic myelogenous leukaemia in patients resistant to University of Rome, Rome, Italy imatinib in Colombia and Venezuela John Jairo Orozco1, Juan Esteban Valencia Zapata1, Gabriel Germán Ribon2, Fernando Guerrero2, Eleonora M2-45 3 2 Analysis of cost-effectiveness of the age of beginning of Aiello , Maximilian Lebmeier 1Universidad CES, Medellín, Colombia, 2Bristol-Myers mammographic screening Squibb, Bogotá, Colombia, 3Bristol-Myers Squibb, Intercon, Antonio Peregrino1, Cid Vianna2, Rosangela Caetano2, Argentina Gabriela Mosegui3, Carlos de Almeida1, Samara Ferreira-Machado4 M2-51 1Universidade do Estado do Rio de Janeiro/Laboratório Economic analysis of the impact of health status and de Ciencias Radiológicas, Rio de Janeiro/Rio de Janeiro, smoking behaviour on labour wage in Indonesia: The case of Indonesia family life survey data Brazil, 2Universidade do Estado do Rio deJaneiro/ Instituto Heni Wahyuni de Medicina Social, Rio de Janeiro/Rio de Janeiro, Brazil, Universitas Gadjah Mada, Yogyakarta, Indonesia 3Universidade Federal Fluminense, Niterói/ Rio de Janeiro, Brazil, 4Universidade Federal Fluminense/Departamento de M2-52 Biologia, Niterói/Rio de Janeiro, Brazil An integrated health-economic analysis of diagnostic and therapeutic strategies in the treatment of obstructive M2-46 sleep apnea (OSA): Model results and implications for technology and policy development Cost-effectiveness of interventions for reducing road Jan B Pietzsch1 ,2, Abigail Garner1, Lauren E. Cipriano2, traffi c injuries related to driving under the infl uence of John H. Linehan3 alcohol in Thailand 1 2 Vallop Ditsuwan1 ,2, Lennert Veerman2, Melanie WingTech Inc., Menlo Park,CA, United States, Stanford 3 Bertram2, Theo Vos2 University, Stanford, CA, United States, Northwestern 1Faculty of Health and Sport Science, Thaksin University, University, Chicago, IL, United States Phatthalung Province, Thailand, 2The University of Queensland, School of Population Health, Brisbane, Australia

M2-47 Cost-effectiveness analysis of a FOBT based colorectal cancer screening programme Elena Pizzo1, Enrico Bracci2, Emidia Vagnoni2, Janneke 12 Wilschut3, Marjolein van Ballegooijen3 1Imperial College Business School, London, United Kingdom, 2University of Ferrara, Department of Economics, Ferrara, Italy, 3Erasmus MC, Department of Public Health, Rotterdam, Netherlands POSTERS

92 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

M3 - Healthcare Policy

M3-01 M3-09 Do models help for reimbursement decisions? Towards a behavioural analysis of research funding Gottfried Endel1, Niki Popper2 ,3, Günther Zauner2 ,3 decisions: Analysis of the UK’s NIHR HTA programme 1Head association of the Austrain social insurance funds, James Raftery Vienna, Austria, 2Technical university of Vienna, Vienna, School of Medicine, University of Southampton, United Austria, 3Drahtwarenhandlung, Vienna, Austria Kingdom

M3-02 M3-10 Community health care programs assessment - The new Funding genetic tests - Ethical Dilemmas and task of Polish Agency for Health Technology Assessment implications in shaping public policy (AHTAPol) Orna Tal1 ,2, Miriam Ines Siebzehner1 ,2 Anna Zawada 1Ministry of Health, Jerusalem, Israel, 2Gertner Institute, Tel Polish Agency for Health Technology Assessment, Warsaw, Hashomer, Israel Poland M3-11 M3-03 A national network to coordinate HTA, health technology The proper role of effi ciency in “priority setting” in health uptake and evaluation 1 2 3 care Paul Fennessy , Mandy Forster , Simon Towler 1 2 J. Jaime Caro1 Department of Health, Victoria, Australia, Queensland 3 1United Biosource Corporation, Lexington, MA, United Health, Queensland, Australia, Department of Health, States, 2Mc Gill University, Montreal, Quebec, Canada Western Australia, Australia

M3-04 M3-12 The process and the result of topic selection of NECA Decision making on newborn screening programs across in 2009 Europe Min-Kyung Hyun, Dae-Seog Heo, Chung-Jong Kim, Katharina Fischer, Wolf Rogwoski Seok-Won Hong, Young-Gook Shin, Jae-Suk Lee, Hyun- Helmholtz Zentrum Muenchen - German Research Center Ji Baek, Na-Ra Yun, Sang-Moo Lee for Environmental Health, Institute of Health Economics and National Evidence-based healthcare Collaborating Agency, Health Care Management, Neuherberg, Germany Seoul, Korea, Republic of M3-13 M3-05 Try, try, try again- HTA as a structured framework f Health technology assessment in Slovenia - Wishful or IVF thinking or possible solution? Miriam Ines Siebzehner1 ,2, Orna Tal1 ,2 2 1 ,3 1 Eva Turk , Valentina Prevolnik Rupel , Dorjan Marusic 1Ministry of Health, Jerusalem, Israel, 2ICTHAC Gertner 1 Health Insurance Institute of Slovenia, Ljubljana, Slovenia, Institute, Tel Hashomer, Israel, 3Tel Aviv University, Tel Aviv, 2Institute for Public Health, Ljubljana, Slovenia, 3Institute for Israel Economic Research, Ljubljana, Slovenia 10 M3-14 M3-06 International perspectives on cancer control: The Evidence-based medicine, health technology assessment all-Ireland NCI cancer consortium and comparative effectiveness research: clearing the Isabel Otero confusion 1 2 3 U.S. National Cancer Institute, Bethesda, Maryland, Bryan Luce , Michael Drummond , Bengt Jonsson , Peter 4 5 6 United States Neumann , Sandford Schwartz , Uwe Siebert , Sean Sullivan7 M3-07 1United Biosource Corporation, Washington DC, United 2 12 Environmental scanning in a decentralized health care States, University of York, York, United Kingdom, system 3Stockholm School of Economics, Stockholm, Sweden, Andra Morrison, Tammy Clifford 4Tufts University, Boston, United States, 5University CADTH, Ottawa, Canada of Pennsylvania, Philadelphia, United States, 6UMIT, Innsbruck, Austria, 7University of Washington, Seattle, M3-08 United States Improving policy and processes for health technology investment and disinvestment Paul Fennessy1, Richard King1 ,2, Stephen Blamey1 ,2, Kylie Mayo1 1Department of Health, Melbourne, Victoria, Australia, 2

Southern Health, Melbourne, Victoria, Australia POSTERS

93 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

M3-15 Complexity increases uncertainty: The impact of PBAC M3-22 Guidelines (version 4) on PBAC decision making NHS EED: Content, structure and developments Maxime Chollet, Paul Lindsay, Fernando Gonzalo Dawn Craig, Steve Rice, Alison Booth sanofi -aventis Australia, Macquarie Park, NSW, Australia Centre for Reviews and Dissemination, University of York, United Kingdom M3-16 Emergence of biosimilars: A challenge for the NICE M3-23 Technology Appraisal Programme? DARE: Content, structure and developments Fay McCracken, Carina Righetti, Nicola Hay, Frances Alison Booth, Paul Wilson Sutcliffe, Meindert Boysen Centre for Reviews and Dissemination, University of York, National Institute for Health and Clinical Excellence, United Kingdom Manchester/London, United Kingdom M3-24 M3-17 HTA Database: Content, structure and developments Maximizing value through topic selection Alison Booth, Dave Fox Jennifer Priaulx, Colm Leonard, Janet Robertson Centre for Reviews and Dissemination, University of York, National Institute for Health and Clinical Excellence, United Kingdom Manchester/London, United Kingdom M3-25 M3-18 Mapping of the NICE STA process Institutional and performance indicators to assess the Eva Kaltenthaler1, Diana Papaioannou1, Angela Boland2, level of development of Health Technology Assessment Rumona Dickson2 units, programs or agencies 1University of Sheffi eld, Sheffi eld, United Kingdom, Montse Moharra1, Antonio Sarría2, Hindrik Vondeling3, 2University of Liverpool, Liverpool, United Kingdom Martin Raab4 1Catalan Agency for Health Technology Assessment and M3-26 Research, Barcelona, Spain, 2Agencia de Evaluación de Directing HTA resources to make the greatest impact Tecnologías Sanitarias (AETS, Madrid, Spain, 3University in pandemic fl u South Denmark, Odense, Denmark, 4Swiss Centre for Peter Davidson1, Tom Walley1 International Health, Basel, Switzerland 1NIHR Evaluation Trials and Studies Coordinating Centre University of Southampton, Southampton, Hampshire, M3-19 United Kingdom, 2NIHR Evaluations, Trials and Studies, Private evidence for public policy: A template for Liverpool, United Kingdom manufacturer/sponsor submission of evidence Prashanth Kandaswamy, Nicola Hay, Helen Chung M3-27 National Institute for Health and Clinical Excellence, Keeping healthcare technology assessment of new Manchester/London, United Kingdom interventional procedures ‘up-to-date’: A case study Steven Barnes, Heather Stegenga, Suzi Peden, Bruce M3-20 Campbell, Georgios Lyratzopoulos Impact of economic evaluation of health technologies on National Institute for Health and Clinical Excellence, London, medical decision making: A survey of Spanish decision- United Kingdom makers Melany Worbes-Cerezo1 ,2, Juan Oliva-Moreno3 ,1, Julio M3-28 Lopez-Bastida2 ,1, Pedro Serrano-Aguilar2 ,1 HTA in Germany: Process and methods at DIMDI 1CIBER epidemiología y Salud Pública, Barcelona, Sunya-Lee Antoine, Britta Göhlen Cataluña, Spain, 2Evaluation UNit, Canary Health Service, German Institute of Medical Documentation and Santa Cruz de Tenerife, Islas Canarias, Spain, 3Castilla La Information, Cologne, Germany 12 Mancha University, Toledo, Castilla La Mancha, Spain M3-29 M3-21 “Obsoleteness by indication”: A missing link between Dissemination of a systematic review of lesbian, gay, disinvestment initiatives and technology assessment bisexual and transgender (lgbt) health impact Catherine Meads1, Mary Pennant1, James McManus2, Philipp Storz, Annette Riesberg Sue Bayliss1 GKV-Spitzenverband (National Association of Statutory 1Department of Public Health, University of Birmingham, Health Insurance Funds), Department of Medicine, Berlin, Birmingham, United Kingdom, 2Birmingham East and Germany, Germany North PCT, Birmingham City Council), Birmingham, United Kingdom POSTERS

94 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

M3-30 M3-37 Establishing HTA in Italian Regions: The Institution of Incorporating citizen views into the adaptation process to the Italian Network for Health Technology Assessment the Spanish context of the Intrapartum Care Guideline Fulvio Moirano1, Marina Cerbo1, Alessandra Lo Scalzo1 Itziar Etxeandia-Ikobaltzeta1, Rosa Rico-Iturrioz1, Luis 1National Agency for Regional Healthcare, Rome, Italy, Fernández Llebrez-Del Rey2, Rosario Quintana-Pantaleon3, 2National agency for Regional Healthcare and Italian Maria Pilar De La Cueva-Barrao4 ,6, Idoia Armendariz- Network for Health Technology Assessment (RIHTA), Rome, Mántaras4 ,5, Isabel Fernández Del Castillo-Sainz4 3 Italy, National agency for Regional Healthcare and Italian 1Osteba. Basque Offi ce for HTA., Gasteiz, Araba, Spain, Network for Health Technology Assessment (RIHTA), Rome, 2Osakidetza. Basque Health Service. Cruces Hospital, Italy Barakaldo, Bizkaia, Spain, 3Marqués de Valdecilla University Hospital, santader, Cantabria, Spain, 4El parto es nuestro, M3-31 Madrid, Madrid, Spain, 5Haurdun, Bilbao, Bizkaia, Spain, Evaluation of telemedicine adoption by health professionals 6General de la Defensa Hospital, Zaragoza, Aragon, Spain using a modifi ed technology acceptance model Estibalitz Orruño1, Marie-Pierre Gagnon2, José Asua1 1Basque Offi ce for HTA, Vitoria-Gasteiz, Spain, 2Faculté des Sciences Infi rmières, Université Laval. Centre de Recherche du CHUQ, Hôpital St-François d’Assise, Québec, Canada M4 - Methods M3-32 Setting priority for health technology assessment in M4-01 Thailand: Experiences from the Health Intervention and National library of medicine resources for informing Technology Assessment Program comparative effectiveness research (CER) Jomkwan Yothasamut, Pitsaphun Werayingyong, Yot Ione Auston Teerawattanano Health Intervention and Technology Assessment Program, National Library of Medicine, Bethesda, MD, United States Bangkok, Thailand M3-33 M4-02 Promoting a culture of evidence-based medicine and the Applying the item response theory (IRT) to maximizing use of Health Technology Assessment (HTA) in decision- the value of HTA making, through the implementation of an HTA nucleus Igor Menezes1, Fernanda Mussi1, Miako Kimura2, Katia (NATS, for its acronym in Portuguese) in the University of Freitas1, Ana Cristina Gomes1 Campinas, Clinical Hospital in Brazil 1Federal University of Bahia, Salvador, Bahia, Brazil, 2São Grace Pfaffenbach, Juan Diaz, Luiz Carlos Zeferino, Paulo University, São Paulo, São Paulo, Brazil Joaquim Murray Burstoff-Silva University of Campinas, Hospital de Clínicas, NATS, Campinas, São Paulo, Brazil M4-03 Point of care tests in sexually transmitted infections - a M3-34 novel identifi cation method: vertical scanning review Conceptual framework for assessing users’ roles in medical Jo Smith, Ali Cook, Claire Packer device development National Horizon Scanning Centre, Birmingham, United Anila Shah, Sarmad Alshawi Kingdom Brunel University, Uxbridge, Middlesex, United Kingdom M4-04 10 M3-35 Improving search effi ciency for economic evaluations in Stimulating HTA culture among Federal University of Rio major databases using semantic technology 1 2 2 de Janeiro (UFRJ) graduation students Julie Glanville , Bill Porter , Pamela Negosanti , Carol 3 Uliana Pontes Lefebvre 1York Health Economics Consortium, York, United Kingdom, Federal University of Rio de Janeiro, Macaé, Rio de Janeiro, 2Expert System SpA, Modena, Italy, 3UK Cochrane Centre, Brazil Oxford, United Kingdom 12 M3-36 M4-05 Leveraging HTM for Improved HTA Implementation Use of disease prevalence when estimating the positive 1 2 3 Thomas Judd , Adriana Velazquez , Antonio Hernandez predictive value of a test can mislead: the spectrum effect 1 2 Kaiser Permanente, Atlanta, GA, United States, PAHO, Elizabeth Buckley, Shuhong Wang, Tracy Merlin, Janet 3 Washington, DC, United States, WHO, Geneva, Switzerland, Hiller Switzerland University of Adelaide, Adelaide, South Australia, Australia POSTERS

95 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

M4-06 International Network (G-I-N), Oslo, Norway A novel method to improve adjustment for publication biases by borrowing strength across similar interventions M4-12 Santiago Gutierrez Moreno1 ,2, Alex J Sutton1, A E Ades3, Methods for assessment of innovative medical Nicola J Cooper1, Keith R Abrams1 technologies during early stages of development 1Dept of Health Sciences, Unicersity of Leicester, Leicester, Anja Hagen1, Marc Bartelmes1, Ulrike Neumann1, 2 United Kingdom, Evaluation of Innovation and New Dagmar Lühmann1, Matthias Schönermark1 Technologies, Hospital Clinic/Fundacio Clinic, Barcelona, 1Medical School Hannover, Hannover, Germany, 2University 3 Spain, Dept of Community Based Medicine, University of Medical Center Schleswig-Holstein, Lübeck, Germany Bristol, Bristol, United Kingdom M4-13 M4-07 Future need for PET-facilities in Norway- applying Between trial and decision: Improving the value of Health HTA and methods of forecasting in health care decision Technology Assessments for real world decision making making Manuela Joore1 ,2, Janneke Grutters2 Anen Ringard1 ,2, Berit Morland1 ,2 1Maastricht University Medical Centre, Maastricht, 1Secretariat of the Norwegian Council for Priority Setting in Netherlands, 2Maastricht University, Maastricht, Netherlands Health Care, Oslo, Norway, 2Norwegian Knowledge Centre for the Health Services, Oslo, Norway M4-08 Multi data synthesis: A pragmatic approach to gathering M4-14 and synthesising primary and secondary data in ‘I just want to talk to a few patients’. Patient involvement health technology assessments, using an evaluation in HTA: Essential for a balanced perspective or more of psychosocial needs of people with chronic fatigue trouble than it is worth? syndrome in Québec as a case example. Joanne Abbotts, Joanna Kelly 1 2 Vibe Hjelholt Pedersen , Pierre Dagenais , Pascale NHS Quality Improvement Scotland, Glasgow, United 3 Lehoux Kingdom 1King’s College London, London, United Kingdom, 2L’Agence d’Évaluation des Technologies et Modes M4-15 d’Intervention de la Santé (AETMIS), Montréal, Québec, Optimization of the participation of patients, Canada, 3Department of Health Administration, University clinicians and methodological advisor in the of Montréal, Montréal, Québec, Canada consensus of clinical recommendations Marta Lopez-Argumedo1, Virginia Guillen1, Sonia M4-09 Gaztambide2, Maria Angeles Anton2, Beatriz Assessment of intervention effects in systematic reviews Corcostegui2, Alicia Cortazar2, Paz Gallego2, / HTA in the case of heterogeneity between three Federico Vazquez2, Itxaso Rica2, Alfredo Yoldi2, subgroups Paloma Jimenez2, Eva Reviriego1 Guido Skipka 1Basque Office for Health Technology Assessment, Institute for Quality and Effi ciency in Health Care, Cologne, Basque Country, Spain, 2Osakidetza, Basque Health Germany Service, Basque Country, Spain

M4-10 M4-16 An open business model approach as a framework to Challenges in trial interpretation: anti-tumour necrosis assess the early value proposition of emerging healthcare factor therapy for maintenance treatment of Crohn’s disease technologies Janine Dretzke, Martin Connock, Anne Fry-Smith, Shirley Davey, Michael Brennan, Rodney McAdam, Catherine Meads Brian Meenan West Midlands Health Technology Assessment Collaboration MATCH, University of Ulster, Co. Antrim, Northern Ireland, (WMHTAC), University of Birmingham, Birmingham, United United Kingdom Kingdom

12 M4-11 M4-17 Summarizing and sharing appraised studies: Templates Maximizing the processes of identifi cation, prioritisation of the G-I-N Evidence Tables working group and evaluation of new and emerging health technologies Najoua Mlika-Cabanne1, Magali Remy-Stockinger4, in the Basque Country Hans de Beer3, Robin Harbour2, Sara Twaddle2 Gaizka Benguria-Arrate, Iñaki Gutierrez-Ibarluzea, 1Haute Autorite de Sante (HAS), Paris, France, 2Scottish Nora Ibargoyen-Roteta, Lorea Galnares-Cordero Intercollegiate Guidelines Network (SIGN), Edinburgh, Basque Offi ce for Health Technology Assessment. Basque Government, Vitoria - Gasteiz, Spain United Kingdom, 3Dutch Institute for Healthcare Improvement (CBO), Utrecht, Netherlands, 4Guidelines POSTERS

96 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

M4-18 Rapid vs. exhaustive HTA reports: Methodology to M4-24 compare the information they provide How can international collaboration in pragmatic trials Zuleika Saz-Parkinson, Teresa López-Cuadrado, Matilde be facilitated? Palma-Ruíz, Carmen Bouza, José María Amate, Eleanor Woodford Guegan, Andrew Cook Antonio Sarría NETSCC, University of Southampton, Southampton, United Instituto de Salud Carlos III, Madrid, Spain Kingdom

M4-19 M4-25 The fi rst UK specifi c cost effectiveness analysis of How can patients and carers be involved in research to ablative therapies for Barrett’s oesophagus: A practical improve care: developing a model of involvement Bridie Evans, Helen Snooks, David Rea, Service User example of the use of Bayesian and value of information Steering Group members techniques in NICE clinical guidelines Swansea University, Swansea, United Kingdom Prashanth Kandaswamy Centre for Clinical Practice, National Institute for Health M4-26 and Clinical Excellence, Manchester, United Kingdom A Bayesian method for synthesis of evidence using implantable cardioverter defi brillators (ICDs) as an M4-20 example Preliminary study of rapid vs. exhaustive HTA reports: Ji-Hee Youn1, Joanne Lord1, Martin Buxton1, Alan comparison of their usefulness in the decision-making Girling2, Karla Hemming2, Terry Young1 process. 1Multidisciplinary Assessment of Technology Centre for Zuleika Saz Parkinson, Teresa López-Cuadrado, Matilde Healthcare (MATCH) / Brunel University, Uxbridge, United Palma-Ruíz, Carmen Bouza, José María Amate, Antonio Kingdom, 2Multidisciplinary Assessment of Technology Sarría Centre for Healthcare (MATCH) / University of Birmingham, Instituto de Salud Carlos III, Madrid, Spain Birmingham, United Kingdom

M4-21 M4-27 The measurement properties of Japanese HUI3. MiniHTA for new cancer drugs - recycling or Construct validity observed in local community sample development? with chronic clinical conditions- 1 2 Takamoto Uemura1, Hisashi Moriguchi2, Shinichi Noto3, Mirja Elisabeth Kloejgaard , Malene Fabricius Jensen Hiroteru Oakmoto1, Toru Tsunoda1 1DACEHTA, Copenhagen, Denmark, 2National Board of 1Dept of Public health and hygiene, School of medicine, Health. Division of Health Planning, Copenhagen, Denmark Kyorin university, Mitaka, Tokyo, Japan, 2RCAST, University of Tokyo, Tokyo, Japan, 3Dept of Occupational therapy, M4-28 School of health science, Niigata university of health and Can routine data sources be used to monitor innovation welfare, Niigata, Japan and develop the HTA evidence base? Suzi Peden1, Hannah Patrick1, David Cunningham2, M4-22 Barrie White1, Bruce Campbell1 Mind the Gap! Developing a matrix to identify and 1 prioritise research recommendations in HIV Prevention National Institute for Health and Clinical Excellence, 2 10 Sydney Anstee, Alison Price, Amanda Young, Bob Coates, London, United Kingdom, Central Cardiac Audit Database, Kath Barnard, Becs Moran London, United Kingdom NETSCC, University of Southampton, Southampton, United Kingdom

M4-23 Method for aggregating the reporting of interventions in complex studies - the MATRICS tool Kymberley Thorne1, Ian Russell1, Gabi Jerzembek1, Wai- 12 Yee Cheung1, David Cohen3, Hayley Huchings1, Frances Rapport1, Anne Seagrove1, John Williams1 1Centre for Health Information, Research & Evaluation, Swansea University, Swansea, United Kingdom, 2Cardiff Institute of Society, Health & Ethics, Cardiff University, Cardiff, United Kingdom, 3School of Care Sciences, University of Glamorgan, Pontypridd, United Kingdom POSTERS

97 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

M4-29 Post-introduction observation of new health technologies: M5 - Other, non-clinical the neglected gap in HTA 1 1 M5-01 Leonor Varela Lema , Alberto Ruano Raviña , Teresa Quality of Life scale for patients with work-related 1 4 Cerdá Mota , José Antonio Blasco Amaro , Gutierrez musculoskeletal disorders (QoL-WMSD Scale) - Initial 2 2 Ibarluzea Iñaki , Ibargoyen Roteta Nora , Imaz Iglesias Measure Development Process in Brazil Iñaki3, Sampietro Colom Laura6, Soto Pedre Enrique5, Igor Menezes1, Ana Cristina Gomes1, Fernanda Mussi1, Villegas Portero Román6 Miako Kimura2, Katia Freitas1 1Galician Health Technology Assessment Agency (avalia-t), 1Federal University of Bahia, Salvador, Bahia, Brazil, 2São Santiago de Compostela, Galician Region, Spain, 2Basque Paulo University, São Paulo, São Paulo, Brazil Government Health Technology Assessment Department (Osteba), Basque Country, Spain, 3Health Technology M5-02 Assessment Agency of Carlos III Institute of Health (AETS), Integrating ethical issues in HTAs: More methods than Madrid, Spain, 4Laín Entralgo Agency. Madrid Regional applications? Health Technology Assessment Unit., Madrid, Spain, Sigrid Droste, Charalabos-Markos Dintsios, Andreas 5Canary Island Health Assessment Department, Canary Gerber, Alric Rüther Islands, Spain, 6Barcelona Clinical Hospital Innovation Institute for Quality and Effi ciency in Health Care (IQWiG), & New Technology Assessment Unit, Barcelona, Spain, Cologne, Germany 7Andalusian Health Technology Assessment Agency (AETSA), Andalusian Region, Spain M5-03 Horizon scanning for new and emerging health M4-30 technologies in Australia: Does it address the Australian national health priority areas? Predicting the discharge outcomes after Total Knee Alexandra Penner, Linda Mundy, Janet Hiller Replacement (TKR) in Singapore using the Risk School of Population Health and Clinical Practice, Assessment and Predictor Tool (RAPT) University of Adelaide, Adelaide, South Australia, Australia Celia Tan1, Yong-Hao Pua1, Hwei-Chi Chong1, William Yeo 1, Ngai-Nung Lo1, Garry Allison2 1Singapore General Hospital, Singapore, Singapore, 2School M5-04 of Physiotherapy, Curtin University of Technology, Australia, Systematic review of the effectiveness and cost- Australia effectiveness of psychoeducational interventions in people with bipolar disorder and their families 1 ,2 1 ,3 M4-31 Lilisbeth Perestelo-Perez , Jeanette Perez-Ramos , The simplest way to be unsure yet comfortable in Lidia Garcia-Perez1 ,2, Amado Rivero-Santana1 ,3, Marien deciding; practical experiences in using Bayesian Gonzalez-Lorenzo1 ,3, Montserrat Alviani Rodriguez- methods for HTA. Franco4, Aintzane Intxausti-Zugarramurdi4 Cathal Walsh1 ,2 1Evaluation and Planning Unit. Canary Islands Health 1Trinity College Dublin, Dublin 2, Ireland, 2National Centre Service, Tenerife, Spain, 2CIBER de Epidemiologia y for Pharmacoeconomics, Dublin 8, Ireland Salud Publica (CIBERESP), Tenerife, Spain, 3Canarian Foundation of Health and Research, Tenerife, Spain, 4Mental M4-32 Health Service. University Hospital Nuestra Señora de la Healthcare assessment methodology in developing country Candelaria. Canary Islands Health Service, Tenerife, Spain Shambhu D. Joshi1, Rajan P. Bhandari1 1Primary Health Cener, Kailali, Nepal, 2Community Health M5-05 and Environmental Society Nepal, KTM, Nepal Evaluation of features of blood glucose meters infl uencing correct use and adherence to self-monitoring M4-33 of Type II diabetics Technology adoption in healthcare settings - choice of Michael Craven, Alexandra Lang, Jennifer Martin, use or acceptance - which comes fi rst and what is the Sarah Sharples 12 difference? A systematic review MATCH, University of Nottingham, Nottingham, United Urvashi Sharma, Malcolm Clarke Kingdom Brunel University, West London, United Kingdom POSTERS

98 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

M5-06 M5-12 HTA for resource allocation decisions: Are key principles Agreement among generic and disease-specifi c measures relevant for Latin America? of health-related quality of life about which patients Andres Pichon-Riviere1 ,2, Federico Augustovski1 ,2, Adolfo change over time: Cautionary evidence from applications Rubinstein1 ,2, Sean Sullivan3, Michael Drummond4 to cataract and heart failure patients 1Institute for Clinical Effectiveness and Health Policy - David Feeny1, Karen Spritzer2, Ron Hays2, Honghu Liu2, IECS, Buenos Aires, Argentina, 2School of Public Health, Theodore Ganiats3, Robert Kaplan2, Mari Palta4, Dennis University of Buenos Aires, Buenos Aires, Argentina, Fryback4 3Pharmaceutical Outcomes Research and Policy Program, 1Center for Health Research, Kaiser Permanente Northwest, University of Washington, Washington, United States, Portland, OR, United States, 2University of California, 4Centre for Health Economics, University of York, York, Los Angeles, Los Angeles, CA, United States, 3University United Kingdom of California, San Diego, La Jolla, CA, United States, 4University of Wisconsin, Madison, WI, United States M5-07 Engagement by design: Prioritisation of local HTA M5-13 research by multiple stakeholders CRD databases: new interface, new content Rebecca Whear, Kate Boddy, Julie Frier, Ken Stein, Jo Alison Booth, Paul Wilson, Dawn Craig Centre for Reviews and Dissemination, University of York, Thompson-Coon United Kingdom Peninsula College of Medicine and Dentistry, University of Exeter, Devon, United Kingdom M5-14 Enhancing process improvement decision-making M5-08 framework with discrete event simulation in a diagnostic An analysis on the effect of Betel Quid chewing and Its radiology department combined use with cigarettes on mortality: Evidence Hong Choon Oh1, Veena Joshi1, Kiki Erf Van Der Saskia1, from the elderly in Taiwan Hong Guan Toh2, Eddy Cheong2 Shao-Hsun Keng, Sheng-Jang Sheu 1Singapore Health Services Pte Ltd, Singapore, Singapore, 2 National University of Kaohsiung, Kaohsiung, Taiwan Singapore General Hospital, Singapore, Singapore

M5-09 M5-15 Gap between dissemination of cancer screening Looking for a cost-effectiveness threshold in Korea 1 1 1 guidelines and appropriate understanding Jeonghoon Ahn , Younhee Kim , Sangjin Shin , Sunyoung 1 1 1 2 Chisato Hamashima1, Ryoko Tsuruno2, Hiroshi Saito1, Park , Hyunjin Song , Jooyeon Park , Eunyoung Bae 1 2 Tomotaka Sobue1 NECA, Seoul, Korea, Republic of, Sangji University, Wonju, 1National Cancer Center of Japan, Tokyo, Japan, 2Keio Korea, Republic of University, Fujisawa, Japan M5-16 M5-10 Adolescent participation in HTA: the identifi cation of The benefi ts and fl aws of the Linked Evidence Approach appropriate proxies for adolescent user needs of medical (LEA) to assess diagnostic and screening tests devices Tracy Merlin, Sam Lehman Alexandra Lang1 ,2, Jennifer Martin1 ,2, Sarah Sharples1 ,2, 10 Adelaide Health Technology Assessment (AHTA), School John Crowe1 ,2 of Population Health and Clinical Practice, University of 1MATCH (Multidisciplinary Assessment of Technology Adelaide, Adelaide, South Australia, Australia Centre for Healthcare), Nottingham, United Kingdom, 2University of Nottingham, Nottingham, United Kingdom M5-11 Literature searching in systematic reviews: Is the gold M5-17 standard tarnished? The effects of gatekeeping: A systematic review of the Preethy J. Mathew, Joseph L. Mathew literature 12 Postgraduate Institute of Medical Education and Research, Marcial Velasco Garrido, Annette Zentner, Reinhard Chandigarh, India Busse Dpt. of Health Care Management, Technische Universität Berlin, Berlin, Germany POSTERS

99 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

M5-18 M5-23 Governance of preventive health intervention and on Relationship between horizon scanning and burden of time verifi cation of its effi ciency in a region of southern disease: Analysis of topics reported by EuroScan from Italy 2003 to 2008 Francesco Saverio Mennini1, Gianluca Baio2 ,3, Giuseppe Orsolina Martino1, Sue Simpson1, Andrew Stevens2, Montagano4, Gabriella Cauzillo4, Francesco Locuratolo4, Claire Packer1, Alison Cook1 Lara Gitto1, Andrea Marcellusi1, Michael Drummond5, 1National Horizon Scanning Centre, University of Bengt Jonsson6, Peter Zweifel7 Birmingham, Birmingham, United Kingdom, 2Public Health, 1CEIS Sanità (CHEM - Centre for Health Economics Epidemiology & Biostatistics, University of Birmingham, and Management), Faculty of Economics, University of Birmingham, United Kingdom Tor Vergata, Rome, Italy, 2Department of Epidemiology and Public Health, University College, London, United M5-24 Kingdom, 3Unità di Biostatistica, Dipartimento di Statistica, HTA of knee prostheses: do registers represent a valid Università di Milano Bicocca, Milano, Italy, 4Basilicata source of effectiveness data? Region, Potenza, Italy, 5Centre for Health Economics York Maria Rosaria Perrini, Antonio Migliore, Simona Paone, University, York, United Kingdom, 6Stockholm School of Tom Jefferson, Laura Velardi, Marina Cerbo Economics, Stockholm, Sweden, 7Zurich University, Zurich, Agenas, Agenzia nazionale per i servizi sanitari regionali, Switzerland Sez. ISS – Innovazione, sperimentazione e sviluppo, Rome, Italy M5-19 Evaluation of child and adolescent psychiatry: M5-25 Dimensions, indicators and instruments COTE: The Italian national observatory for new and Roman Winkler emerging health technologies Ludwig Boltzmann Institute for HTA, Vienna, Austria Maria Rosaria Perrini, Marina Cerbo, Alessandra Lo Scalzo, Antonio Migliore, Tom Jefferson M5-20 Agenas, Agenzia nazionale per i servizi sanitari regionali, Mapping patients’ perspectives about self-testing of Sez. ISS – Innovazione, sperimentazione e sviluppo, Rome, oral anticoagulation therapy: A qualitative analysis of Italy patients’ Internet blogs Syed Ghulam Sarwar Shah1, Ian Robinson2 ,1 M5-26 1Multidisciplinary Assessment of Technology Centre for Telephone triage and home care as an alternative to Healthcare, School of Information Systems, Computing accident & emergency overcrowding: A review and Mathematics, Brunel University, Uxbridge, Middlesex, Oriol de Solà-Morales1 ,3, Josep Fuster2 United Kingdom, 2Centre for the Study of Health and Illness, 1CAHTA, Barcelona, Spain, 2Department of Health, School of Social Sciences, Brunel Univeristy, Uxbridge, Barcelona, Spain, 3Universitat Autònoma Barcelona, Escola Middlesex, United Kingdom Docorat, Bellaterra, Spain M5-21 M5-27 Preventing medication errors in care homes through use Appropriate use of imaging technologies for the of an electronic, bar-code validated drug administration diagnosis of low back pain: Views from radiologists and system - Is it cost-effective? rheumatologists 2 1 ,2 2 ,1 Sara Nelson , Ala Szczepura , Deidre Wild Oriol de Solà-Morales1 ,2, Josep Fuster3, Jordi Galimany3 ,4 1University of Warwick, Coventry, United Kingdom, 1CAHTA, Barcelona, Spain, 2Universitat Autònoma 2University of the West of England, Bristol, United Kingdom Barcelona, Escola Docorat, Bellaterra, Spain, 3Department of Health, Barcelona, Spain, 4Universitat de Barcelona, M5-22 Barcelona, Spain Duplication of HTA reports; Conservation of effort and maximising the value M5-28 12 Sheila Turner1, Neil Adams2, Andrew Cook1, Ruairidh WHO checklist for safe surgery. An early warning report Milne1 provided by the Norwegian Knowledge Centre for the 1NETSCC, Southampton, United Kingdom, 2NHS Health Services Southampton City, Southampton, United Kingdom Vigdis Lauvrak1, Elisabeth Jeppesen1, Unni Krogstad2, Lene K. Juvet1 1The Norwegian Knowledge Centre for the Health Services (NOKC). Department of Evidence-Based Health Services, Oslo, Norway, 2The Norwegian Knowledge Centre for the Health Services (NOKC). Department of Quality Measurement and Patient Safety, Oslo, Norway POSTERS

100 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

Canario de la Salud, Santa Cruz de Tenerife/Santa Cruz M5-29 de Tenerife, Spain, 4CIBER Epidemiología y Salud Pública HTA for patients: Using information design to convey (CIBERESP), Barcelona/Cataluña, Spain treatment effi cacy and risk to consumers Elisabeth Houtsmuller, Susan Levine M5-35 Hayes, Inc., Lansdale, PA, United States Equality and diversity considerations in NICE health technology appraisals M5-30 Scott Goulden, Helen Tucker, Elisabeth George Animal foetal cell therapy: a rapid technology assessment National Institute for Health and Clinical Excellence, Sandi Chit Lwin, Mien Chew Chin, Keng Ho Pwee Manchester/London, United Kingdom Ministry of Health, Singapore, Singapore M5-36 M5-31 Review of NICE’s Health Technology Appraisal Telemedicine in acute stroke management- Systematic recommendations review Fiona Rinaldi, Joanne Fielding, Elisabeth George Tim Johansson, Claudia Wild National Institute for Health and Clinical Excellence, Ludwig Boltzmann Institute for Health Technology Manchester/London, United Kingdom Assessment, Vienna, Austria M5-37 M5-32 Trends in the number of UK RCTs Exploratory and confi rmatory analysis of the attitudes Eleanor Fairbank, Louise Dent, Lisa Douet, Alison Price, toward guidelines questionnaire James Raftery, Ruairidh Milne Esther Torres1, Eva Reviriego3, Itziar Pérez-Irazusta2, NETSCC, University of Southampton, Southampton, United Idoia Alcorta2, Arritxu Etxeberria2, Rafael Rotaeche2, Kingdom Rosario Sanz-Echave2 1The University of the Basque Country, Donostia-San M5-38 Sebastian, Spain, 2Osakidetza, Basque Health Service, Quality of life assessment in high risk breast cancer Donostia-San Sebastian, Spain, 3Osteba, Basque Offi ce for patients treated with autologous stem cell transplantation HTA, Health Department-Basque Government, Vitoria- - A systematic review Gasteiz, Spain Annegret Herrmann-Frank1, Sibylle Sturtz1, Sigrid Droste1, Christian Lerch2, Bernd Richter2, Carmen M5-33 Bartel1, Stefan Lange1 Health related quality of life of Canary Island citizens: 1Institute for Quality and Effi ciency in Health Care, Cologne, Combining a general health survey and observational Germany, 2Cochrane Metabolic and Endocrine Disorders studies Review Group, Duesseldorf, Germany Melany Worbes-Cerezo1 ,2, Juan Oliva-Moreno3 ,1, Julio López-bastida2 ,1, Pedro Serrano-Aguilar2 ,1 M5-39 1CIBER Epidemiología y Salud Pública, Barcelona, Spain, New pervasive healthcare technology: The effect of 2Evaluation Unit, Canary Islands Health Service, Santa implementing the Interactive Hospital (iHospital) Cruz de Tenerife, Islas Canarias, Spain, 3Castilla La Mancha Lotte Groth Jensen1, Lars Holger Ehelers3, Thomas 10 University, Toledo, Castilla La Mancha, Spain, 4University Riisgaard Hansen2 Hospital Nuestra, Santa Cruz de Tenerife, Islas Canarias, 1Department of HTA, Institute of Public Health, Aarhus Spain University, Aarhus, Denmark, 2Department of Computer Science, Aarhus University, Aarhus, Denmark, 3University of M5-34 Aalborg, Aalborg, Denmark Fluoride varnish effectiveness in preventing dental caries in children aged 0-5 years: A meta-analysis M5-40 Yolanda Ramallo-Fariña1 ,4, M.Mar Trujillo-Martín1 ,4, Patient involvement between ideals and reality - an 12 Gladys Gómez-Santos3, Javier Vázquez-García- empirical study of shared decision-Making in ordinary Machiñena3, Beatriz Duque-Gonzalez1, clinical praxis Pedro Serrano-Aguilar2 ,4 Charlotte Bredahl Jacobsen2, Vibe Hjelholt Pedersen2, 1Fundación Canaria de Investigación y Salud (FUNCIS), Kristina Albeck2, Helga Sigmund1 Santa Cruz de Tenerife/Santa Cruz de Tenerife, Spain, 1National Board of Health, Copenhagen, Denmark, 2Danish 2Servicio de Evaluación y Planifi cación del Servicio Canario Institute for Health Services Research, Copenhagen, de la Salud, Santa Cruz de Tenerife/Santa Cruz de Tenerife, Denmark Spain, 3Dirección General de Salud Pública. Servicio POSTERS

101 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

M5-41 M5-48 Supporting healthcare decision in innovative technology: EBM methodology for appraisals on health technology The example of carbon ion radiotherapy assessment for the Ministry of Health of Brazil: The case Sophie Blanchard, Sun Hae Lee Robin, Francois Meyer of surrogate endpoint in rheumatoid arthritis treated French National Authority for Health (HAS), Saint Denis la with anti-TNFs Plaine, France Moacyr Nobre1, Gustavo Rosal2, Henry Dan1, Fernanda Costa1, Bruna Taino2, Rachel Zanetta2 M5-42 1InCor-HCFMUSP, São Paulo, Brazil, 2Cognos-Educação What is transparent about the French and Scottish em Saúde, São Paulo, Brazil approach to single technology assessment (STA)? Matthew Bending1, John Hutton1, Clare McGrath2 M5-49 1University of York, York, United Kingdom, 2Pfi zer, Surrey, Use of probiotics for the prevention and treatment of United Kingdom diarrhea: a HTA for evidence-based hospital decision making M5-43 Brigitte Larocque, Marc Rhainds, Martin Bussières, Scientifi c basis and content of drug HTA reports in eight Mélanie Hamel European countries UETMIS, Centre hospitalier universitaire de Québec, 1 1 1 Joan Bigorra , Pili Colom , Carlos Lurigados , Laura Québec, Canada Sampietro-Colom1, Alicia Granados2 1Evaluation of Innovation and New technologies, Innovation M5-50 Directorate, Hospital Clinic, Barcelona, Catalonia, Spain, The carbon cost of HTA research 2MSD EUCAN Region, Barcelona, Catalonia, Spain Louise Dent1, Alison Mortlock1, Katy Lyle1, Sally Bailey1, Lynn Kerridge1, Ian Roberts2, Ruairidh Milne1 M5-44 1NIHR Evaluation, Trials and Studies Coordinating Predictors of success in competitive funding bids Centre, School of Medicine, University of Southampton, Sheila Turner, Louise Dent, Victoria Bowness, Ria Southampton, Hampshire, United Kingdom, 2London School Skelton, Peter Davidson of Hygiene and Tropical Medicine, London, Hampshire, NETSCC, Southampton, United Kingdom United Kingdom

M5-45 M5-51 Who are the players in HTA for drugs and what their Assessing payback from research: Bibliometric analysis impact is? An European landscape of research into schizophrenia in Spain (1999-2004), 1 2 2 Alicia Granados , Laura Sampietro-Colom , Pili Colom , productivity, visibility and collaboration Carlos Lurigados2, Joan Bigorra2 Pedro Gallo1 ,2, Silvia Noguer2, Antoni Parada3, Mireya 1MSD EUCAN Region, Barcelona, Catalonia, Spain, Garcia-Duran2, Raul Mendez3 ,4, Eduard Suñen3 ,4 2Evaluation of Innovation and Newt technologies, Innovation 1University of Barcelona, Barcelona, Spain, 2SENYFundacio, Directorate, Hospital Clinic, Barcelona, Catalonia, Spain Barcelona, Spain, 3CAHTA, Barcelona, Spain, 4PRBB, Barcelona, Spain M5-46 Maximising the international value of HTA; ‘Filling the M5-52 gaps’ between the US and the UK Advanced licensing and accreditation of health Virginia Boon, Eleanor Woodford Guegan, James organizations Raftery Shirnen Lkhamsuren, Oyuntsetseg Gur-Osor, Darimaa NIHR Evaluation, Trials and Studies Coordinating Centre Tsevegdoo (NETSCC), School of Medicine, University of Southampton, Department of Heath - Implementing Agency of the Southampton, Hampshire, United Kingdom Government of Mongolia, Ulaanbaatar, Mongolia

M5-47 How closely do international HTAs follow a best 12 practice approach? : An illustration using implantable cardioverter defi brillators (ICDs) for primary and secondary prevention Pascale Dequen1, Kathy Cargill2, Liesl Birinyi-Strachan2 1London School of Economics, London, United Kingdom, 2Medtronic International Trading Sarl, Tolochenaz, Switzerland POSTERS

102 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

M5-53 The time-trade off approach to measure patients’ preferences for health states associated with HPV-related pathologies: A multicenter study performed in Italy. Francesco Saverio Mennini1, Donatella Panatto2, Paolo Cristoforoni3, Elisa Di Capua3, Rosa De Vincenzo4, Gabriella Ferrandina5, Marco Petrillo4, Tiziana Sasso2, Caterina Ricci4, Giovanni Scambia4, Nausica Trivellizzi4, Alessandro Capone1, Andrea Marcellusi1, Roberto Gasparini2 1CEIS Sanità (CHEM - Centre for Health Economics and Management), Faculty of Economics, Rome, Italy, 2Department of Health Sciences of Genoa University, Genoa, Italy, 3Oncologic Gynecology, National Institute for Cancer Research, Genoa, Italy, 4Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy, 5Gynecologic Oncology Unity, Catholic University of the Sacred Heart, Campobasso, Italy

M5-54 Differences between two programs for tuberculosis control in the city of Dourados, Brazil Julio Croda1, Gisele Teixeira1, Débora Rigo1, Vanessa Maldonado1, Mariana Croda2, Renata Maronna1, Célia Mota3, Roberto Oliveira3, Zelik Trajab4 1Faculty of Health Sciences, Federal University of Grande Dourados, Dourados/Mato Grosso do Sul, Brazil, 2Universitary Hospital, Federal University of Grande Dourados, Dourados/Mato Grosso do Sul, Brazil, 3Municipal Health Department of Dourados, Dourados/Mato Grosso do Sul, Brazil, 4National Health Fundation, Dourados/Mato Grsso do Sul, Brazil

M5-55 Research on shortcomings found by the quality control of health care system Maitsetseg Badarch, Damdinjav Hamar Lecinsing department of Health department, Ulaanbaatar, Mongolia

M5-56 Ethical concerns and telemedicine in developing country Shambhu D. Joshi1, Rajan P. Bhandari2 1Primary Health Cener, Kailali, Nepal, 2Community Health 10 and Environmental Society Nepal, KTM, Nepal

12 POSTERS

103 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

POSTER SESSIONS Tuesday

T1-07 T1 - Clinical The effectiveness of smoking cessation groups offered to T1-01 hospitalised patients with symptoms of exacerbations of Systematic review on the effectiveness of Computer- chronic obstructive pulmonary disease (COPD) 1 1 assisted Cognitive Intervention for Dementia Anders Borglykke , Charlotta Pisinger , Torben 1 2 3 Heeyoung Lee, Yeongchull Choi, Yoonjae Lee, Heejung Jørgensen , Hans Ibsen , Mikkel Bernt Nielsen , Kåre Son, In-sun Hwang Hansen3 National Evidence-based Healthcare Collaborating Agency, 1Research Centre for Prevention and Health, Glostrup Seoul, Korea, Republic of University Hospita, Glostrup, Denmark, 2Holbæk Hospital, Medical Department, Holbæk, Denmark, 3National Board of T1-02 Health, Danish Centre for Health Technology Assessment Recommendations on a widely used technique with very (DACEHTA),, Copenhagen, Denmark limited evidence: The example of Negative Pressure Wound Therapy (NPWT) T1-08 Michel Vaeau, Hubert Galmiche, Catherine Denis, Assessment of prosthetic mesh for hernia repair François Meyer Laurence Matheron, Corinne Collignon, Catherine Haute Autorité de Santé, Saint Denis, France Denis, François Meyer Haute Autorité de Santé, Saint-Denis, France T1-03 Safety and effi cacy in reuse of single-use medical devices T1-09 Hyun-Ju Seo, Sang-Moo Lee, Ji Eun Park, Sang-Jin Systematic vaccination of hepatitis a in children, Shin, YoonJae Lee, JooYeon Park assessment of its effectiveness, costs and applicability in Health technology assessment research division, National the basque health system Evidence-based healthcare Collaborating Agency, Seoul, Carmen Esmeralda Santana Perez, Marta Lopez de Korea, Republic of Argumedo Gonzalez de Durana, Rosa Rico Iturrioz, Iñaki Gutierrez Ibarluzea T1-04 Basque Offi ce For Health Technology Assessment, Health Compensated review using existing systematic review on Department. Basque Goverment, Basque Country, Spain effectiveness of ginkgo biloba for dementia Yeongchull Choi, Heeyoung Lee, Yoonjae Lee, Heejung T1-10 Son, In-sun Hwang Adaptation of evidence developed in other contexts for Korean National Evidence-based Healthcare Collaborating the Brazilian Bulletin of HTA: Deferasirox for treatment Agency (NECA), Seoul, Korea, Republic of of iron overload Marcus Silva1, Vania Santos1, Aline Mesquita2, Cintia T1-05 Gava3, Clarisse Lobo4, Everton Silva1, Gabriela Mosegui5, Topical negative pressure wound therapy: Several Luiz Henrique Furlan6, Misani Ronchini3, Rodolfo systematic reviews but still no evidence Cançado7, Suzana Fujimoto3, Taís Galvão8, Alexandre Joanna Kelly, Joanne Abbotts Lemgruber3, Clarice Petramale3, Isabela Santos2, Flávia NHS Quality Improvement Scotland, Glasgow, United Elias1 Kingdom 1Ministério da Saúde; Secretaria de Ciência, Tecnologia e Insumos Estratégicos; Departamento de Ciência e 12 T1-06 Tecnologia, Brasília, DF, Brazil, 2Agência Nacional de Saúde Role of rapid screening tests in HIV infection screening Suplementar, Rio de Janeiro, RJ, Brazil, 3Agência Nacional strategy in France de Vigilância Sanitária, Brasília, DF, Brazil, 4Instituto Anne-Isabelle Poullié, Olivier Scemama Estadual de Hematologia Arthur de Siqueira Cavalcanti, 5 Haute Autorité de Santé, Saint Denis La Plaine, France Rio de Janeiro, RJ, Brazil, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil, 6Unimed, Curitiba, PR, Brazil, 7Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil, 8Universidade Federal do Amazonas, Manaus, AM, Brazil POSTERS

104 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

T1-11 Aberdeen, Aberdeen, Scotland, United Kingdom Prenatal screening in China: analysis on infl uencing factors of service utilization T1-17 Jiayan Huang, Yingyao Chen Diagnostic imaging protocol for acute abdominal Fudan University, Shanghai, China pathologies Beatriz Valentín1, Juan Antonio Blasco1, Nerea T1-12 Fernández de Larrea1, Nieves Gómez1, Sofía Escalona1, Safety and effectiveness of robotic gynecological surgery. Ana López-Polín1 A systematic review and meta-analysis 1Health Technology Assessment Unit (UETS), Madrid, Spain, Mercedes Reza1, Sergio Maeso1, Juan Antonio Blasco1, 2Hospital Universitario La Princesa, Madrid, Spain Nieves Calcerrada1, Elena Andradas2, Sofía Escalona1 1 Health Technology Assessment Unit (UETS), Madrid, Spain, T1-18 2 Lain Entralgo Agency, Madrid, Spain Why some diabetic patients aren’t screened for diabetic retinopathy? A systematic review of the evidence T1-13 Agnès Dessaigne, Véronique Raimond, Philippe Canet, A systematic review of agreement between measurement Renée Cardoso tools: Alternative tonometers for monitoring ocular Haute Autorité de santé, Saint-Denis (93), France hypertension Adriana Paola Botello, Alia Ali, Jonathan Cook, Augusto Azuara-Blanco, Jennifer Burr T1-19 Health Services Research Unit, University of Aberdeen, The effectiveness of genotyping for CYP2D6 for the Aberdeen, United Kingdom provision of adjuvant hormonal therapy for women with breast cancer T1-14 Nigel Fleeman, Carlos Martin Saborido, Rumona Is it useful to screen institutionalized people for vision Dickson, Yenal Dundar problems? Liverpool Reviews and Implementation Group, University of K.M. Holtzer-Goor1, H. Talsma2, C. Diepeveen2, Liverpool, Liverpool, Merseyside, United Kingdom C. Vellekoop3, F. Hiddema4, T. Keuzekamp5, M.A. Koopmanschap1 T1-20 1Erasmus University Rotterdam, Rotterdam, Netherlands, A systematic review of photodynamic therapy in the 2Royal Visio National Foundation for the Visually Impaired treatment of pre-cancerous skin conditions, Barrett’s and Blind, Rotterdam, Netherlands, 3Ergra Low Vision, oesophagus and cancers of the biliary tract, brain, head Institute for Eye care, The Hague, Netherlands, 4Rotterdam and neck, lung, oesophagus and skin. Eye Hospital, Rotterdam, Netherlands, 5De stromen Opmaat Morag Heirs, Debra Fayter, Mark Corbett, Alison Groep, Rotterdam, Netherlands Eastwood, Dave Fox, Alison Booth University of York, York, United Kingdom T1-15 Effi cacy and safety of the percutaneous aortic valve T1-21 implantation and a Hospital experience Mapping the evidence base and use of neurostimulators Nieves Calcerrada1, María José López-Pedraza1, Daniel Kinga Malottki, Anne Fry-Smith, David Moore 10 Callejo1, Mercedes Reza1, Elena Andradas2, Sergio West Midlands Health Technology Assessment Maeso1 Collaboration, University of Birmingham, Birmingham, 1Health Technology Assessment Unit, Madrid, Spain, 2Laín United Kingdom Entralgo Agency, Madrid, Spain T1-22 T1-16 Bilateral cochlear ear implants in children: Effi cacy/ Cancer of oesophagus or gastricus - New Assessment of effectiveness, safety and cost 1 1 Technology of Endosonography (COGNATE): Findings Dolors Benítez , M Dolors Estrada , Leticia Barajas- 2 1 Ian Russell1 ,2, Stephen Attwood3, Hugh Barr4, Rhiannon Nava , Mireia Espallargues 12 1 Tudor Edwards1, Angela Gliddon1, David Ingledew1, Catalan Agency for Health Technology Assessment and 2 Kenneth Park5, Daphne Russell1, Rhiannon Whitaker1, Research, Barcelona, Spain, Iberoamerican Cochrane Seow Tien Yeo1 Centre, Barcelona (Spain)., Barcelona, Spain 1Bangor University, Bangor, Wales, United Kingdom, 2Swansea University, Swansea, Wales, United Kingdom, 3Northumbria Healthcare Trust, North Tyneside, England, United Kingdom, 4Gloucestershire Hospitals Trust, Gloucester, England, United Kingdom, 5University of POSTERS

105 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

T1-23 T1-28 Drugs for the treatment of rheumatoid arthritis in What are the effects of interventions for chronic fatigue patients who have failed a Tumour Necrosis Factor syndrome? 1 1 (TNF) inhibitor - Systematic review María Graciela Rodríguez , Maria-Dolores Estrada , 1 1 1 1 Mireia Espallargues Kinga Malottki , Abdulrahman Uthman , Zulian Liu , 1 Kristina Routh3, Paresh Jobanputra2, David Moore1, Catalan Agency for Health Technology Assessment and 1 1 Research (CAHTA). Catalan Health Service. Catalan Anne Fry-Smith , Yen-Fu Chen 2 1 Department of Health., Barcelona, Catalonia, Spain, CIBER West Midlands Health Technology Assessment epidemiology and public Health (CIBERESP), Barcelona, Collaboration, University of Birmingham, Birmingham, Catalonia, Spain United Kingdom, 2Rheumatology - University Hospitals Birmingham, Selly Oak Hospital, Birmingham, United T1-29 3 Kingdom, Unit of Public Health, Epidemiology and Magnetic resonance imaging (MRI) for assessment Biostatistics, University of Birmingham, Birmingham, of axillary lymph node metastases in breast cancer: United Kingdom systematic review Sue Harnan1, Katy Cooper1, Yang Meng1, Sue Ward1, T1-24 Patrick FitzGerald1, Diana Papaioannou1, Lynda Wyld2 ,3, Evaluation of the Phase III Cardiac Rehabilitation in Christine Ingham2 ,5, Iain Wilkinson2 ,4, Eleanor Lorenz2 ,5 Austria using billing data of the Austrian health care 1School of Health and Related Research, University of system Sheffi eld, Sheffi eld, United Kingdom, 2Sheffi eld Teaching Michael Gyimesi, Brigitte Piso Hospitals NHS Foundation Trust, Sheffi eld, United Kingdom, Ludwig Boltzmann Institution for Health Technology 3Academic Surgical Oncology Unit, University of Sheffi eld, Assessment, Vienna, Austria Sheffi eld, United Kingdom, 4Academic Unit of Radiology, University of Sheffi eld, Sheffi eld, United Kingdom, T1-25 5University of Sheffi eld, Sheffi eld, United Kingdom Assessment of Diabetes Clinical Outcomes and Medication Adherence in a Member Benefi t Medication T1-30 Management Program Neutropenia during chemotherapy treatment in women 1 ,2 2 1 Yoona Kim , Karim Prasla , Karen Rascati , Tricia with breast cancer 2 2 2 Tabor , Joyce Juan , Paul Godley Thais de Oliveira Gozzo1, Helio Humberto Angotti 1 The University of Texas at Austin, Austin, TX, United States, Carrara2, Marislei Sanches Panobianco1, Ana Maria 2 Scott & White Health Plan, Temple, TX, United States Almeida1 1University of São Paulo at Ribeirão Preto College of T1-26 Nursing, Ribeirão Preto, São Paulo, Brazil, 2University of Drugs for the treatment of rheumatoid arthritis in São Paulo at Ribeirão Preto Medical Scholl, Ribeirão Preto, patients who have failed a Tumour Necrosis Factor São Paulo, Brazil (TNF) inhibitor - Subgroup analyses 1 1 1 Yen-Fu Chen , Kinga Malottki , Abdulrahman Uthman , T1-31 1 3 2 Zulian Liu , Kristina Routh , Paresh Jobanputra , Effectiveness of triple therapy for the management of 1 1 David Moore , Anne Fry-Smith Chronic Obstructive Pulmonary Disease 1 West Midlands Health Technology Assessment Kathryn Gaebel2 ,3, Gord Blackhouse1 ,3, Diana Collaboration, University of Birmingham, Birmingham, Robertson1 ,3, Feng Xie1 ,3, Nazila Assasi1 ,3, Andrew 2 United Kingdom, Rheumatology - University Hospitals McIvor2 ,5, Paul Hernandez4 ,6, Ronald Goeree1 ,3 Birmingham, Selly Oak Hospital, Birmingham, United 1McMaster University, Hamilton, Ontario, Canada, 2St 3 Kingdom, Unit of Public Health, Epidemiology and Josephs Healthcare Hamilton, Hamilton, Ontario, Canada, Biostatistics, University of Birmingham, Birmingham, 3Program for Assessment of Technology in Health Rsearch United Kingdom Institute, Hamilton, Ontario, Canada, 4Dalhousie University, Halifax, Nova Scotia, Canada, 5Firestone Institute of 12 T1-27 Respirology Health, Hamilton, Ontario, Canada, 6QEII Use of point-of-care devices in patients on long term oral Hospital, Halifax, Nova Scotia, Canada anticoagulation therapy: A health technology assessment Sophie Gerkens, Jeannine Gailly, Ann Van Den Bruel, Stephan Devriese, Caroline Obyn, Irina Cleemput Belgian Health Care Knowledge Centre (KCE), Brussels, Belgium POSTERS

106 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

T1-32 T1-36 Use of diagnostic technology in human communication Evaluation of effectiveness and safety comparing the disorders in rural workers underwent total laryngectomy treatment of spasticity with two different commercial Hilton Justino Silva1, Daniele Andrade Da Cunha1, presentations of TBA Renata Andrade Da Cunha1, Cleide Fernandes Teixeira1, Fábio C. Guarany1 ,2, Nicole Ruas1 ,2, Bianca Mentz1, Adriana Di Donato Chaves1, Patricia Mendes Balata1, Bárbara Krug1, Lucia Fendt2, Carolina R. Barone2, 1 ,2 1 ,2 Leandro De Araújo Pernambuco1 Antonio C. dos Santos , Paulo D. Picon 1 1Universidade Federal De Pernambuco, Recife/Pernambuco, Hospital de Clínicas de Porto Alegre, Rio Grande do Sul, 2 Brazil, 2Faculdade Integrada Do Recife, Recife/Pernambuco, Brazil, Faculdade Medicina - UFRGS, Rio Grande do Sul, Brazil Brazil

T1-33 T1-37 Anti-TNF-α drugs for treatment of ulcerative colitis: Glycated haemoglobin as a surrogate marker for the A systematic review and meta-analysis appearance and progression of retinopathy in type 2 1 ,2 1 ,2 1 ,2 diabetes mellitus: Systematic review and meta-analysis Nazila Assasi , Gord Blackhouse , Feng Xie , John 1 1 4 5 1 ,3 Aleksandra Wieczorek , Przemyslaw Rys , Anna K. Marshall , E. Jan Irvine , Kathryn Gaebel , Diana 1 2 1 1 ,2 1 ,2 1 ,2 Marcisz , Iwona Skrzekowska-Baran , Robert Plisko , Robertson , Kaitryn Campbell , Rob Hopkins , Ron 1 1 ,2 Magdalena Wladysiuk Goeree 1 2 1Programs for Assessment of Technology in Health Research HTA Consulting, Krakow, Poland, NovoNordisk, Warsaw, Institute, McMaster University, Hamilton, ON, Canada, Poland 2Department of Clinical Epidemiology & Biostatistics, T1-38 McMaster University, Hamilton, ON, Canada, 3Centre for Rapid-acting insulin analogues in children and Evaluation of Medicines, St. Josephs Healthcare Hamilton, adolescents with type 1 diabetes - A systematic review Hamilton, ON, Canada, 4Division of Gastroenterology, including previously unpublished data McMaster University Medical Centre, Hamilton, ON, Regine Potthast, Guido Skipka, Thomas Kaiser Canada, 5University of Toronto/St. Michael’s Hospital, Institute for Quality and Effi ciency in Health Care (IQWiG), Toronto, ON, Canada Cologne, Germany T1-39 T1-34 Analysis of drug eluting stent utilization in a private Evaluation of rapid Hepatitis C virus (HCV) serological Health Maintenance Organization in Brazil assays for screening and confi rming HCV infection in Luiz Henrique Furlan, Tania Conte, Marcelo Dallagassa, Brazil Gisele Bohn, Marlus Moraes Livia Villar1, Vanessa Marques1, Rosane Oliveira1, Lucy Unimed do Estado do Paraná, Curitiba, Paraná, Brazil Silva1, Sabrina Oliveira2, Elisangela Silva1, Juliana Miguel1, Jaqueline Oliveira1, Clara Yoshida1, Lia Lewis- T1-40 1 1 Ximenez , Elisabeth Lampe Using medical records to estimate the burden of 1 2 Focruz, Rio De Janeiro, Brazil, Hospital Dos Servidores rheumatoid-arthritis in Ontario Do Estado Do Rio De Janeiro, Rio De Janeiro, Brazil Jean-Eric Tarride1 ,2, Mahbubul Haq1 ,2, James M Bowen1 ,2, Matthias Bischof1 ,2, Feng Xie1 ,2, Gord Blackhouse1 ,2, T1-35 Daria O’Reilly1 ,2, Ron Goeree1 ,2 The impact of enzyme replacement therapy in 10 1PATH Research Institute, St Joseph Healthcare Hamilton, the functionality of children under 5 years with Hamilton, Ontario, Canada, 2McMaster University, Mucopolysaccharidosis I (MPS I)- Hurler Hamilton, Ontario, Canada Nicole Ruas1, Ida Vanessa D. Schwartz1 ,2, Fábio Coelho Guarany1 ,2, Maria Verônica Muñoz-Rojas1, Carolina F. Souza1 ,2, Louise L. C. Pinto1 ,2, Taiane A. Vieira1 ,2, T1-41 Roberto Giugliani1 ,2 Assessing the effectiveness of vaccination against measles, 1Universidade Federal do Rio Grande do Sul, Porto Alegre/ rubella and mumps in patients receiving autologous Rio Grande do Sul, Brazil, 2Hospital de Clínicas de Porto transplantation of peripheral blood stem cell (PBSCT). Alegre, Porto Alegre/ Rio Grande do Sul, Brazil Systematic review of the literature 12 Beatriz Pacho1 ,2, Iñaki Gutiérrez-Ibarluzea1, Marta López de Argumedo1, José Asua3 1Cruces Hospital, Barakaldo/Basque Country, Spain, 2Osteba, Basque Offi ce for HTA, Vitoria-Gasteiz/Basque Country, Spain, 3Ministry of Health and Consumer Affairs, Vitoria-Gasteiz/Basque Country, Spain POSTERS

107 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

T1-42 HAS, Saint-Denis La PLaine, France Current prevalence and incidence of type 2 diabetes in T2-04 the primary care setting in Ontario A randomised clinical trial to assess the cost-effectiveness 1 1 2 Robert J Petrella , Paul Michialitis , Mahbubul Haq , of home telemonitoring for patients with heart failure Daria OReilly2, Ron Goeree2, Vincent Raymond3, Farzad 3 3 and chronic obstructive pulmonary disease Ali , Jean-Eric Tarride Juan Carlos Bayón, Estibalitz Orruño, José Asua 1Lawson Health Research Institute, University of Western Basque Offi ce for HTA, Vitoria-Gasteiz, Spain Ontario, London, Ontario, Canada, 2PATH Research Institute, McMaster University, Hamilton, Ontario, Canada, 3Outcomes Research, Pfi zer Canada Inc., Kirkland, Quebec, T2-05 Canada The application of HTA in a rare disease: Eltrombopag T1-43 in chronic immune thrombocytopenia Analysis of clinical practice in the Basque Country and Federica Basso1, Francesco Rodeghiero2, Simone evidence based recommendations regarding Attention Gerzeli3, Francesco Bamfi 1 Defi cit Hyperactivity Disorder (ADHD) 1HTA, Clinical Safety and Medical Information Cristina Jorquera1, Alberto Lasa2, Iñaki Gutierrez1 GlaxoSmithKline, Verona, Italy, 2Department of Cell Therapy 1Basque Offi ce for Health Technology Assessment and Haematology, S.Bortolo Hospital, Vicenza, Italy, (OSTEBA), Vitoria (Álava - Basque Country), Spain, 2Uribe- 3Department of Applied Statistics and Economics “Libero Costa Mental Health Service for children (Basque Health Lenti”, University of Pavia, Pavia, Italy Service - Osakidetza), Algorta (Vizcaya - Basque Country), Spain T2-06 T1-44 Economic burden of chronic immune thrombocytopenia Effectiveness and safety of motor cortex stimulation with in Italy implantable pulse generators for chronic neuropathic Francesco Rodeghiero1, Simone Gerzeli2, Gwilym pain: A systematic review Thompson4, Federica Basso3 Chang Ik Kwon1, Min Lee1, Ju Seong Kim2, Sang Won 1Department of cell Therapy and Haematology, S.Bortolo Lee3, Kwang Seon Lee4 Hospital, Vicenza, Italy, 2Department of Applied Statistics 1Department of Health Technology Assessment, Health and Economics, Libero Lenti, University of Pavia, Pavia, 3 Insurance Review and Assessment Service, Seoul, Korea, Italy, HTA,Clinical Safety and Medical information 4 Republic of, 2Department of Neurosurgery, Eulji University GlaxoSmithKline, Verona, Italy, Global Health Outcomes College of Medicine, Seoul, Korea, Republic of, 3Department Oncology, GlaxoSmithKline, London, United Kingdom of Neurosurgery, Catholic University of Korea College of Medicine, Seoul, Korea, Republic of, 4Department T2-07 of otorhinolaryngology, University of Ulsan College of Methylnaltrexone for Opioid-induced Constipation in Medicine, Seoul, Korea, Republic of, 5Departments of Palliative Cancer Treatment 1 1 Neurology, Ewha Womans University School of Medicine, Espen Movik , Tove Ringerike , Kristin Kamilla 1 1 ,2 1 Seoul, Korea, Republic of Linnestad , Bjørn Hofmann , Marianne Klemp 1Norwegian Knowledge Centre for the Health Services, Oslo, Norway, 2University of Oslo, Oslo, Norway T2 - Economics T2-08 T2-01 The building blocks for complex decision making: an Potential reduction of costs with a store-and-forward example of HTA in chronic kidney disease care teledermatology consult system for general practitioners Pawana Sharma1, Corri Black1, Graham Scotland1, Keith Juan Carlos Bayón, Estibalitz Orruño, José Asua McCullough2, Lynn Robertson1, Nick Fluck2, Alison M. Basque Offi ce for HTA, Vitoria-Gasteiz, Spain Macleod1, Paul McNamee1, Gordon Prescott1, W Cairns Smith1 T2-02 1 A systematic review of the evidence on cost and health- University of Aberdeen, Aberdeen, United Kingdom, 2 related quality of life of diabetic retinopathy Aberdeen Royal Infi rmary Renal Unit, NHS Grampian, Véronique Raimond, Philippe Canet, Renée Cardoso, Aberdeen, United Kingdom 12 Agnès Dessaigne Haute Autorité de santé, Saint-Denis (93), France T2-09 Economic, clinical, operational and organizational T2-03 assessment concerning the introduction of a triple Assessment of coagulometers for self-testing and self- quadrupole mass spectrometer (lc-ms/ms) in the irccs management of oral anticoagulation therapy (OAT) in “burlo garofolo” laboratories adult patients Addobbati Riccardo, Amadori Nicola, Estelle Piotto, Isabelle Bongiovanni, Corinne Collignon, Zangrando Riccardo Catherine Denis, Catherine Rumeau-Pichon, François Meyer IRCCS Burlo Garofolo, Trieste, Italy POSTERS

108 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

T2-10 T2-15 From models to practice at meso (hospital based) level: Cardiac resynchronization therapy: economic evaluation role, methods and results of unità di valutazione delle Daniel Callejo, Mercedes Guerra, Juan Antonio Blasco, technologie compared to international experiences Beatriz Valentín, Nieves Calcerrada Lorenzo Leogrande1, Carmen Furno1, Marco Marchetti1, Health Technology Assessment Unit (UETS), Madrid, Spain Americo Cicchetti2 1 T2-16 Unità di Valutazione delle Tecnologie, A. Gemelli University Healthcare services utilization in patients with drug- Hospital, Rome, Italy, 2UCSC Catholic University of Sacred eluting stents versus bare-metal stents in Brazil. Edital Hearth, Rome, Italy MCT/CNPq/ANS 25/2007CNPq, Number 402667/2007-7 Carlos Amaral2 ,3, Silvana Kelles1 ,2, Christiane Bretas1 T2-11 ,2, Izabel Mendonça1 ,2, Antonio Luiz Ribeiro2 ,3, Lelia 1 ,2 2 3 Treatment of Gaucher disease in Brazil: evidence for Carvalho , Sandra Sapori , Arlaine Silva 1Unimed-BH, Belo Horizonte, Brazil, 2Heath Technology waist of public resources 1 ,2 1 ,2 Assessment Nucleus, Hospital das Clínicas, Federal Bárbara Krug , Ida Vanessa Schwartz , Elaine University of Minas Gerais (NATS/HC/UFMG) and National Laporte1 ,2, Indara Saccilotto1 ,3, Maria Inês Gadelha1, Institute of Science and Technology for Health Technology Paulo Picon1 ,3 Assessment (IATS) , Belo Horizonte, Brazil, 3Federal 1Brazilian Ministry of Health, Brasília, Brazil, 2Public University of Minas Gerais, Belo Horizonte, Brazil Health State Secretariat of Rio Grande do Sul, Rio Grande do Sul, Brazil, 3Hospital de Clínicas de Porto Alegre, Rio T2-17 Grande do Sul, Brazil Switzerland’s innovative tariff model for the offi cial list of reimbursable laboratory analyses Barbara Freche1, Maya Züllig1, Famh Foederatio T2-12 Analyticorum Medicinalium Helveticorum2, Prime Title: Cost impact of use of trastuzmab prescribing in Networks Corporation3 the treatment of advanced Her2 positive gastric cancer. A 1Swiss Federal Offi ce of Public Health, Liebefeld, single institution report. Switzerland, 2Association Suisse des Chefs de Laboratoires Fionnuala King, Ian Collins, Ken O Byrne d’Analyses Médicales, Solothurn, Switzerland, 3Prime St James Hospital, Dublin, Ireland Networks Corporation, Basel, Switzerland

T2-13 T2-18 SAFER 2: Support and Assessment for Fall Emergency Cost-effectiveness of diagnosis and management of Referrals- (part of the SAFER Research Programme) Group A Haemolytic Streptococcal pharyngitis in the 1 1 1 Spanish paediatric population Helen Snooks , Wai Yee Cheung , Clare Clement , 1 2 2 3 1 Carolina del Valle Giráldez-García , Beltrán Rubio , José Jeremy Dale , Rachael Donohoe , Sarah Gaze , Mary 1 2 4 1 5 1 Francisco Gallegos-Braun , Iñaki Imaz , Jesús González- Halter , Gareth Lloyd , Phillippa Logan , Ronan Lyons , Enríquez2, Antonio Sarría-Santamera2 6 6 1 Suzanne Mason , Jonathon Nicholl , Julie Peconi , Ceri 1Preventive Medicine Service, La Paz Hospital, Madrid, Phillips1, Judith Phillips1, Elizabeth Rees9, Ian Russell1, Spain, 2AETS (Agencia de Evaluación de Tecnologías Niro Siriwardena7, Mushtaq Wani1, Richard Whitfi eld8 Sanitarias), Carlos III Health Institute, Science and 1Swansea University, Swansea, United Kingdom, 2Warwick Innovation Ministry, Madrid, Spain University, Warwick, United Kingdom, 3London Ambulance Service, London, United Kingdom, 4University of London, T2-19 10 London, United Kingdom, 5Nottingham City Primary Care The impact of gestational diabetes mellitus in Ireland Trust, Nottingham, United Kingdom, 6Sheffi eld University, Paddy Gillespie, Gloria Avalos, Michael O’Reilly, Ciaran Sheffi eld, United Kingdom, 7East Midlands Ambulance O’Neill, Fidelma Dunne Service, East Midlands, United Kingdom, 8Wales Ambulance NUI Galway, Galway, Ireland Service, Wales, United Kingdom, 9Age Concern Swansea, Wales, United Kingdom T2-20 Percutaneous vertebroplasty as a treatment for T2-14 osteoporotic vertebral fractures - a Health Technology 12 Cost-effectiveness of a school-based tobacco-use Assessment Rikke Rousing1, Jens Lauritsen1, Karsten Thomsen1, prevention program in Spain 4 1 1 ,2 1 ,2 Diana Reerman , Mikkel Andersen , Stig Mindedahl Juan Manuel Ramos Goñi , Renata Linertová , 1 2 2 1 ,2 2 Jespersen , Kristian Kidholm , Lisa Korsbek , Leif Yolanda Ramallo Fariña , Antonio Torres Lana 3 1 Sørensen Foundation for Health and Research, FUNCIS, Tenerife/ 1 2 Department of Orthopaedics, Odense, Denmark, Canary Island, Spain, Canary Islands Health Service, 2 Tenerife/Canary Island, Spain Department for Research and HTA, Odense, Denmark, 3Aarhus University Hospital, Aarhus, Denmark, 4Danish Centre for Health Technology Assessment, National Board of Health, Copenhagen, Denmark POSTERS

109 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

T2-21 T2-27 Cost-effectiveness of bariatric surgical procedures versus Cost-effectiveness of Transcatheter Heart Valve no treatment for morbid obesity Implantation (TAVI) in Scotland Anjori Pasricha, Gord Blackhouse, Ron Goeree, Jean- Aileen Murphy1 ,2, Andrew Briggs1, Elisabeth Fenwick1 Eric Tarride, Daria O’Reilly 1Public Health & Health Policy, University of Glasgow, PATH Research Institute, McMaster University, Hamilton, Glasgow, United Kingdom, 2Department of Economics, Ontario, Canada University College Cork, Cork, Ireland

T2-22 T2-28 Health economic evaluations in child and adolescent The topic negative pressure therapy for closure of acute and chronic wounds psychiatry 1 3 1 Philipp Radlberger Paolo Giorgi Rossi , Antonio Fortino , Laura Camilloni , Livia Di Bernardo2, Giacomo Furnari1, Anna Rita Ludwig Boltzmann Institute for Health Technology Todini2, Leonardo Frigerio3 Assessment, Vienna, Austria 1Laziosanità, Agency for Public Health, Rome, Italy, 2Azienda Ospedaliera S. Camillo, Rome, Italy, 3ASL Roma D, T2-23 Rome, Italy Relative effi cacy, safety and cost-effectiveness of nicotine replacement therapy, bupropion and varenicline for T2-29 smoking cessation in Norway Eculizumab for paroxysmal nocturnal haemoglobinuria Gunhild Hagen1, Ingvil Sæterdal1, Torbjørn Wisløff1 ,2, (PNH): Prevalence, clinical effectiveness, cost- Jan Odgaard-Jensen1, Ingrid Harboe1, Tove Ringerike1, effectiveness and budget implications Marianne Klemp1 ,2 David Moore, Martin Connock, Dechao Wang, Anne Fry- 1Norwegian Knowledge Centre for the Health Services, Oslo, Smith Norway, 2University of Oslo, Oslo, Norway University of Birmingham, Birmingham, United Kingdom

T2-24 T2-30 Real world data about management, costs and quality of Cost analysis of the da Vinci Surgical Robotic System in life in Chronic Lymphocytic Leukemia China K.M. Holtzer-Goor1, C.A.M Bouwmans-Frijters1, M.G. Yingyao Chen, Zhixin Ge, Chuanlin Li Franken1, M.R. Schaafsma2, C.A. Uyl-de Groot1 Key Lab of HTA, Fudan University, Shanghai, China 1Erasmus University Rotterdam, Rotterdam, Netherlands, 2Medisch Spectrum Twente, Enschede, Netherlands T2-31 Cost effectiveness of non invasive ventilation in Motor T2-25 Neuron Disease versus standard care New oral antithrombotic drugs for the VTE prevention Edward Mwarangu in orthopaedic surgery: the HT assessment and appraisal National Institute for Health and Clinical Excellence, process of the Veneto Region in Italy Manchester, United Kingdom Chiara Alberti, Francesca Venturini, Francesco Berardo, Elena Visentin, Andrea Aiello, Paola Rosa Maran, T2-32 Giovanna Scroccaro Cost-effectiveness of initiation and maintenance Drug Effectiveness Evaluation Unit of the Regional treatment with anti-tnf-α drugs for refracrtory crohn’s Reference Centre for drugs (UVEF) - Department of disease Pharmacy of the University Hospital of Verona, Verona, Gord Blackhouse1 ,2, Feng Xie1 ,2, Nazilla Assasi1 ,2, Kathy Veneto Region, Italy Gaebel1 ,3, John Marshall1 ,6, E. Jan Irvine4 ,5, Diana Robertson1 ,2, Ron Goeree1 ,2 T2-26 1PATH Research Institute, Hamilton,Ontario, Canada, Can C-Reactive Protein (CRP) be used as a predictive 2McMaster University, Hamilton, Ontario, Canada, 3St. 12 variable of pre-eclampsia: preliminary results from a Joseph’s Hospital, Hamilton,Ontario, Canada, 4University of systematic literature review Toronto, Toronto, Ontario, Canada, 5St. Michael’s Hospital, Gilberto Kac, Fernanda Rebelo, Michael Maia, Toronto,Ontario, Canada, 6Hamilton health Sciences, Juliana Vaz Rio de Janeiro Federal University, Rio de Hamilton,Ontario, Canada Janeiro, Brazil POSTERS

110 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

T2-33 T2-39 An early-stage cost-effectiveness analysis of a surgical Effectiveness and cost-effectiveness in Spain of technology: the case of TAVI for severe aortic stenosis in treatments for advanced Parkinson’s disease: high risk patients preliminary results Maureen Watt, Stuart Mealing, Mark Sculpher, James Lidia García-Pérez, Renata Linertová, Virginia Yanes- Eaton López Oxford Outcomes Ltd., Oxford, United Kingdom Fundación Canaria de Investigación y Salud, Santa Cruz de Tenerife, Canarias, Spain T2-34 Consequences of population screening for abdominal T2-40 aortic aneurysm (AAA) - a health technology assessment Health economic evaluation of acute treatment of Mette Kjølby1 ,2, Lotte Groth Jensen1 ,2, Claus Løvschall1 patients in stroke unit (with or without early supported ,2, Merete Bech3, Lars Ehlers4 discharge) 1Department of HTA, Institute of Public Health, Aarhus Vida Hamidi, Torbjørn Wisløff, Tove Ringerike, Kristin University, Aarhus, Denmark, 2HTA & Health Services Linnestad, Ingrid Harboe, Marianne Klemp Research, Centre for Public Health, Central Denmark Norwegian Knowledge Centre for the Health Services, Oslo, Region, Denmark, 3The Projectdepartment for The New Norway University Hospital in Aarhus, Central Denmark Region, Denmark, 4Health Economics and Management, Aalborg T2-41 University, Aalborg, Denmark Clinical and economic impact of use of a pocket-sized ultrasound device for Heart Failure Hospitalizations T2-35 Pankaj Patel1, Manan Shah2, Anna DSouza2, James Min3 Nucleic Acid Amplifi cation Tests (NAT) for HIV 1GE Healthcare, Barrington, Illinois, United States, 2Xcenda, Screening of Donated Blood in Brazil: building a Markov Palm Harbor, Florida, United States, 3Weill Medical College Model of Cornell University, New York, New York, United States Diogo Soares1, Marcus Araújo1, Gustavo Garcia1, Ana Cristina Martins2 T2-42 1National Health Surveillance Agency, Brasília, DF, Brazil, Learning from a decade of international experience in 2National Supplementary Health Agency, Rio de Janeiro, RJ, HTA for genetic/genomic tests Brazil Linda Bradley, Glenn Palomaki Women & Infants Hospital/Alpert Medical School of Brown T2-36 University, Providence, RI, United States Data sources for decision analytic models applied to the economic evaluation of health care T2-43 Carla Rodrigues Health Technology Assessment for Rare Diseases: a National Agency for Supplementary Health, Rio de Janeiro, Markovian Model for Fabry Disease (FD) considering RJ, Brazil Enzyme Replacement Therapy (ERT) Monica Vinhas de Souza1, Ida Doederlein Schawartz1 ,2 T2-37 1Universidade Federal do Rio Grande do Sul/UFRGS, Porto Negative pressure wound therapy for the chronic wounds Alegre/RS, Brazil, 2Hospital de Clinicas de Porto Alegre/ 10 healing: toward a regional consensus for healthcare HCPA, Porto Alegre/RS, Brazil organisation services Mélanie Hamel1, Claire Dumont2, Marc Rhainds1, Martin T2-44 Bussières1, Brigitte Larocque1 The humanistic and economic burden of osteo-arthritis 1UETMIS, Centre hospitalier universitaire de Québec in Ontario (CHUQ), Québec, QC, Canada, 2Institut de réadaptation Jean-Eric Tarride1 ,2, Mahbubul Haq1 ,2, Matthias Bischof1 en défi cience physique de Québec (IRDPQ), Québec, QC, ,2, Gord Blackhouse1 ,2, James M Bowen1 ,2, Feng Xie1 ,2, Canada Daria O’Reilly1 ,2, Ron Goeree1 ,2 12 1PATH Research Institute, St Joseph Healthcare Hamilton, T2-38 Ontario, Canada, 2McMaster University, Ontario, Canada Factors infl uencing the cost-effectiveness of CT colonography in screening for colorectal cancer: A review and critique of the evidence Paul Hanly, Alan O Ceilleachair, Linda Sharp National Cancer Registry Ireland, Cork, Ireland POSTERS

111 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

T2-45 T2-50 Health resources utilization by dyspeptic patients in Amotosalen (Intercept®) for the inactivation of Brazil pathogens for transfusion therapy Guilherme Sander1 ,2, Luiz Edmundo Mazzoleni1 ,2, Laura Navarro1 ,2, Miquel Lozano3, Lluis Puig4, Cari Carlos Francesconi1 ,2, Andre Wortmann1 Almazán1 ,2 1Universidade Federal do Rio Grande do Sul, Porto Alegre, 1CIBER Epidemiology and Public Health, CIBERESP, 2 Rio Grande do Sul, Brazil, 2Hospital de Clínicas de Porto Barcelona, Spain, Health Technologies of the Catalan Alegre, Porto Alegre, Rio Grande do Sul, Brazil Agency for Health Technology Assessment and Research, Barcelona, Spain, 3Hospital Clínic de Barcelona, Barcelona, 4 T2-46 Spain, Banc de Sang i Teixits, Barcelona, Spain Infl uence of variations in anatomic pathology on T2-51 technology assessment and cost effectiveness of new Multiple regression analysis for identifi cation of technology: The example of anular reconstruction for risk factors related to the development of chronic lumbar disc herniation 1 ,2 2 2 complications of type 1 diabetes - econometric analysis David Wong , Libby Mauter , Vera Murdock , Fernanda Laranjeira 1 Caroline Wong Ministry of Health of Brazil, Brasilia, DF, Brazil 1Denver Spine, Greenwood Village, Colorado, United States, 2 Presbyterian St. Luke’s Medical Center, Denver, Colorado, T2-52 United States Evaluation of motorcycle helmet interventions in high and middle-income countries: an economic review T2-47 Ferruccio Pelone1, Marta Marino2, Giuseppe Avallone2, Antipsychotic polypharmacy- a Health Technology Danila Basso2, Maria Avolio3, Walter Ricciardi2, Antonio Assessment 2 1 2 6 Giulio de Belvis Lone Bandrup , Diana Reerman , Lisa von Huth Smith , 1Health Care Management and Economics PhD Student, Birte Glenthøj1, Henrik Lublin1, Merete Nordentoft2, Department of Public Health and Preventive Medicine, Linda Peacock3, Jan Sørensen4, Stig Ejdrup Andersen5 Catholic University of Sacred Heart, Rome, Italy, 1Center for Neuropsychiatric Schizophrenia Research, 2Department of Public Health and Preventive Medicine, University of Copenhagen, Psychiatric Centre Glostrup, 3 Glostrup, Denmark, 2Psychiatric Centre Bispebjerg, Catholic University of Sacred Heart, Rome, Italy, Institute Bispebjerg, Denmark, 3Psychiatric Centre North Sealand, for Social Affairs, Rome, Italy North Sealand, Denmark, 4Centre for Applied Health Services Research and Technology Assessment, Odense, T2-53 Denmark, 5Bispebjerg Hospital, Bispebjerg, Denmark, Robot-assisted surgery: love it or leave it 6Danish Centre for Health Technology Assessment, National Chris De Laet, Cécile Camberlin, Arnaud Senn Board of Health, Copenhagen, Denmark Belgian Health Care Knowledge Centre (KCE), Brussels, Belgium T2-48 A cost-effectiveness study of zoledronic acid 5mg infusion T2-54 for the treatment of osteoporosis Economic evaluation of hip replacement therapy in Brenda Gannon2, John Carey1 patients with Osteoarthritis in Italy 1University College Hospital Galway, Galway, Ireland, Ruben E Mujica Mota1 ,2, Aleksandra Torbica1 ,2, Elio 2National University of Ireland Galway, Galway, Ireland Borgonovi1 ,2 Background: Currently 70 million persons have 1Universita Bocconi, Milan, Italy, 2European Health osteoporosis Technology Institute for Socio-economic Research (EHTI), Brussels, Belgium T2-49 Counting the Cost of Chronic Pain: An Analysis of Pain Clinic Attendees in Ireland Brenda Gannon1 ,3, Edel Smith1, David Finn3 ,4, David 12 O’Gorman4, Nancy Ruane5, Brian McGuire3 ,5 1Department of Economics, National University of Ireland Galway, Galway, Ireland, 2Department of Pharmacology and Therapeutics, National University of Ireland, Galway, Galway, Ireland, 3Centre for Pain Research, National University of Ireland, Galway, Galway, Ireland, 4Division of Pain Medicine, Galway University Hospital, Galway, Ireland, 5School of Psychology, National University of Ireland, Galway, Galway, Ireland POSTERS

112 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

T3-08 T3 - Healthcare Policy The Information System of the Brazilian Network for Health Technology Assessment: A tool to spread T3-01 researches results for decision-making process Rapid HTA reviews in cancer guideline development Margarete Oliveira, Rimena Araujo, Isadora Patterson, Lene Kristine Juvet1, Espen Movik1, Borghild Svorken2, Valdete Melo, Flavia Elias Stein Kaasa2, Inger Natvig Norderhaug1 Ministry of Health, Brasilia, DF, Brazil 1Norwegian Knowledge Centre for the Health Services, Oslo, Norway, 2Norwegian Directorate of Health, Oslo, Norway T3-09 T3-02 Core HTAs - Towards cooperation and reduction of Centralized Procedures and International Collaboration duplicate work within HTA to Overcome the Uncertainty in Reimbursement of Kristian Lampe1, Alessandra Lo Scalzo2, Marina Cerbo2, Orphan Drugs Marjukka Mäkelä1, Iris Pasternack1, Maria Rosaria Orly Tamir1, Naomi Friedman1, Sharona Vaknin1, Ifat Perrini2, Leena Raustia1, Oskari Saarekas1 Abadi-Korek1, Tal Morginstein2, Joshua Shemer1 1THL/FINOHTA, Helsinki, Finland, 2AGENAS, Rome, Italy 1Israeli Center for Technology Assessment in Health Care, Ramat Gan, Israel, 2Ministry of Health, Jerusalem, Israel T3-10 HTA applied to hospital context: The case of sinus T3-03 balloon system Right place, fi rst time? Use of services for unscheduled 1 1 health care needs Carmen Furno , Lorenzo Leogrande , Emanuele Alison Porter, Lori Button, Angela Evans, Rob Lowe, Scarano2, Marco Marchetti1, Americo Cicchetti3, Gaetano Helen Snooks, Alan Watkins, Claire Williams Paludetti2 Swansea University, Swansea, United Kingdom 1Unità di valutazione delle Tecnogie, Agostino Gemelli University Hospital, Rome, Italy, 2Department of T3-04 Othorinolaryngoiatry, Agostiono Gemelli University Identifi cation and prioritization of HTA topics in Brazil: Hospital, Rome, Italy, 3UCSC - Catholic University of Sacred methods and results Marcus Silva, Mariama Falcão, Everton Silva, Natália Hearh, Rome, Italy Veloso, Vania Santos, Flávia Elias Ministério da Saúde; Secretaria de Ciência, Tecnologia T3-11 e Insumos Estratégicos; Departamento de Ciência e Organizational aspects in HTA Tecnologia, Brasília, DF, Brazil Ulla Saalasti-Koskinen1, Juha Koivisto1, Camilla 2 1 T3-05 Palmhøj-Nielsen , Päivi Reiman-Möttönen , Marcial Health and Economy Report - Economic assessment of Velasco Garrido3, Marco Marchetti4, Charlotte Bredahl health care technologies popularization Jacobsen5, Finn Børlum Kristensen2 Telma Rodrigues Caldeira, Giselle Silva Pereira 1National Institute for Health and Welfare, Helsinki, Finland, Calais, Gustavo Cunha Garcia, Symone Oliveira Lima, 2The Danish National Board of Health, Copenhagen, Fernanda Maciel Rebelo, Alexandre Portugal D’Oliveira Denmark, 3Technische Universität Berlin, Berlin, Germany, Lemgruber 4Università Cattolica del Sacro Cuore, Rome, Italy, 5Danish Health Surveillance National Agency, Brasília, DF, Brazil Institute for Health Services Research, Copenhagen, T3-06 Denmark 10 Bringing policy makers closer to HTA research: Brazilian strategies T3-12 Marcus Silva, Everton Silva, Natalia Veloso, Advancing the use of evidence on the effects of health Margarete Oliveira, Mariama Falcão, Isadora Patterson, Flávia Elias care in the West Midlands UK: A retrospective overview Ministério da Saúde; Secretaria de Ciência, Tecnologia of ARIF e Insumos Estratégicos; Departamento de Ciência e Anne Fry-Smith, Sue Bayliss, David Moore Tecnologia, Brasília, DF, Brazil University of Birmingham, Birmingham, United Kingdom 12 T3-07 T3-13 Ultra-orphan drug status, but not innovativeness, Assessment of health technology assessment: By what was associated with increased rates of positive recommendations of new medicines by the All Wales standards? 1 Medicines Strategy Group Bjørn Hofmann Warren Linley, Dyfrig Hughes 1Norwegian Knowledge Centre for the Health Services, Oslo, Bangor University, Bangor, Gwynedd, United Kingdom Norway, 2University College of Gjøvik, Gjøvik, Norway POSTERS

113 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

T3-14 T3-21 Establishment of Health Technology Assessment Centers Systematic approach to integrate ethical analysis in (NATS) in Hospitals in Brazil health technology assessment at the hospital level Vania Santos1, Diogo Soares2, Clarice Petramale2, Flavia Marc Rhainds1, Marcel Melançon2, Chantale Simard3, Elias1 Dolorès Lepage Savary1 1Ministry of Health of Brazil, Brasília, Brazil, 2National 1UETMIS, Centre Hospitalier Universitaire de Québec 2 Health Surveillance Agency, Brasilia, Brazil (CHUQ), Québec, Canada, Université du Québec à Chicoutimi, Chicoutimi, Canada, 3CSSS de Portneuf, T3-15 Donnacona, Canada Strengthening the Brazilian Network for HTA in 2009: Call for proposal and funding T3-22 Flávia Elias1, Leonor Santos1, Natália Veloso1, Eduardo Process Automation in Managing Medical Devices: The Assis1, Marcus Silva1, Reinaldo Guimarães1 Experience of a Clinical Engineering Department 1Ministério da Saúde; Secretaria de Ciência, Tecnologia Federico Nocchi1 ,2, Carlo Capussotto1, Tiziana Franchin1, e Insumos Estratégicos; Departamento de Ciência e Simona Bufalari1, Pietro Derrico1 Tecnologia, Brasília, DF, Brazil, 2Ministério da Saúde; 1Bambino Gesù Children’s Hospital, Roma, Italy, 2University Secretaria de Ciência, Tecnologia e Insumos Estratégicos, of Roma Tre, Roma, Italy Brasília, DF, Brazil T3-23 T3-16 Profi le of HTA studies were used on helping decision Strategies for capacitating Brazilian professionals on making process in Ministry of Health of Brazil clinical, effectiveness and cost-effectiveness Priscila Gebrim Louly, Aline Silveira Silva, Fernanda de Everton Silva, Marge Tenório, Flávia Elias, Ana Patrícia Oliveira Laranjeira, Flávia Cristina Ribeiro Salomon, de Paula, Marcus Silva Mariama Gaspar Falcão, Mario Henrique Osanai, Celine Ministério da Saúde; Secretaria de Ciência, Tecnologia de Kerchove de Almeida Prado, Luiz Henrique Picolo e Insumos Estratégicos; Departamento de Ciência e Furlan, Vania Cristina Canuto Santos, Flávia Tavares Silva Elias Tecnologia, Brasília, DF, Brazil Ministry of Health, Brasilia / DF, Brazil T3-17 T3-24 The Brazilian Methodological guidelines for economic The Brazilian experience in training health decision evaluation of health technologies makers and technicians on elaboration and Everton Silva, Flávia Elias, Marcus Silva interpretation of rapid-HTA Ministério da Saúde; Secretaria de Ciência, Tecnologia Flavia Salomon, Fernanda Laranjeira, Omar Til, Priscila e Insumos Estratégicos; Departamento de Ciência e Louly, Mario Henrique Osanai, Marcela Conti, Flavia Tecnologia, Brasília, DF, Brazil Elias Ministry of Health, Brasilia / DF, Brazil T3-18 Local HTA Systems - What Challenges Do They Face? Lanting Lu, Jaime Peters, Ken Stein T3-25 PenTAG/PenCLAHRC, Exeter, United Kingdom Health Technology Assessment in critical appraisal of clinical guidelines in Ministry of Health of Brazil T3-19 Priscila Gebrim Louly, Mario Henrique Osanai, Luiz H Thoughts about the judicialization of health Picolo Furlan, Flávia TS Elias Isadora Patterson, Omar Layunta, Flávia Elias Ministry of Health, Brasilia - DF, Brazil Department of Science and Technology - Ministry of Health of Brazil, Brasília, DF, Brazil T3-26 Infl uence of HTA on the review and development of T3-20 clinical guidelines of Ministry of Health of Brazil Support of the Health Technology Assessment in the Priscila Gebrim Louly, Mariama G Falcão, Flávia CR 12 Brazilian List of Essential Medicines in 2009 Salomon, Vania C Canuto Santos, Flávia TS Elias Mariama Falcão, Aline Silva, Priscila Louly, Vânia Ministry of Health, Brasilia - DF, Brazil Santos, Marcus Silva, Flávia Salomon, Marcela Conti, Flávia Elias T3-27 Ministry of Health of Brazil, Brasília, Brazil HTA and guidelines - Parallels and perspectives for synergies Michaela Eikermann, Alric Rüther Institute for Quality and Effi ciency in Health Care, Cologne, Germany POSTERS

114 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

T3-28 T3-35 Tailoring HTA for the requirements of national Health Comparison between “Looking Back” and “Horizon Care systems? Lessons learned: The Bismarck system, Scanning” example of Germany and Austria 1 2 1 2 3 Mario Fregonara Medici , Roberto Miniati , Alric Ruether , Ingrid Rosian , Britta Goehlen Massimiliano Monti1 1IQWiG, Cologne, Germany, 2GÖG, Vienna, Austria, 1Clinical Engineering at University Hospital “Careggi”, 3DIMDI, Cologne, Germany Florence, Italy, 2University of Floreence, Dept. Electronics T3-29 and Telecommunications., Florence, Italy Implementing HTA into a Bismarck health care system -Challenges for building up a national HTA strategy in Austria Elisabeth Breyer, Ingrid Rosian Gesundheit Österreich GmbH, Vienna, Austria T4 - Methods

T3-30 T4-01 Utilization of HTA in Danish policy-making - Theoretical Defi nition of a check list to increase medical devices considerations and results of an empirical study 1 availability in hospital Camilla Palmhøj Nielsen 1 1 1 1 Fabrizio Dori , Ernesto Iadanza , Roberto Miniati , Danish Centre for Health Technology Assessment, Mario Fregonara Medici2 Copenhagen, Denmark, 2Department of Political Science, 1Department of Electronics and Telecommunications - University of Copenhagen, Copenhagen, Denmark University of Florence, Florence, Italy, 2AOU Careggi Hospital, Florence, Italy T3-31 Uncontrollable factors that affect the decision making T4-02 process and their impact on the value of the HTA A process analysis for hospital-based use of CVVH: a evidence proposal for HTA methodology Christa Harstall1, Joan Berezanski2 Fabrizio Dori1, GianFranco Gensini2, Roberto Gusinu2, 1Institute of Health Economics, Edmonton Alberta, Canada, Serafi na Valente2 2Alberta Health and Wellness, Edmonton Alberta, Canada 1Department of Electronics and Telecommunications - University of Florence, Florence, Italy, 2Department of Heart T3-32 and Vessels - University of Florence, Florence, Italy Disease Management programs in the setting of community care in Italy T4-03 1, Ambrogio Aquilino2, Alberto Deales3, Andrea Musilli An application for critical appraisal and synthesis of Antonio Pagano4, Marina Panfi lo1, Matteo Ruggieri5 the evidence is now available in Spanish and English 1Pfi zer Italy, Roma, Italy, 2ARES Puglia - Agenzia Regionale language Sanitaria, Bari, Italy, 3ARS Marche - Agenzia Regionale Marta Lopez-Argumedo, Eva Reviriego, Rosa Rico, Asun Sanitaria, Ancona, Italy, 4ASP Lazio - Agenzia di Sanità Gutierrez Pubblica, Roma, Italy, 5Universita’ Cattolica del Sacro Basque Offi ce for Health Technology Assessment, Osteba, Cuore, Rome, Italy Basque Country, Spain 10 T3-33 T4-04 Project “Building bridges between scientifi c evidence and management in health: elaboration of HTA studies PriTecTool. Development of a prioritisation tool for post- results bulletins for subsidize the decision-making introduction observation of new technologies 1 1 processes” Leonor Varela Lema , Alberto Ruano Raviña , Teresa 1 1 Uliana Pontes Cerdá Mota , Teresa Queiro Verdes , José Antonio Blasco 2 3 Federal University of Rio de Janeiro, Macaé, Rio de Janeiro, Amaro , Iñaki Gutierrez Ibarluzea , Nora Ibargoyen Brazil Roteta3, Iñaki Imaz Iglesias4, Laura Sampietro Colom5, 12 Enrique Soto Pedre6, Román Villegas Portero7 T3-34 1Galician Health Technology Assessment Agency (avalia-t), Leveraging International Collaborations - Developing Santiago de Compostela, Galicia, Spain, 2Lain Entralgo a National Plan for Eliminating Needless Blindness in Agency. Madrid Regional Health Technology Assessment Rwanda Unit (UETS), Madrid, Spain, 3Basque Government Health Raja Bollineni Technology Assessment Department (Osteba), Basque ACCESS Health Initiative, Hyderabad,ANDHRA PARDESH, Country, Spain, 4Health Technology Assessment Agency of India the Carlos III Institute of Health (AETS), Madrid, Spain, POSTERS

115 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

5Barcelona Clinical Hospital Innovation & New Technology T4-10 Assessment Unit, Barcelona, Spain, 6Canary Island Health Improving data on clinical trials (‘metadata’) Department, Canary Islands, Spain, 7Andalusian Health Amanda Young1, Louise Dent1 ,2, Andrew Cook2, Peter Technology Assessment Agency (AETSA), Andalusian Davidson2, Ruairidh Milne2, David Turner1, James Region, Spain Raftery1 ,2 1University of Southampton Wessex Institute, Southampton, T4-05 United Kingdom, 2NETSCC, University of Southampton, Enhancing HTA through Multi-Criteria Decision Southampton, United Kingdom Analysis: Concepts and applications across multiple contexts T4-11 1 1 Jack Dowie , Mette Kjer Kaltoft Do clinical trials follow protocol? A review of the NIHR 1 2 LSHTM, London, United Kingdom, Odense University clinical trials Hospital Svendborg, Svendborg, Denmark Amanda Young1, Louise Dent1 ,2, James Raftery1 ,2, David Turner1, Ruairidh Milne2, Peter Davidson2, Andrew T4-06 Cook2 PriTecTools. Prioritisation software for continuous 1University of Southampton Wessex Institute, Southampton, assessment of health technologies United Kingdom, 2NETSCC, University of Southampton, Leonor Varela Lema, Alberto Ruano Raviña, Teresa Southampton, United Kingdom Queiro Verdes, Teresa Cerdá Mota Galician Health Technology Assessment Agency (avalia-t), T4-12 Santiago de Compostela, Galician Region, Spain Does the Model match the Market? Then make the Model match the Market! T4-07 Tobias Gantner, Timo Wasmuth, Katharina Schalk, The pitfalls of translating search strategies across a wide Florian Muschaweck range of bibliographic databases: A case study from Novartis Pharma, Nuremberg, Bavaria, Germany injury prevention/safety promotion 1 1 1 Sue Bayliss , Anne Fry-Smith , Ismail Yahaya , Khalid T4-13 2 3 Ashfaq , Rob Anderson Drawing up a protocol for conducting systematic reviews 1 West Midlands Health Technology Assessment on the effectiveness of tests for indicating the presence of 2 Collaboration, Birmingham, United Kingdom, National residues in hemodialysis Collaborating Centre for Women’s & Children’s Health, Taís Freire Galvão1, Elizete Araujo1, Victor Braule Pinto1, 3 London, United Kingdom, Peninsula Technology Assessment Angela Líbia de Melo Pereira Cardoso2, Ivoneide de Group (PenTAG), Exeter, United Kingdom Carvalho Lopes Barros3 1Amazonas Federal University / Getúlio Vargas University T4-08 Hospital, Manaus, Amazonas, Brazil, 2Amazonas Federal Extending the range of HTA products: A brief, rapid University / Pharmacist Sciences College, Manaus, and structured format for dissemination of HTA reports, Amazonas, Brazil, 3Amazonas Federal University / Cochrane and Campbell Reviews Chemistry College, Manaus, Amazonas, Brazil Ingvil Sæterdal, Elin Strømme Nilsen, Inger Natvig Norderhaug, Gro Jamtvedt T4-14 Norwegian Knowledge Centre for the Health Services, Oslo, Inadequate reporting of dose information in drug Norway trials: Impact on systematic review workload and policy implications Pawana Sharma, Jenni Hislop, Cynthia Fraser, Graham T4-09 Mowatt Transparent Interactive Decision Interrogator (TIDI): Health Services Research Unit, University of Aberdeen, An interface for facilitating transparent decision making Aberdeen, United Kingdom in HTA 12 Sylwia Bujkiewicz1, Monica Lai1, Nicola Cooper1, Keith Abrams1, Neil Hawkins2 ,4, Hayley Jones3, David Spiegelhalter3, Alex Sutton1 1University of Leicester, Leicester, United Kingdom, 2Oxford Outcomes, Oxford, United Kingdom, 3University of Cambridge, Cambridge, United Kingdom, 4University of York, York, United Kingdom POSTERS

116 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

T4-15 Study Group7 Do we need another systematic review if results from 1Serviço de Genética Médica, Hospital de Clínicas de high- Quality secondary literature already exist? - Porto Alegre, Porto Alegre, RS, Brazil, 2Departamento de IQWiG’s experience Genética, Universidade Federal do Rio Grande do Sul, Fueloep Scheibler1, Robert Grosselfi nger1, Lars Porto Alegre, RS, Brazil, 3Programa de Pós-Graduação em Hemkens1, Karl Horvath2, Inger Janssen1, Klaus Jeitler2, Ciências Médicas, Universidade Federal do Rio Grande Eva Matyas2, Milly Schroeer-Guenther1, Thomas do Sul, Porto Alegre, RS, Brazil, 4Serviço de Psiquiatria, Semlitsch2, Andrea Siebenhofer-Kroitzsch3 ,2, Stefan Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Lange1 Brazil, 5Universidade Federal do Rio de Janeiro, Rio de 1Institute for Quality and Effi ciency in Health Care, Cologne, Janeiro, RJ, Brazil, 6Universidade Federal Fluminense, Rio Germany, 2Department of Internal Medicine, EBM Review de Janeiro, RJ, Brazil, 7MPS Brazil Network, Porto Alegre, Center, Medical University of Graz, Styria, Austria, 3Institute RS, Brazil for General Practice, Goethe University, Frankfurt am Main, Germany T4-21 Equity and Health Technology Assessment: Reviewing T4-16 the literature Implementing a process for the rapid support of health Dimitra Panteli, Annette Zentner, Reinhard Busse decision making Technische Universität, Berlin, Germany Stefan Mathis Ludwig Boltzmann Institute Health Technology Assessment, T4-22 Vienna, Austria Piloting a newly developed quality assessment tool for case series studies T4-17 Bing Guo, Christa Harstall, Carmen Moga The use of an online clinical information system (GeneCIS) for trial management and data collection Institute of Health Economics, Edmonton, Alberta, Canada in a UK wide study: COmparison of iNfl iximab and ciclosporin in STeroid Resistant Ulcerative Colitis: A T4-23 Trial (CONSTRUCT) Supporting policy decisions about neonatal screening: Anne Seagrove1, Fasihul Alam2, Wai-Yee Cheung1, David Where do logic models, screening criteria and grading of Cohen2, Jayne Morgan1, Frances Rapport1, Stephen evidence fi t in? Roberts1, Daphne Russell1, Ian T Russell1, Linzi Thomas1, Ingeborg Blancquaert Kymberley Thorne1, John G Williams1 Institut National de Santé Publique du Québec, Direction 1Swansea University, Swansea, United Kingdom, 2University des systèmes de soins et services et maladies chroniques, of Glamorgan, Pontypridd, United Kingdom Unité programmes de dépistage et lutte au cancer, Montréal, Canada T4-18 T4-24 HTA and Health Services Planning Standards to support interoperability of information Stefan Mathis systems and ameliorate effi ciency of information Ludwig Boltzmann Institute Health Technology Assessment, exchange Vienna, Austria Patrice Chalon KCE, Brussels, Belgium 10 T4-19 Potential applications of text mining and machine T4-25 learning in Health Technology Assessment Graphical overview of clinical effectiveness data: A Joao Santiago Filho1, Carla Rodrigues2 usability evaluation of small multiple Sankey diagrams 1Military Engineering Institute, Rio de Janeiro, RJ, Brazil, for presenting information on the clinical effectiveness of 2National Agency for Supplementary Health, Rio de Janeiro, cochlear implants RJ, Brazil Will Stahl-Timmins1 ,2, Martin Pitt1 Objectives: This research aims to search studies where 1Exeter University, Exeter, United Kingdom, 2Peninsula Medical School, Exeter, United Kingdom 12 T4-20 Dealing with methodological challenges of constructing T4-26 a specifi c quality of life measure for rare diseases: The Needs assessment of graphical information display in HTA example of Mucopolysaccharidoses 1 ,2 1 1 ,2 4 Will Stahl-Timmins , Martin Pitt Ida Vanessa Schwartz , Neusa Sica Rocha , Heber Maia 1 2 6 5 3 3 Exeter University, Exeter, United Kingdom, Peninsula Filho , Marcia Ribeiro , Liciane Costa , Julia Protas , Medical School, Exeter, United Kingdom Fabricio Marchioi1, Brazilian Quality of Life on MPS POSTERS

117 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

T4-27 Incorporating life-cycle information into the decision- T5 - Other, non-clincial making process for replacement of medical technology Jair Villanueva Padilla2, Fabiola Martínez Licona1, T5-01 Joaquín Azpiroz-Leehan1, Miguel Cadena Méndez1 Clinical practice guideline on eating disorders 1 1 2 1Universidad Autonoma Metropolitana-Iztapalapa, Anna Kotzeva , Maria-Dolors Estrada , Vicente Turón , 1 Mexico, D.F., Mexico, 2Universidad Autonoma del Caribe, Dolors Benítez , Maria-Graciela Rodríguez on behalf of 1 Barranquilla, Colombia guideline development group 1Catalan Agency for Health Technology Assessment and T4-28 Research (CAHTA). Catalan Health Service. Catalan Decision analysis and the role of technology assessment Department of Health, Barcelona, Spain, 2Catalan in reimbursement decisions for new technology: The Department of Health, Barcelona, Spain example of lumbar disc arthroplasty David Wong, Katherine Wong T5-02 Denver Spine, Greenwood Village/ Colorado, United States Court decisions and pharmaceutical policy in Brazil: Odds for the patients and the State T4-29 Paulo D. Picon1 ,4, Rodrigo S. Gonzales1, Rafael V. Picon1 Benefi t of searching different databases to identify health ,4, Cláudio D. Terra3, Alex Gertner2, Jefferson Barbosa3, economic evaluations included in German HTA-reports Mariana Socal2, Janaína Gonçalves3, Adriana Petryna5, Siw Waffenschmidt, Elke Hausner, Lidia Engel, Fabian João G. Biehl2 Volz, Thomas Kaiser 1Universidade Federal do Rio Grande do Sul, Porto Alegre, Institute for Quality and Effi ciency in Health Care (IQWiG), Rio Grande do Sul, Brazil, 2Princeton University, Princeton, Cologne, Germany New Jersey, United States, 3Attorney General’s Offi ce of the State of Rio Grande do Sul, Porto Alegre, Rio Grande do T4-30 Sul, Brazil, 4Hospital de Clínicas de Porto Alegre, Porto Estimation of an early intervention ‘premium’ in Alegre, Rio Grande do Sul, Brazil, 5Pennsylvania State the treatment of chronic MSDs in the working age University, Pennsylvania, United States population: Some methodological considerations Stephen Bevan T5-03 The Work Foundation, London, United Kingdom The impact of plaintiff economic status on access to the legal system: Suing the state for medicines in Rio Grande T4-31 do Sul, Brazil. Does cost-effectiveness analysis discriminate against Paulo D. Picon1 ,4, Rodrigo S. Gonzales1, Rafael V. Picon1 patients with short life expectancy? Matters of logic and ,4, Cláudio D. Terra3, Alex Gertner2, Jefferson Barbosa3, matters of context Mariana Socal2, Paulo M. Jardim3, Adriana Petryna5, Mike Paulden1, Anthony Culyer1 João G. Biehl2 1University of Toronto, Toronto, ON, Canada, 2University of 1Universidade Federal do Rio Grande Do Sul, Porto Alegre, York, York, United Kingdom Rio Grande do Sul, Brazil, 2Princeton University, Princeton, New Jersey, United States, 3Attorney General’s Offi ce, Porto T4-32 Alegre, Rio Grande do Sul, Brazil, 4Hospital de Clínicas Language criteria used in systematic review could de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, negatively infl uence fi nal conclusions of technology 5Pennsylvania State University, Pennsylvania, United States evaluation Rafal Nizankowski1, Michal Seweryn2 T5-04 1Jagiellonian University Medical College Faculty of Evidence for the effectiveness of telerehabilitation Medicine, Cracov, Poland, 2Jagiellonian University Medical Risto Roine1, David Hailey2, Arto Ohinmaa2 College Faculty of Health Science Institute of Public Health, 1Helsinki & Uusimaa Hospital Group, Helsinki, Finland, 12 Cracov, Poland 2Institute of Health Economics, Edmonton, Alberta, Canada T4-33 T5-05 The “Mini-HTA” is a sustainable approach The diffusion and assessment of positron emission Silvia Asaro, Mario Fregonara Medici, Giusi Piccinno tomography in Japan A.O.U. Careggi, Firenze, Italy Akinori Hisashige Institute of Healthcare Technology Assessment, Tokushima, Japan POSTERS

118 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

T5-06 T5-12 Decision to make whether to use existing systematic Obstacles to organ donation - A health technology reviews or perform de novo systematic review: A case assessment perspective on the views of the personnel of of drug-eluting stents versus bare-metal stents for acute intensive care units myocardial infarction Eva Draborg1, Jane Linnet2, Annette Boe2, Karsten Haesun Suh1, Hyejin Hwang2, Sang-Moo Lee1, Dong- Bülow3, Mette Bruun Mortensen2 Hoon Choi2 1University of Southern Denmark, Institute of Public Health 1National Evidence-based Collaborating Agence, Seoul, - Health Economics, Odense, Denmark, 2University Hospital Korea, Republic of, 2Yonsei University College of Medicine, of Odense, Dept. of Neurosurgery, Odense, Denmark, Seoul, Korea, Republic of 3University Hospital of Odense, Dept. of Anaesthesiology and Intensive Care, Odense, Denmark T5-07 Introducing patient perspective in health technology T5-13 assessment: A systematic review Case management at hospitals - The perspective of the Marie-Pierre Gagnon1 ,2, Marie Desmartis2, Hugo patients Pollender2, Renald Lemieux3, François-Pierre Gauvin5, Eva Draborg1, Trine Kjaer1, Mickael Bech1, Mette France Légaré2 ,4 Mollerup2 1Laval University, Faculty of Nursing, Quebec, Quebec, 1University of Southern Denmark, Institute of Public Health Canada, 2CHUQ Research Centre, Quebec, Quebec, Canada, - Health Economics, Odense, Denmark, 2University Hospital 3Sherbrooke University Medical Centre, Sherbrooke, of Odense, Dept. of Research and HTA, Odense, Denmark Quebec, Canada, 4Laval University, Faculty of Medicine, Quebec, Quebec, Canada, 5National Collaborating Centre T5-14 for Healthy Public Policy, Quebec, Quebec, Canada Multidisciplinary interventions towards patients with back pain - A health technology assessment T5-08 Claus Løvschall1, Mirja Elisabeth Kløjgaard2, Tom The persuasive power of disease awareness media: Do Petersen3, Jan Hartvigsen4, Claus Rasmussen5, Merete they subvert restrictions on direct to consumer Bech6 advertising? 1Department of HTA, Institute of Public Health, Aarhus Stephanie Krawczyk1, Adam Elshaug1 ,2, Janet Hiller1 ,2 University, Aarhus, Denmark, 2Monitoring & Health 1Discipline of Public Health, School of Population Health Technology Assesment, DACEHTA, Copenhagen, Denmark, and Clinical Practice, The University of Adelaide, Adelaide, 3Back Center Copenhagen, Copenhagen, Denmark, 4Institute SA, Australia, 2Hanson Institute, Institute for Medical and of Sports Science and Clinical Biomechanics, University of Veterinary Science (IMVS), Adelaide, SA, Australia Southern Denmark, Odense, Denmark, 5Dept. Rheumatology, Regional Hospital Vendsyssel, Hjørring, Denmark, 6The T5-09 Projectdepartment for The New University Hospital in Direct-to-consumer advertising of healthcare products: Aarhus, Central Denmark Region, Denmark Evidence of increasing impact on population patterns of health technology use T5-15 1 1 ,2 1 ,2 Thomas Vreugdenburg , Adam Elshaug , Janet Hiller Measuring patient satisfaction with telemedicine 1Adelaide Health Technology Assessment, Discipline of Duncan Jackson, Sally Mcclean Public Health, The University of Adelaide, Adelaide, SA, Australia, 2Hanson Institute, Institute of Medical and University Of Ulster, Northern Ireland, United Kingdom Veterinary Science (IMVS), Adelaide, SA, Australia 10 T5-16 T5-10 Waiting times for patients undergoing surgery for carotid Association of preoperative knee mobility and strength stenosis in Denmark with postoperative self-report physical function in total Claus Løvschall1, Lars Ehlers1 knee replacement 1Department of HTA, Institute of Public Health, Aarhus Yong-Hao Pua, Celia Tan, Hwei-Chi Chong, William Yeo, University, Aarhus, Denmark, 2Health Economics and Ngai-Nung Lo Management, Aalborg University, Aalborg, Denmark Singapore General Hospital, Singapore, Singapore T5-17 12 T5-11 The management of patient and consumer involvement Electronic patient record (EPR) evaluation during the in medical device development and HTA: A case study shakedown phase: Method development and assessment Jennifer Martin1, Julie Barnett1 of immediate system success 1 1 1 1 MATCH, University of Nottingham, Nottingham, United Flemming Witt , Lotte Groth Jensen , Tine Andresen , 2 Mette Kjølby1, Claus Bossen2 Kingdom, MATCH, Brunel University, Uxbridge, United 1Department of HTA, Institute of Public Health, Aarhus Kingdom University, Aarhus, Denmark, 2Department of Information and Media Studies, Aarhus University, Aarhus, Denmark POSTERS

119 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

T5-18 3Spanish Agency for HTA (AETS), Madrid, Spain, 4Galician Sexual harassment of nurses at the workplace in Japan Agency for HTA (Avalia-t), Santiago de Compostela, Spain Akinori Hisashige Institute of Healthcare Technology Assessment, Tokushima, T5-25 Japan Communicating risk and benefi t in evidence based medicine: Healthcare professionals perception T5-19 Namrata Dhillon, Louise Dent, Vaughan Thomas Primary trauma course (PTC); A cost effective course University Of Southampton, Southampton, United Kingdom to train emergency doctors in the hospitals with limited resources. T5-26 Tanwir Khaliq, Rizwan Hameed, Imran Sikandar Pakistan Institute of Medical Sciences, Islamabad, Pakistan Thematic analysis of strengths and weaknesses of manufacturers’ submissions to the NICE STA process 1 1 T5-20 Christopher Carroll , Eva Kaltenthaler , Patrick 1 2 2 Light source facility: An emerging new health technology FitzGerald , Angela Boland , Rumona Dickinson Montse Moharra, Cari Almazán 1University of Sheffi eld, Sheffi eld, United Kingdom, Catalan Agency for Health Technology Assessment and 2Liverpool University, Liverpool, United Kingdom Research, Barcelona, Spain T5-27 T5-21 Using routinely collected data to identify the clinicians Identifying peer reviewers from online information most likely to infl uence colleagues to use health retrieval systems: Sharing methodological evidence innovations Donna Chatting, Louise Dent, Dani Preedy, Ian Cree NIHR Evaluation, Trials and Studies Coordinating Centre Andrew Hoy (NETSCC), University of Southampton, Southampton, National Institute for Health and Clinical Excellence, United Kingdom London, United Kingdom

T5-22 T5-28 The infl uence of publication on translational medicine Pilot project on mini-HTA to support evidence-based research decisions for new health technologies in hospitals Lisa Douet, Danielle Preedy, Vaughan Thomas, Ian Cree NETSCC, Southampton, United Kingdom Helene Arentz-Hansen, Sari Susanna Ormstad, Bjørn Anton Graff, Inger Natvig Norderhaug T5-23 Norwegian Knowledge Centre for the Health Services, Oslo, Post-introduction assessment of health technologies: Norway The analysis of an experience from health professionals’ perspective T5-29 Nora Ibargoyen-Roteta1, Jose Luis Cabriada-Nuño2, Survey of existing mini-HTA systems internationally 3 4 Juan Clofent-Vilaplana , Eugeni Doménech-Morral , Sari Susanna Ormstad, Bjørn Anton Graff, Inger Natvig Daniel Ginard-Vicens5, Iñaki Gutierrez-Ibarluzea1, Norderhaug Vicent Hernandez-Ramirez6, Gloria Oliva-Oliva7, Teresa Queiro-Verdes8 Norwegian Knowledge Centre for the Health Services, Oslo, 1Basque Offi ce for HTA (Osteba), Vitoria-Gasteiz, Norway Spain, 2Department of Gastroenterology, Galdakao- Usansolo Hospital, Galdakao, Spain, 3Department of T5-30 Gastroenterology, La Fe University Hospital, Valencia, Which resources of information are used in HTA 4 Spain, Department of Gastroenterology, Germans Trias i reports? Pujol University Hospital, Badalona, Spain, 5Department of Lorea Galnares-Cordero, Iñaki Gutierrez-Ibarluzea Gastroenterology, Son Dureta Hospital, Palma de Mallorca, Spain, 6Department of Gastroenterology, Meixoeiro Hospital, OSTEBA. Basque Offi ce for Health Technology Assessment, Vigo, Spain, 7Catalan Agency for HTA (AATRM), Barcelona, Vitoria-Gasteiz/Basque Country, Spain Spain, 8Galician Agency for HTA (Avalia-t), Santiago de 12 Compostela, Spain T5-31 What determines the cost of clinical trials? T5-24 Lisa Douet, David Turner, James Raftery The identifi cation process of new and emerging health NETSCC, Southampton, United Kingdom technologies: The case of Spain Nora Ibargoyen-Roteta1, Gaizka Benguria-Arrate1, Iñaki Gutiérrez-Ibarluzea1, Aurora Llanos-Méndez2, Mª Mar Polo-de Santos3, Leonor Varela-Lema4 1Basque Offi ce for HTA (Osteba), Vitoria-Gasteiz, Spain, 2Andalusian Agency for HTA (AETSA), Sevilla, Spain, POSTERS

120 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

T5-32 T5-38 Treatments and actions for osteoporotic vertebral Which factors determine the number of visits to Primary fractures (OVF) according to primary care physicians. Care in Madrid? Paloma Conde Espejo, Matilde Palma Ruiz, Zuleika Saz Rocío Carmona Alférez, María Auxiliadora Martín Martínez, Pilar Gallego Berciano, Patricia Cediel García, Parkinson Antonio Sarría Santamera Instituto de Salud Carlos III (ISCIII) Agencia de Evaluacion Instituto De Salud Carlos III, Madrid, Spain de Tecnologias Sanitarias (AETS), Madrid, Spain T5-39 T5-33 Protocols of quality of life and its relations with human Laparoscopic surgery in colorectal cancer: Quality of communication in rural workers underwent total life, psychological effect and patient satisfaction laryngectomy Daniele Andrade Da Cunha1 ,2 María Soriano, Nerea Fernández de Larrea, Andrés , Hilton Justino Da Silva1, Cleide Fernandes Teixeira1, Adriana Di Donato Haussman, Mercedes Guerra, Juan Antonio Blasco Chaves1, Patricia Mendes Balata1, Leandro De Araújo Health Technology Assessment Unit (UETS), Madrid, Spain Pernambuco1 1Universidade Federal De Pernambuco, Recife/Pernambuco, T5-34 Brazil, 2Faculdade INTEGRADA Do Recife, Recife/ Infl uence of environmental factors on frequent Pernambuco, Brazil attendance according to primary care physicians. 1 2 2 ,1 T5-40 Maria Sandin , Paloma Conde , Antonio Sarria Adding qualitative understanding to quantitative 1Universidad de Alcalá de Henares, Alcalá de Henares, measurements - Patient perspectives on effects of a new Madrid, Spain, 2Instituto de Salud Carlos III (ISCIII) social-Psychiatric treatment modality in Denmark Agencia de Evaluacion de Tecnologias Sanitarias (AETS), Ulla Vaeggemose1 ,2, Lotte Groth Jensen1, Ida Madrid, Spain Christensen1, Merete Bech4, Lars Ehlers3, Joergen Aagaard5, Mette Kjoelby1 ,2 1Department of HTA, Institute of Public Health, Aarhus T5-35 University, Aarhus, Denmark, 2HTA & Health Services Patient Decision Aids (PDA) Tool for Prostate Cancer Research, Centre for Public Health, Central Denmark Raquel Luengo1, Fátima Izquierdo1, María Soriano1, Region, Denmark, 3Health Economics and Management, Javier Gracia1, Juan Antonio Blasco1, Lilisbeth Perestelo2 Aalborg University, Aalborg, Denmark, 4Projectdepartment, 1Health Technology Assessment Unit (UETS), Madrid, Spain, New University Hospital in Aarhus, Aarhus, Denmark, 2Servicio de Evaluación del Servicio Canario de la Salud 5Centre for Psychiatric Research, Århus University Hospital, (SESCS) y la Fundación Canaria de Investigación y Salud Risskov, Denmark (FUNCIS), Canarias, Spain T5-41 T5-36 Assessment of methods to increase compliance of Approaches to care in chronic kidney disease: Screening Programmes for breast, cervical and colorectal Understanding the intervention cancer, a Health Technology Assessment Report. Pawana Sharma1, Corri Black1, Graham Scotland1, Keith Preliminary results McCullough2, Lynn Robertson1, Nick Fluck2, Alison Beatriz Jiménez, Paolo Giorgi Rossi, Piero Borgia, Macleod1, Paul McNamee1, Gordon Prescott1, W Cairns Gabriella Guasticchi 1 Smith Laziosanità - Agency for Public Health, Rome, Italy 1University of Aberdeen, Aberdeen, United Kingdom, 10 2Aberdeen Royal Infi rmary Renal Unit, NHS Grampian, Aberdeen, United Kingdom T5-42 A method to identify players that could facilitate HTA institutionalization in European countries T5-37 Raimundo Alcázar-Alcázar1, Iñaki Imaz1, Montserrat Predictive factors of hospital readmissions in elderly Moharra2, Antonio Sarría-Santamera1 patients: A systematic review 1AETS, Instituto de Salud Carlos III, Madrid, Spain, 1 1 Lidia García-Pérez , Renata Linertová , Antonio 2CAHTAR, Barcelona, Spain Lorenzo-Riera2, José-Ramón Vázquez-Díaz3, Beatriz 1 12 Duque-González T5-43 1Fundación Canaria de Investigación y Salud, Santa Cruz de Policy innovation in Chronic Conditions Management: Tenerife, Canarias, Spain, 2Gerencia de Atención Primaria Collecting a baseline dataset de Gran Canaria, Santa Cruz de Tenerife, Canarias, Spain, Alison Porter1, Angela Evans1, Dianna McDonald2, Steve 3Hospital Universitario de Canarias, La Laguna, Canarias, Sizmur2, Helen Snooks1, Claire Williams1 Spain 1Swansea University, Swansea, United Kingdom, 2Picker Institute Europe, Oxford, United Kingdom

POSTERS

121 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA

T5-44 T5-50 Evaluating the quality of life of women with breast Impact of functional dyspepsia on work productivity cancer before chemotherapy treatment Guilherme Sander1 ,2, Luiz Edmundo Mazzoleni1 ,2, 1 1 Thais de Oliveira Gozzo , Cristiane Regina Soares , Helio 1 ,2 1 2 1 Carlos Francesconi , Andre Wortmann Humberto Angotti Carrara , Ana Maria Almeida 1 1University of São Paulo at Ribeirão Preto College of Universidade Federal do Rio Grande do Sul, Porto Alegre, 2 Nursing, Ribeirão Preto, São Paulo, Brazil, 2University of Rio Grande do Sul, Brazil, Hospital de Clínicas de Porto São Paulo at Ribeirão Preto Medical Scholl, Ribeirão Preto, Alegre, Porto Alegre, Rio Grande do Sul, Brazil São Paulo, Brazil T5-51 T5-45 The impact of sentinel hospital project (SHP) on the Can older people who fall be identifi ed in the ambulance hospital risks management (HRM) for improving call centre to enable alternative responses or care healthcare quality and safety pathways? Juang Jyh, Loraine Diamente Antonio Sánchez1, Wai Yee Cheung1, Stella May Gwini3, Hospital Municipal “Dr. Carmino Caricchio” - Tatuapé, São Ioan Humphreys1, Robin Lawrenson4, Helen Snooks1, A Paulo/SP, Brazil Niroshan Siriwardena2 1 2 Swansea University, Swansea, United Kingdom, Lincoln T5-52 3 University, Lincoln, United Kingdom, East Midlands What do they think about us? A thousand of respondents Ambulance Service NHS Trust, Nottingham, United 4 give their opinion on Spanish HTA agencies Kingdom, Scottish Ambulance Service, Edinburgh, United Antoni Parada1, Iñaki Gutiérrez-Ibarluzea2, Mercedes Kingdom Guerra3, Beatriz Duque4, Lorea Galnares2, Rocio Rodriguez5, Maria Sobrido6, Marta Millaret1, Montserrat T5-46 Salas7, Raimundo Alcazar8 Child’s health care in Latin America: Do policy makers 1AATRM, Catalonian Agency for HTA, Barcelona/Catalonia, really know what they need to do? Spain, 2Osteba, Basque Offi ce for HTA, Vitoria-Gasteiz/ Marcia Galvao, Marilene Santos, Antonio Cunha Basque Country, Spain, 3UETS. Lain Entralgo, Madrid, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Spain, 4Canary Island Health Service, Canarias, Spain, Brazil 5AETSA, andalusian agency for HTA, Sevilla/Andalusia, Spain, 6Avalia-T, galician Agency for HTA, Santiago/Galicia, T5-47 Spain, 7ICS, Aragon, Zaragoza/Aragon, Spain, 8AETS-ISCIII, Effect of exercise on health-related quality of life in Madrid, Spain breast cancer patients - A randomized controlled trial Eija Roine1, Tiina Saarto1, Harri Sintonen2 ,3, Carl T5-53 Blomqvist1 Judicialization of access to high cost medicines in southern Brazil 1Helsinki University Central Hospital, Department of Cláudio D. Terra1, Paulo D. Picon2 ,3, Jefferson Borbosa1, Oncology, Helsinki, Finland, 2Univerisity of Helsinki, Rafael V. Picon2 ,3, Rodrigo S. Gonzales2, Cristina Department of Public Health, Helsinki, Finland, 3Finnish Machado1, Alex Gertner4, Adriana Petryna5, Offi ce for Health Technology Assessment, Helsinki, Finland João G. Biehl4 1Attorney General’s Offi ce of Rio Grande do Sul, Porto T5-48 Alegre, Rio Grande do Sul, Brazil, 2Universidade Federal Hospital Based Health Technology Assessment (HB-HTA) do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, of an invasive electroencephalography (EEG) monitoring 3 system in a paediatric epilepsy surgery center Brazil, Hospital de Clínicas de Porto Alegre, Porto Alegre, 4 Simona Bufalari1, Carlo Capussotto1, Federico Nocchi1 ,2, Rio Grande do Sul, Brazil, Princeton University, Princeton, 5 Tiziana Franchin1, Pietro Derrico1 New Jersey, United States, Pennsylvania State University, 1Bambino Gesù Children’s Hospital, Rome, Italy, 2University Pennsylvania, United States of Roma Tre, Rome, Italy T5-54 12 T5-49 Technical and productive effi ciency indicators of the Effects of a weight loss program with or without a cervical cancer screening programme in Rio de Janeiro maintenance program on health-related quality of life in State, Brazil Maria Deolinda B Cabral1 ,2, Rosimary T Almeida1, severely obese patients - A randomized controlled trial. 3 4 1 2 2 Tereza M P Feitosa , Risoleide M Figueiredo Tuula Pekkarinen , Pirjo Räsänen , Risto Roine 1 1 Universidade Federal do Rio de Janeiro, Rio de Janeiro/RJ, Helsinki and Uusimaa Hospital district, Vantaa, Finland, 2 2 Brazil, Instituto Brasileiro de Geografi a e Estaistica, Rio National Institute of health and Welfare, Helsinki, Finland, 3 3 de Janeiro/RJ, Brazil, Intituto Nacional do Câncer - INCA, Helsinki and Uusimaa Hospital District, Helsinki, Finland Rio de Janeiro/RJ, Brazil, 4Secretaria de Estado de Saúde e Defesa Civil do Rio de Janeiro, Rio de Janeiro/RJ, Brazil POSTERS

122 Maximising the Value of HTA HTAi 7th ANNUAL MEETING DUBLIN 2010

T5-55 T5-57 Self-medication among children and adolescents, an A comparison of United States and United Kingdom increasingly important public health concern EQ-5D health states valuations using a nonparametric Grace Pfaffenbach1, Juan Diaz1, Francis Solange Vieira Bayesian method Tourinho3, Fabio Bucaretchi2 Samer Kharroubi1, Tony O’Hagan2, John Brazier2 1University of Campinas, Hospital de Clinicas, NATS, 1University of York, York, United Kingdom, 2University of Campinas, São Paulo, Brazil, 2University of Campinas, Sheffi eld, Sheffi eld, United Kingdom Faculty of Medical Sciences, Department of Pediatrics, Campinas, São Paulo, Brazil, 3Federal University of Rio T5-58 Grande do Norte, Nursing School, Natal, Rio Grande do From evidence to practice: Changing the approach to Norte, Brazil self-management of diabetes Barb Shea, Denis Belanger T5-56 Canadian Agency for Drugs and Technologies in Health Compliance measurement-guided medication (CADTH), Ottawa, ON, Canada management programs in hypertension Sergey Golubev Vitebsk Regional Clinical Hospital, Vitebsk, Belarus

Protecting public health through the regulation of healthcare products 10

12

The Irish Medicines Board’s role is to protect and enhance public and animal health through the regulation of medicines, medical devices and healthcare products.

www.imb.ie POSTERS

123 HTAI 7TH ANNUAL MEETING DUBLIN 2010 13 Maximising the Value of HTA Acknowledgements

The HTAi 2010 Local Organising Committee would like to sincerely thank the following for their sponsorship and support of the conference.

MAIN SPONSOR AND HOST ACKNOWLEDGEMENTS

PLATINUM SPONSOR DIAMOND SPONSOR

GOLD SPONSORS

SATELLITE SYMPOSIA SPONSORS

SPONSORS

Travel Grant Sponsor We would like to thank MSD for their contribution to enable delegates from low- and middle-income countries attend the conference.

124 14 EXHIBITION Floorplan: Industries Hall - Exhibition Booths 1-14

SERVICE COUNTER

SERVICE COUNTER SERVICE COUNTER OFFICE AREA HOSPITALITY OPTIONS CATERING INTERNET CAFE INTERNET CAFE EE 150 151 148 149 152 147 153 145146 154 D4 DINER EXHIBITION MAPS AND EXHIBITOR INFORMATION AND EXHIBITOR EXHIBITION MAPS 3 6 6 55 54 127 8/7 56 125 126 3 5 16 17 18 ER 88 89 90 T SHUT 22 21 20 19 94 93 92 91 87 2 23 49 50 51 52 53 24 132 131 130 129 128 121 122 123 124 96 95 85 86 EE 3 9 61 60 59 58 57 120 22 11 12 13 14 15 154 POSTER PANELS 10 82 83 84 27 26 25 99 98 97 28 65 64 63 62 44 45 46 47 48 80 81 137 136 135 134 133 66 115 116 117 118 119 79 138 102 101 100 3 2 INSPIRE RESTAURANT 3 1 POSTER PANELS TO BE RE-NUMBERED 1- 168 WHEN PLAN IS FINALISED 6789 114 103 3 2 12 32 31 30 29 77 78 104 113 33 76 112 2 70 69 68 67 39 40 41 42 43 75 142 141 140 139 111 TO A/B 71 74 38 EE 110 DODDER 12345 36 35 34 37 72 73 108107 106 105 109 144 143 3

13 OIEBOARD NOTICE 2 14

3 SERVICE OFFICE TUBE TO STORE POSTER HALL TO PRESS SERPENTINE LANSDOWNE DODDER B / C / D 1 2 3 4 5 6 7

REGISTRATION SPEAK READY ROOM

BAGS

A EL TE EG

D 5 .5

R T U E N

CO UP

.5 OM OAKR C O L

2

O LS STO HIGH DOCK Counter

2.5 COFFEE SHELVES 3 STORE STORE EE ORG. TOILET DISABLED OFFICE GENTS TOILET TOILET STORE LADIES UP EE EE ENTRANCE

125 HTAi 7th ANNUAL MEETING DUBLIN 2010 141 Maximising the Value of HTA

Floorplan: Serpentine Hall - Exhibition Booths 15-28 ENTRANCE

FOYER FOYER

CLYDE ROOM 1 FROM INDUSTRIES HALL EE

SERPENTINE HALL CLYDE ROOM 2 13 POSTERS 15 18 19 20 1 EE EE 16 17 22 21 POSTERS LOUNGE AREA EXHIBITION MAPS AND EXHIBITOR INFORMATION AND EXHIBITOR EXHIBITION MAPS 7O no POSTER PANELS POSTERS

TO 28 27 26 25 24 23 CONCERT POSTERS HALL

STAGE

CONFERENCE AREA EE

350 Seats

CONCERT HALL

RETRACTED SEATING

EE

CLOAK ROOM

126 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA 141 HTAi 2010 EXHIBITOR PROFILES

ABACUS INTERNATIONAL CAMBRIDGE UNIVERSITY PRESS – Booth 13, Industries Hall – Booth 17, Serpentine Hall Abacus International specialises in health outcomes: Please stop by to browse our world-renowned journals, economic modelling, HTA, medical writing and market including the International Journal of Technology access services. Our client base includes the global and Assessment in Health Care, offi cial journal of HTAi. local affi liates of many of the leading pharmaceutical Visit Cambridge Journals Online at http://journals. and device companies. Abacus International’s key cambridge.org/thc to view sample content, sign up for deliverables include: tables of content alerts, and more. • Health economic models • HTA submissions • Systematic reviews • Value dossiers • Market access models www.abacusint.com COMPLETE MARKET ACCESS

– Booth 16, Serpentine Hall INFORMATION AND EXHIBITOR EXHIBITION MAPS We specialise in evidence based value demonstration and communication to support successful market access ADIS initiatives, built on a platform of quality, fl exibility and – Booth 21, Serpentine Hall robust scientifi c methodology. In the last 10 years, we have conducted over 30 systematic reviews, and helped Adis, a Wolters Kluwer company. Adis journals provide deliver over 60 HTA submissions to NICE, SMC and independent, peer-reviewed coverage of all aspects of AWMSG. drugs and drug development. These highly regarded and www.complete-ma.com frequently cited publications provide comprehensive and current information on all aspects of drug development, clinical pharmacology, safety, pharmacoeconomics, patient outcomes and health policy. www.adisinsight.com HTAi – Booth 27, Serpentine Hall Health Technology Assessment International (HTAi) is the international society dedicated to promoting the use BARRINGTON JAMES and development of HTA. HTAi is a global forum for – Booth 28, Serpentine Hall the exchange of information, methods, and expertise for all those who produce and use HTA, including agencies, Barrington James is a specialist pharmaceutical industry, governments, health care providers, and recruitment consultancy with trained professional academic institutions. consultants actively engaged within the recruitment of www.htai.org niche functions. Our experienced team of recruiters for Market Access, HTA and HEOR positions has one of the largest networks of candidates worldwide with more than six years experience within this area. For more information about how Barrington James can secure the best talent for your organisation, please contact David Nolan, Senior Consultant, on +44 (0) 1293 77 66 44 or visit exhibition booth 28 at HTAi 2010. www.barringtonjames.com

127 HTAi 7th ANNUAL MEETING DUBLIN 2010 141 Maximising the Value of HTA

HTAi 2011 JANSSEN-CILAG LIMITED – Booth 26, Serpentine Hall – Booth 9, Industries Hall HTAi 2011: HTA FOR HEALTH SYSTEM Janssen-Cilag Limited is part of the Johnson and Johnson SUSTAINABILITY network of pharmaceutical companies. At Janssen- Rio de Janeiro, June 25-29, 2011 Cilag, we maintain the belief that our fi rst responsibility is to the doctors, nurses and patients, to mothers and Health systems face increasing challenges to fathers and all others who use our products and services. sustainability: growing or ageing populations, changing Even with the rapidly changing health-care systems public expectations, and the need to manage the cost worldwide, this mission will remain our focus. This of new technologies. As a tool for evidence-based, ambition continues to drive our company. We strive to accountable decision-making, HTA has the potential to constantly maintain the same high level of commitment play a crucial role in health system sustainability. to Research and Development in our company to uncover What is the role of HTA in sustainability? Does HTA the ways in which diseases can impinge upon our bodies respond to decision-makers’ needs? How can HTA and to fi nd the means by which these effects can be

EXHIBITION MAPS AND EXHIBITOR INFORMATION AND EXHIBITOR EXHIBITION MAPS evolve to support more sustainable health systems? countered. Our strength lies in what we value: customers, innovation, integrity, people and performance. Our mission is to put patients at the heart of everything we do, and this is achieved through customer focus, personal and organizational leadership and process excellence. IMS www.janssen-cilag.ie – Booth 12, Industries Hall The IMS team of 300 specialists drive continued excellence in HEOR, pricing and market access with unparalleled research and consulting expertise globally and locally. Leveraging robust analytics, rigorous methodologies and an extensive network of THE NATIONAL INSTITUTE FOR decision-maker contacts, they ensure marketrelevant, HEALTH AND CLINICAL EXCELLENCE commercially-focused strategy and evidence (NICE) – Booth 19, Serpentine Hall development – supported by best patient data assets. www.imshealth.com The National Institute for Health and Clinical Excellence (NICE) is the independent organisation responsible for providing national guidance on the promotion of good health and the prevention and treatment of ill health. NICE produces guidance in three areas of health; public health, health technologies and clinical practice. A key INAHTA part of the Institute’s work is deciding how the NHS – Booth 24, Serpentine Hall should best use certain new drugs and other health INAHTA was established in 1993 and has now grown technologies. NICE has to assess not only how well to 50 member agencies from 24 countries. The Network drugs and devices work, but whether paying for them is a stretches from North and Latin America to Europe, Asia, good use of NHS resources. and Australasia. INAHTA´s mission is to provide a forum www.nice.org.uk for the identifi cation and pursuit of interests common to HTA agencies. The network aims to: • Accelerate exchange and collaboration among agencies • Promote information sharing and comparison • Prevent unnecessary duplication of activities. www.inahta.org

128 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA 141

NETSCC valuable data? – Booths 7 & 8, Industries Hall • Have the systems to compile and analyse the replies? • And fi nally build further measures to deal with some NETSCC is funded by the National Institute for Health of the issues that arise? Research (NIHR) and was established at the University of Southampton in 2008. It was set up to take on some of the emerging challenges of the Cooksey Report (A If the answer is no to any of the questions then come and review of Health Research Funding, 2006) by managing talk to us at Stand 18 in the Serpentine Hall the NIHR Evaluation, Trials and Studies (NETS) Contact Information: research programmes. Patients Direct www.netscc.ac.uk 3 Todd Campus West of Scotland Science Park Glasgow, G20 0XA UK

Phone no / Email address: OXFORD OUTCOMES +44 141 946 7888 / [email protected] INFORMATION AND EXHIBITOR EXHIBITION MAPS – Booth 22, Serpentine Hall Primary contact name: Dr Neil Pumford, CEO Oxford Outcomes is a leading international health Phone no / email address: outcomes consultancy with offi ces in North America +44 141 946 7888/ [email protected] and the UK. Our specialist services; translation and linguistic validation, medical translation, patient reported www.patientsdirect.org outcomes, ePRO development and validation, health economics, and epidemiology come together to support all stages of the drug development lifecycle. www.oxfordoutcomes.com

PFIZER HEALTHCARE IRELAND – Booth 1, Industries Hall Pfi zer Healthcare Ireland: Pfi zer is Ireland’s largest PATIENTS DIRECT biopharmaceutical company and a leading employer with over 5,000 colleagues at locations across the country. – Booth 18, Serpentine Hall With a rich heritage of innovation and expansion over Patients Direct are specialists in recruiting patients. Our a forty year period in Ireland, our capital investment web based systems collect information directly and these exceeds $7billion. We are committed to applying patient reported outcomes can be used appropriately for: science and our global resources to improve health and well-being at every stage of life. Through working in 1. Strategic planning e.g. disease modelling partnership our goal is to ensure that people everywhere 2. Regulatory e.g. in risk management plans have access to innovative treatments and quality health 3. Pharmaco-economics e.g. in HTA’s care. 4. Marketing e.g. product and competitor analysis www.pfi zer.ie 5. Pharmaco-vigilance e.g. post marketing surveillance

Are you able to target your patient audience? • Engage with them? • Already have the means to capture their responses? • Know the questions to ask to gain credible and

129 HTAi 7th ANNUAL MEETING DUBLIN 2010 141 Maximising the Value of HTA

PTOOLS ROCHE – Booth 2, Industries Hall – Booth 20, Serpentine Hall pTools is a leading developer of enterprise-level Content Headquartered in Basel, Switzerland, Roche is a leader Management Software for Healthcare Organisations. in research-focused healthcare with combined strengths pTools Healthcare Solutions equip organisations with in pharmaceuticals and diagnostics. Roche is the world’s enterprise web content management solutions and largest biotech company with truly differentiated applications for intranet, extranet, Internet initiatives. medicines in oncology, virology, infl ammation, pTools emphasise continuous and effi cient content metabolism and CNS. Roche is also the world leader in services and online processes and provide seamless in-vitro diagnostics, tissue-based cancer diagnostics and collaboration between departments, service providers, a pioneer in diabetes management. Roche’s personalised service users and stakeholders for effi cient delivery of healthcare strategy aims at providing medicines and single point of service. pTools Healthcare Solutions diagnostic tools that enable tangible improvements in ensure compliance, accessibility, multi-language and the health, quality of life and survival of patients. In security standards required of Healthcare Organisations 2008, Roche had over 80,000 employees worldwide

EXHIBITION MAPS AND EXHIBITOR INFORMATION AND EXHIBITOR EXHIBITION MAPS and provide managed and secure access to emerging and invested almost 9 billion Swiss francs in R&D. technologies. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of Customers include; HSE, Mental Health Commission, the Roche Group. Roche has a majority stake in Chugai Irish Blood Transfusion Service, Galway University Pharmaceutical, Japan. For more information: Hospital, Cork University Hospital, HSE Ethics, NIRE, www.roche.com Our Ladies Children’s Hospital Crumlin, AMNCH, Health & Safety Authority, Injuries Board and others in Public & Private Health Sectors. www.ptools.com

SANOFI AVENTIS – Booth 6, Industries Hall Sanofi -aventis, one of the world’s leading global pharmaceutical companies, discovers, develops and THE SCOTTISH MEDICINES distributes therapeutic solutions to improve the lives of CONSORTIUM (SMC) everyone. Sanofi -aventis provides patients and healthcare professionals in Ireland with effi cient and effective – Booth 5, Industries Hall therapeutic responses to diseases in the following The Scottish Medicines Consortium (SMC), formed in areas: thrombotic and cardiovascular diseases, diabetes, 2002, undertakes rapid health technology assessment central nervous system disorders, internal medicine and of all new medicines launched in the United Kingdom. oncology. Following critical appraisal of a submission from www.nice.org.uk the manufacturer of the medicine, SMC assesses its comparative clinical effectiveness and cost-effectiveness and advises the National Health Service in Scotland on whether the medicine should (or should not) be used in the National Health Service in Scotland. The assessment process takes 18 weeks, with most assessments completed within 6 months of launch. SMC advice is often the fi rst published HTA of a new medicine in the world. www.scottishmedicines.org.uk

130 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA 141

SBU – Booth 23, Serpentine Hall SBU (Swedish Council on HTA) is the oldest, still existing, HTA agency in the world. SBU reports help healthcare providers identify methods that offer the greatest patient benefi t. Our publications may be downloaded and ordered at www.sbu.se, where you can also learn more about SBU’s activities. www.sbu.se/en/ EXHIBITION MAPS AND EXHIBITOR INFORMATION AND EXHIBITOR EXHIBITION MAPS THE SCHOOL OF HEALTH AND RELATED RESEARCH (SCHARR) – Booth 15, Serpentine Hall The School of Health and Related Research (ScHARR) is situated within the University of Sheffi eld. ScHARR has a large, diverse, and internationally recognised programme of Health Services Research and Technology Assessment. We employ 210 multidisciplinary staff attract in excess of £6 million per year in external research funding. www.sheffi eld.ac.uk/scharr/

UNITED BIOSOURCE – Booth 25, Serpentine Hall United BioSource Corporation (UBC) is a global biopharmaceutical and medical device services organization that combines deep scientifi c knowledge with broad execution expertise across the product lifecycle. Our focus is strategizing to identify, analyze and present real-world evidence to support the development and commercialization of medical products for emerging and established life science companies. www.unitedbiosource.com

131 HTAi 7th ANNUAL MEETING DUBLIN 2010 151 Maximising the Value of HTA

HTAi POLICY FORUM MEMBERS WELCOME MESSAGES HTAi POLICY FORUM MEMBERS POLICY HTAi

132 HTAi 7th ANNUAL MEETING DUBLIN 2010 Maximising the Value of HTA 161 HTAi 2009-2010 MEMBERSHIP DIRECTORY For Profi t Organisations 01. Abbott Vascular International BVBA 02. Bayer Healthcare/Bayer Pharma Schering 03. Eli Lilly and Company 04. F. Hoffmann-La Roche AG 05. GlaxoSmithKline, Belgium & USA 06. Johnson & Johnson Medical Products 07. Medtronic 08. Merck & Co

09. Merck Serono International SA WELCOME MESSAGES 10. Novartis Pharma AG 11. Pfi zer Limited 12. Stryker Italia s.r.l.

Not For Profi t Organisations 01. Agency for Healthcare Research & Quality (AHRQ) 02. Agency for Quality & Accreditation in Health

03. Andalusian Agency for Health Technology Assessment (AETSA) DIRECTORY 2009-2010 MEMBERSHIP HTAi 04. Australian Government, Department of Health & Ageing (MSAC) 05. Australian Government, Department of Health & Ageing (PBAC) 06. Canadian Agency for Drugs and Technologies in Health (CADTH) 07. Catalan Agency for Health Technology Assessment (CAHTA) 08. Center for Medicare & Medicaid Services 09. Danish Centre for Health Technology Assessment (DACEHTA) 10. Department of Health, Basque Government 11. DIMDI - German Institute of Medical Documentation & Information 12. Dutch health care system (CVZ) 13. Federal Offi ce of Public Health (FOPH) 14. French National Authority for Health (HAS) 15. Healthcare Technology Evaluation Agency (AETS) 16. Hospital Authority 17. Institute for Clinical & Economic Review 18. Institute for Quality and Effi ciency in Health Care (IQWiG) 19. Institute of Health Economics (IHE) 20. Kaiser Permanente 21. Medical Technology Association of Australia (MTAA) 22. Medicines and Healthcare products Regulatory Agency (MHRA) 23. Ministry of Health, Singapore 24. National Agency for Regional Health Services 25. National Healthcare Group 26. National Institute for Health & Welfare, Finohta 27. National Institute for Health and Clinical Excellence (NICE) 28. National Library of Medicine (NLM) 29. NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) 30. Norwegian Knowledge Centre for the Health Services 31. PATH Research Institute 32. Peninsula Technology Assessment Group (PenTAG) 33. Pharmaceutical Management Agency of New Zealand (PHARMAC) 34. Québec government agency responsible for health services and technology assessment (AETMIS) 35. Queensland Health 36. Regione Emilia - Romagna 37. Singapore Health Services 38. Swiss Sickness funds Insurance Body 39. The Galician Agency for Health Technology Assessment (avalia-t) 40. The German health care system (G-BA) 41. The Health Information and Quality Authority 42. The Social Insurance Institution 43. University of Sheffi eld 44. Veteran Affairs Technology Assessment Program

133 Health Economics A comprehensive journal covering all aspects of health economics

Health Economics publishes articles on all aspects of health economics: theoretical contributions, empirical studies and analyses of health policy from the economic perspective.

Its scope includes: • the determinants of health and its defi nition and valuation, as well as the demand for and supply of health care 2008 • planning and market mechanisms IMPACT • microeconomic evaluation of individual procedures and treatments FACTOR: • evaluation of the performance of healthcare systems 1.994* Health Economics publishes 12 issues a year of high quality, peer reviewed articles. You can enjoy the latest research through Wiley InterScience Early View, where articles are published online before appearing in the print issue.

Submit your next paper to Health Economics

Authors publishing in Health Economics enjoy the following benefi ts: • Quick and easy online submission – via ScholarOne Manuscripts • Fast publication times – articles are published online weeks ahead of print publication • Online Open – publish your article open access for a one-time author fee, enabling it to be read by anyone, even those without a subscription • 25% discount – available on all Wiley books http://mc.manuscriptcentral.com/hec

For more information visit www.healtheconjournal.org

*2008 Thomson Reuters Science Citation Index AstraZeneca life inspiring ideas

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines.

For more information about AstraZeneca www.astrazeneca.com

URN: 10/0138 Date of Preparation: April 2010